Menu
Home
About Us
About 340B Report
Who We Are
340B Report Editorial Policy
Job Opportunities
Testimonials
Sample Issue
Subscribe
Contact
Subscriber FAQ
Sponsor/Advertise
Our Sponsors
Why Sponsor?
Podcasts
Inside 340B Report Podcast
340B Leaders Upfront
Resources
Document Center
Special Reports
Webinars
Article Archives
340B Leaders
Industry Insights
Spotlights
340B Industry Leaders
340B Provider Leaders
Our Sponsors
Expert Directory
Expert Tips
Events
340B Trackers
Contract Pharmacy Restrictions Tracker
State Contract Pharmacy Bills & Laws
State Provider Reporting Bills & Laws
State PBM Reimbursement Laws
Drugmaker State Exemptions Tracker
Congressional 340B Bill Tracker
State Litigation Tracker
Subscribe
Sign in
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
340B Report
Work With 340B Report
January 11, 2021
mm@shotgunflat.com
340B Report
Views
Follow the links below to read more about our current job openings, requirements and deliverables. We look forward to talking to you about a future with 340B Report!
Editor in Chief Job Opening
Prescription Drug Pricing Policy Reporter Job Opening
mm@shotgunflat.com
Staff Email
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
*Sign up for news summaries and alerts from 340B Report
Ready to subscribe?
Site Footer Live
Sliding Sidebar
340B Report Categories
Breaking
News Alert
Contract Pharmacy Protection Bills
Covered Entity Reporting Requirement Bills
Exclusive
Judicial
Legislative
Regulatory
Sponsors
State
More Categories
Federal
General
Non-Governmental
PBMs and Payers
Pharma Industry
Other Industry
Providers
Trade Association
From Our Sponsors
Expert Tips
Sponsored Content
Spotlight — Industry Leaders
Spotlight — Provider Leaders
Recent Articles
CMS Finalizes Voluntary 340B Data Repository for Medicare Part D, Hints at Future Mandatory Reporting
Provider Advocates Welcome Virginia Gov.-Elect Spanberger’s Election and Its Potential for 340B Legislation in State
Seven Questions Covered Entities Should Ask TPAs Ahead of the 2026 Rebate Model
Two New Drug Industry Lawsuits Target 340B Contract Pharmacy Laws in Oregon, Oklahoma
Federal Judge Denies AbbVie’s Bid to Block Colorado’s 340B Contract Pharmacy Access Law
Article Archives
►
2025 (577)
►
November (12)
CMS Finalizes Voluntary 340B Data Repository for Medicare Part D, Hints at Future Mandatory Reporting
Provider Advocates Welcome Virginia Gov.-Elect Spanberger’s Election and Its Potential for 340B Legislation in State
Seven Questions Covered Entities Should Ask TPAs Ahead of the 2026 Rebate Model
Two New Drug Industry Lawsuits Target 340B Contract Pharmacy Laws in Oregon, Oklahoma
Federal Judge Denies AbbVie’s Bid to Block Colorado’s 340B Contract Pharmacy Access Law
Beacon Posts Drugmaker 340B Rebate Implementation Plans, Then Changes Rebate FAQs—Drawing Provider Frustration
Drugmakers Ask 2nd Circuit to Reconsider Antitrust Case Decision, Delaying Return to District Court
2026 Changes to the Data Request List
Oklahoma Attorney General Plans to Appeal Federal Judge’s Ruling Blocking 340B Contract Pharmacy Law
Liquidia, Sanofi and Sobi Exempt Oklahoma from 340B Contract Pharmacy Restrictions Despite Court Blocking Law’s Enforcement
Federal Judge Blocks Enforcement of Oklahoma’s 340B Contract Pharmacy Access Law One Day Before it Took Effect
Expert Tip from Plenful
►
October (51)
Novartis Says it Plans to Still Partake in HRSA’s 340B Rebate Pilot; Providers, Drug Industry Diverge on Approvals
HRSA Approves 340B Rebate Proposals for Nine Drugs Under Pilot Program, Expands Data Requirements
House Lawmakers in Talks to Launch Bipartisan 340B Working Group as Counterpart to Senate ‘Gang of Six’
Trump Administration to Accelerate Biosimilar Development; PhRMA Points to PBMs, 340B Program for Slow Uptake
Is Your 340B Partner a Good Fit? Look for These Signs
How New Direct-to-Consumer Drug Platforms like TrumpRx Could Affect 340B
Federal Judge Who Upheld Arkansas’ First-in-Nation 340B Contract Pharmacy Law Dies at 85
State Contract Pharmacy Lawsuit Roundup: New Filings in Tennessee and Colorado
Publisher's Column: The Government Shutdown’s Casualties
Novartis is Second Drugmaker to End 340B Pricing for STD Clinics
Stakeholders Draw Competing Takeaways from Senate 340B Hearing
Navigating the 340B Rebate Model
Senate HELP Committee’s 340B Hearing: What Lawmakers Said
340B Lobbying Held Steady in the Third Quarter of 2025, Filings Show
Panelists Clash on 340B Growth, Rebate Model During Pharmacist Policy Conference
Senate HELP Committee’s 340B Hearing Mixes Calls for Increased Oversight with Bipartisan Program Support
Dark Money Group Brings Anti-340B Messaging to Capitol Hill Ahead of Today’s Senate HELP Committee Hearing on 340B
340B Grantees Fall Conference Recap: Policy Updates, Challenges Ahead and Sue Veer Tribute
Large Health Systems Sue HRSA Over ‘Unreasonable Delay’ in 340B Administrative Dispute Resolution Review
CBO Estimates Reconciliation Act’s Orphan Drug Medicare Negotiation Exemption Could Cost $8.8 Billion
GSK Exempts Oklahoma from 340B Contract Pharmacy Restrictions
Expert Tip from Avita Care Solutions
GAO, CBO Officials, Author of Critical 340B Studies to Testify at HELP Committee’s Thursday Hearing
Kansas Health Center CEO Says Reporter Asked About Debt Collections After He Clashed with Drug Industry Over 340B
Strategic Outlook: Preparing Your Pharmacy and Health System for the Impact of HRSA’s 340B Rebate Pilot & the OBBB
State Contract Pharmacy Lawsuit Roundup: Updates in North Dakota, South Dakota, Maine and Hawaii
340B Report Webinar Recap: Experts Discuss HRSA’s 340B Rebate Pilot and Weigh in on its Merits
Ohio Lawmakers Hear Clashing Testimony on 340B Contract Pharmacy Access Bills
Alkermes Loosens 340B Contract Pharmacy Restrictions in Two States After Appeals Court Ruling
Senate HELP Committee to Hold Oct. 23 Hearing on 340B Program
Government Shutdown Casts Uncertainty on HRSA’s 340B Rebate Pilot Deadline Today
340B Hospitals Provided Nearly $100 Billion in Community Benefits in 2022, AHA Reports
Multiple Massachusetts 340B Bills Move Through Legislative Committee
Report: Trump’s Pharmaceutical Tariffs Will Not Apply to Generic Drugs
Organon Exempts Four New States from 340B Contract Pharmacy Restrictions
Navigating the Complexities of Specialty Medication Claims Processing
State Contract Pharmacy Lawsuit Roundup: Hearing in Oklahoma and New Filing in Vermont
AstraZeneca Challenges Oklahoma’s 340B Contract Pharmacy Access Law
Sean Hall, Senior 340B Program Director, Visante
Hospitals, HRSA Agree to Voluntarily Dismiss Appeal Over J&J 340B Audits
Pfizer Tightens 340B Contract Pharmacy Restrictions for Hospitals It Believes are Not in Compliance; Novartis, Sobi Exempt New States
Drug Industry Files New Lawsuits Against 340B Contract Pharmacy Laws in Rhode Island, Maine, Oregon
State Contract Pharmacy Lawsuit Roundup: Updates in Mississippi, Nebraska and Colorado
Merck, Aurobino Pharma to Refund 340B Covered Entities for Overcharges
Federal Government Shutdown Could Impact 340B Rebate Model Pilot’s Rollout and Other Key 340B Operations
Federal Judge Allows AstraZeneca’s Lawsuit to Proceed Against Arkansas 340B Contract Pharmacy Access Law
How to Help Your Patients Experience the Full Benefits of 340B
Dark Money Group Ramps Up Anti-340B Messaging in Michigan
AHA Urges HRSA to Delay 340B Rebate Pilot, Argues Hospitals Face at Least $400M in Annual Costs
Trump, Pfizer Announce D-T-C Drug Sales, ‘Most Favored Nation’ Medicaid Prices; White House Pauses Tariffs on Companies
Apexus
►
September (58)
Federal Judge Denies Drugmakers’ Bid to Block Rhode Island’s 340B Contract Pharmacy Access Law
Kansas Special Legislative Hearing on 340B Gives Platform to Drug Industry-Aligned Groups
PhRMA, Drugmakers Look to Comply with Parts of ‘Most Favored Nation’ EO, Call on Congress to Address 340B, PBMs
A Coming Storm—or Opportunity: How the 340B Rebate Pilot and Medicare MFP Could Strain or Strengthen the Drug Supply Chain
Trump to Impose Tariffs Oct. 1 on Drugmakers Not Scaling Up U.S. Manufacturing
Ten GOP Governors Ask HRSA to Remove Planned Parenthood from 340B
Column: A Deep Dive into CBO’s New 340B Report and Why It Significantly Misses the Mark
Michigan House Panel Hears Testimony on 340B Bill as Key GOP Leader, Dark Money Group Step Up Attacks on Hospitals
Several Drugmakers Exempt New States from 340B Contract Pharmacy Restrictions
Resolving Negative Accumulations in a Virtual Inventory: What Would You Do?
State Contract Pharmacy Lawsuit Roundup: Updates in Utah, Rhode Island, Colorado, Nebraska
PhRMA Sues South Dakota, Maine Over 340B Contract Pharmacy Access Laws
Federal Court Rejects Drugmakers’ Bid to Block Maine’s 340B Contract Pharmacy Law, One Day Before It Takes Effect
Bausch Health Removes High-Cost Liver Disease, GI Treatment, Many Other Drugs From 340B and Medicaid Rebate Programs
Stakeholders Back CMS’ 340B Data Repository Plan for Medicare Part D, Differ Sharply on Implementation
Michigan House Committee to Debate 340B Contract Pharmacy and Reporting Bill After Senate Passed Similar Measure
Federal Court Sets Mid-November Oral Arguments for Drugmakers’ 340B Rebate Appeals
Wall Street Journal Editorial Takes Aim at 340B Program, PhRMA Touts Op-Ed
Expert Tip from Cervey
CMS Begins Contacting Hospitals About Drug Cost Survey Likely Tied to Future 340B Medicare Cuts
Nonprofit Hospitals’ Tax Exemptions, 340B Status Scrutinized in GOP-led U.S. House Hearing
An Emerging Threat to Your 340B Program: DSH Percentage Reductions
Drugmakers Ask Appeals Court to Reconsider Decision Allowing 340B Antitrust Lawsuit Against Insulin Drugmakers to Advance
Exelixis Tightens 340B Contract Pharmacy Restrictions, Adds Claims Data Requirements
State Contract Pharmacy Lawsuit Roundup: Updates in Tennessee, Arkansas, Colorado, Hawaii, Louisiana
RxParadigm
Expert Tip from The Craneware Group
340B Provider Advocates Slam CBO Report on 340B Growth and Budgetary Impact, Drug Industry Touts Findings
After 340B ACCESS Act’s Reintroduction, Critics Speak Out While Original Supporters Hold Back
FQHCs Face Unique Challenges—Strong Partnerships Can Make All the Difference
Hospitals File Emergency Appeal to Block J&J’s 340B Audits in Federal Court
GSK Exempts Maine and Oregon from 340B Contract Pharmacy Restrictions
Federal Appeals Court Unanimously Upholds Mississippi’s 340B Contract Pharmacy Access Law Against AbbVie Challenge
HRSA Publishes More Stakeholder Comments on Controversial 340B Rebate Pilot Proposal
Federal Appeals Court Hears Arguments in Texas Hospitals’ Lawsuit Challenging DSH Calculation Changes
Four Drugmakers to Refund 340B Covered Entities for Overcharges
Expert Tip from AuthorityRx
Carter, Harshbarger Reintroduce Controversial 340B ACCESS Act in U.S. House—This Time Without a Key Supporter
Federal Appeals Court Holds Combative Oral Arguments on Maryland and West Virginia’s 340B Contract Pharmacy Access Laws
More than 1,200 Stakeholders Comment on HRSA’s Controversial 340B Rebate Pilot
163 Bipartisan U.S. House Members Urge HHS Secretary RFK Jr. to Abandon 340B Rebate Pilot
Rethinking 340B: Where Compliance Ends and Strategy Begins
CBO Report Requested by GOP Congressional Committee Chairs Links 340B Growth to Drug Spending Trends, ACA-Related Changes and Contract Pharmacy Use Expansion
Hospital Group Asks FTC, DOJ to Investigate Drugmakers’ Potential ‘Anticompetitive’ Efforts to Impose 340B Rebate Models
South Carolina Congresswoman Honors Health Center and 340B Leader’s Legacy
State Contract Pharmacy Lawsuit Roundup: Updates in Vermont, Oklahoma, Colorado, Rhode Island
North Dakota Officials Transfer PhRMA’s State 340B Contract Pharmacy Lawsuit to Federal Court
Bipartisan Group of U.S. House Members Urges Colleagues to Sign onto Letter Opposing HHS’ 340B Rebate Pilot
PhRMA Targets 340B Hospitals in Reported ‘Seven Figure’ Ad Campaign—Its 'Biggest' 340B Ad Expenditure Yet
Part 3 of a 4-Part Series: Is In-House Pharmacy Capture the Overlooked Strategy to Growing Your 340B Program?
Mitsubishi Tanabe Pharma Latest Drugmaker to Place 340B Contract Pharmacy Restrictions, Others Add New Drugs, State Exemptions
AstraZeneca Sues Hawaii, Tennessee, Colorado Over 340B Contract Pharmacy Access Laws
Expert Tip from VytlOne
Federal Appeals Court Panel Grills All Parties in Oral Arguments Over Louisiana’s 340B Contract Pharmacy Access Law
Drugmakers Argue HHS Cannot Reject 340B Rebates in Federal Appeals Court Briefs
Mission Multiplied: Unlocking the Full Potential of 340B to Fuel Community Health
Legacy Health Endowment White Paper Calls for More 340B Provider Transparency, Protection of Contract Pharmacies
Clay Cooper, Director, Insights Execution & Innovation, VytlOne
►
August (40)
340B Community Mourns Loss of Longtime Health Center and 340B Advocate and Educator Sue Veer
AHA Urges HRSA to Abandon 340B Rebate Pilot, Warns of Severe Burdens on Hospitals
A Neutral Clearinghouse: An Area of Potential Collaboration Between Covered Entities, Manufacturers and Payers
Federal Court Extends Deadlines in Drugmakers’ 340B Rebate Appeals
Rural Health Advocates Alarmed by Urban Hospitals Reclassifying As ‘Rural’ Under Medicare
340B Lobbying Remained Strong in the Second Quarter of 2025, Filings Show
AstraZeneca Sues Dakotas Over 340B Contract Pharmacy Access Laws
State Contract Pharmacy Lawsuit Roundup: Updates in Missouri, Nebraska, Oklahoma and Rhode Island
Column: The Time Has Come for NACHC to Withdraw from ASAP 340B
Expert Tip from Pillr Health
HRSA Publishes New FAQ on Controversial 340B Rebate Pilot Program
Federal Court Schedules Late-October Oral Arguments for Drugmaker 340B Rebate Appeals
Health System, Insurer Appear to Settle Lawsuit Alleging Medicare Advantage 340B Underpayments
Six Drugmakers to Refund 340B Covered Entities for Overcharges
Stephanie Blaskoski, Regional Manager, SunRx
Federal Judge Rejects Health System’s Bid for Interest on 340B Medicare Lump Sum Repayments
Lilly Looks to Align U.S. Drug Prices with Other Nations Under Trump’s MFN Plan, Cites 340B ‘Abuse’ as Factor in Higher Costs
Two Drugmakers Sue Maine Over 340B Contract Pharmacy Law; Key Lawmaker Condemns Move
Novartis Exempts South Dakota, Colorado from 340B Contract Pharmacy Restrictions
Analysis: PhRMA Member Restrictions on Health Centers Have More Than Doubled Since NACHC-PhRMA Alliance Formed
Two Drugmakers Sue Rhode Island Over 340B Contract Pharmacy Access Law
Anti-340B Dark Money Group Promotes GOP-Passed Reconciliation Bill in New Ad
State Contract Pharmacy Lawsuit Roundup: Briefs in Colorado, Tennessee, Utah and Hawaii
Hospital and Pharmacist Groups ask HRSA to Extend 340B Rebate Model Pilot Proposal Timeline
Commonwealth Fund Explainer Highlights Key Issues Surrounding 340B Program and Potential Reforms
Sobi, J&J Exempt New States from 340B Contract Pharmacy Restrictions
HRSA Terminates Texas Hospital Location from 340B Program
HRSA Proposes Changes to STD Clinics and Other 340B Covered Entities’ Recertification and Enrollment Requirements; Extends Date for Rebate Comments
In Unanimous Decision, Fed Appeals Court Reverses Lower Court Ruling and Allows 340B Antitrust Lawsuit Against Insulin Drugmakers to Advance
HHS Touts 340B Rebate Pilot Proposal to Appeals Court, Hospitals File Amicus Brief Urging Court to Reject Rebates
The Compliance Arms Race: Can Smaller Covered Entities Keep Up?
Judge Rejects HHS’ Partial Motion to Dismiss in Drugmakers’ Lawsuit Challenging STD Site Recertifications
Trump Calls on Drugmakers to Implement ‘Most Favored Nation’ Pricing, Resurrects Idea to Extend MFN to all Medicaid Patients
Plenful
Expert Tip from Visante
Senate HELP Committee Chairman Again Criticizes 340B Hospitals and Calls for Reforms at Hearing
Liquidia Tightens 340B Contract Pharmacy Restrictions; Biogen, Sanofi Exempt New States
Key Takeaways from the 2025 340B Summer Conference
AbbVie, Novartis Sue Oregon Over New 340B Contract Pharmacy Access Law
State Contract Pharmacy Lawsuit Roundup: Hearing in Utah; Updates in Colorado, Nebraska, Oklahoma
►
July (56)
340B Providers, Drug Industry Raise Concerns Over HRSA’s 340B Rebate Model Pilot Proposal
HRSA Proposes 340B Rebate Model Pilot for Narrow Set of Drugs Under Strict Conditions
Who Are the Federal Judges Deciding the High-Stakes Drugmaker 340B Rebate Appeals?
340B Health Survey: Most Hospitals Would Struggle to Stay Open, Maintain Care Levels Under 340B Rebate Model
Dark Money Group’s Survey Claims GOP Primary Voters Oppose State Contract Pharmacy Access Laws
Safeguard Your 340B Program and Increase Compliance Through Automated, 100% Audit Workflows
Patient Groups Back Drugmakers in 340B Rebate Appeal, Without Disclosing Drug Industry Funding or Missed Compliance Deadline
Alkermes, Novartis Exempt Additional States from 340B Contract Pharmacy Restrictions
Merck, Eisai, Vertex to Refund 340B Covered Entities for Overcharges
Record Turnout for Fourth Annual ‘Defend 340B’ March on Capitol Hill
Budget Reconciliation's Effects Could Shape Efforts to Reform 340B, Policy Experts Say at 340B Coalition Conference
Separating AI Hype from Real Value in 340B Program Management
Analysis: How Medicaid Cuts in ‘Big Beautiful Bill’ Could Push Certain Hospitals Out of 340B and the Importance of Planning Ahead
State Contract Pharmacy Lawsuit Roundup: Updates in Colorado, Nebraska
Matsui, Welch Reintroduce 340B PATIENTS Act in Congress During 340B Coalition Summer Conference
OPA Director Touches on 340B Rebate Litigation and Other Key Matters at 340B Coalition Conference
340B PATIENTS Act Reintroduction Expected Soon, Hospital Trade Group Challenges Drug Industry Criticisms
Safeguarding Your 340B Program
Federal Court Consolidates Drugmaker 340B Rebate Appeals, Denies Hospital Group’s Cross-Appeal Request
GSK Exempts New States from 340B Contract Pharmacy Restrictions, Teva Issues New Update on Restricted Drugs
Lilly, Indivior, Kedrion to Refund 340B Covered Entities for Overcharges, Others Announce NDC Changes
For the First Time, CMS Proposes Claims-Based Methods to Identify 340B Drugs Billed to Medicare Part D
Advocates Warn New CMS Proposed Rule Could Hurt 340B Program, Be ‘First Step Towards Payment Cuts’
California Senators Abruptly Pull 340B Bill from Hearing; Massachusetts Lawmakers Debate Drug Pricing Measures
Column: In Memory of My First Mentor
CMS Proposes Accelerated OPPS Cuts to Offset 340B Remedy Payments and Medicare Drug Survey That Could Lead to Significant Part B Cuts
Federal Judge Dismisses AbbVie’s Challenge to Missouri’s 340B Contract Pharmacy Access Law for Lack of Standing
Carter Introduces PBM Reform Bill That Includes 340B ‘Spread Pricing’ Reporting
Verity Solutions Presents: 340B Outlook from Capitol Hill and the States
Griffith, Harshbarger Officially Take Over as E&C Health Subcommittee’s GOP Leaders
Drugmakers File New Appeal Briefs in Push to Overturn 340B Rebate Ruling
PhRMA Sues Hawaii Over New 340B Contract Pharmacy Access Law
Organon, AbbVie Exempt New States From 340B Contract Pharmacy Restrictions
Mike Fish, Senior Vice President of Client Success, Pillr Health
In High-Stakes Meetings, 340B Stakeholders Push to Sway HHS’ Rebate Guidance Ahead of Release
Supreme Court Allows HHS Reorganization and Layoffs to Continue, Effect on 340B Oversight Unclear
Griffith Named U.S. House E&C Committee’s Health Subcommittee Chair, 340B Critic Harshbarger Elevated to Vice Chair
New Oregon Law Lets Health Centers Report 340B Claims Through Clearinghouse Instead of PBMs
Five Drugmakers Exempt New States from 340B Contract Pharmacy Restrictions
State Contract Pharmacy Lawsuit Roundup: Updates in Tennessee and Utah
Providers Slam Newly Enacted GOP Budget Law Over Deep Medicaid Cuts
California Senate Amends 340B Contract Pharmacy Access Bill to Add Provider Reporting, Audit Requirements
New York Assembly Honors Longtime 340B Advocate Mark Malahosky on Retirement
Providers Condemn Reconciliation Bill’s Medicaid Cuts, Urge Lawmakers to Reject Ahead of Final House Vote
Rep. Buddy Carter to Step Down as House E&C Health Subcommittee Chair
Two Drugmakers Sue Oklahoma Over New 340B Contract Pharmacy Access Law
PhRMA Sues Vermont Over New 340B Contract Pharmacy Access Law
Kentucky Launches Voluntary 340B Claims Program Enabling Providers to Carve in Medicaid MCO
State Contract Pharmacy Lawsuit Roundup: Updates in Utah and Tennessee
J&J Appeals 340B Rebate Ruling, Hospitals Laud Federal Judge’s Rejection of Drugmaker Lawsuit
Ohio Becomes Ninth State to Enact 340B Provider Reporting Law
Federal Judge Denies AbbVie’s Bid to Block Tennessee 340B Contract Pharmacy Access Law’s Enforcement
HRSA Reinstates Eight Sagebrush Sites into 340B Program, But Judge Rules Earlier Terminations Were Lawful
Alkermes, Biogen Exempt New States from 340B Contract Pharmacy Restrictions
Drug Industry Takes Aim at 340B Program’s Growth in Pair of Op-Eds
Column: Setting the Record Straight on 340B Growth
►
June (55)
Rhode Island Gov. Signs 340B Contract Pharmacy Access, Provider Reporting Bills into Law
Federal Judge Dismisses J&J’s Lawsuit, Rules HHS Must Preapprove 340B Rebate Models
HRSA Issues New Health Center 340B Requirements for Insulin, EpiPens Following Trump’s April Executive Order
Drugmakers Urge Appeals Court to Toss Hospital Group’s Cross-Appeal in 340B Rebate Case
Don’t Miss a Claim: How to Monitor Disqualified Claims in Your 340B Program
RFK Jr. Touts HHS Budget Plan, PBM Reform & Drug Pricing Efforts; Rep. Harshbarger Suggests 340B Contract Changes
Four Drugmakers Announce New State Exemptions from 340B Contract Pharmacy Restrictions
Lauren Navas, Chief Marketing Officer, Ravin Consultants
Maine Enacts 340B Contract Pharmacy Access Law with Added Hospital Reporting Requirements
Rhode Island Passes Contract Pharmacy Access, Reporting Legislation, Sends to Governor
Drugmakers, Hospital Group Appeal Dueling Aspects of 340B Rebate Ruling
Q+A: Kalderos CEO Angie Franks Talks Truzo, 340B Program Transparency
Trump’s ‘Most Favored Nation’ Order Could Lower 340B Ceiling Prices, but Key Details Remain Unclear
NACHC Raises Concerns About 340B Rebates, Various Stakeholders Meet with Trump Administration on Rebate Guidance
AHA Report: 340B Hospitals Face More Federal Oversight, Fare Better in Audits; HRSA Releases Latest Drugmaker Audit
D.C. Federal District Court Dismisses Hospital Lawsuits Over J&J’s Controversial 340B Audit Requests
Recap of Recent Webinar: Key Issues and What to Expect Next on 340B in Washington, D.C.
Rhode Island House Passes 340B Contract Pharmacy Access, Reporting Bill; Senate to Vote Today
State Contract Pharmacy Lawsuit Roundup: Updates in Utah and South Dakota
Maine Passes 340B Contract Pharmacy Access Bill with Added Hospital Reporting Requirements, Sends to Governor
Why a Health Insurance Crisis Led Vermont Lawmakers to Add Hospital Price Caps to a 340B Contract Pharmacy Access Law
Explore a Forward-Deployed Inventory Model for High-Cost Drugs
Oregon Providers Applaud Passage of 340B Contract Pharmacy Access Law
Major North Carolina Health System Sues Aetna, Humana for Alleged 340B Underpayment
AbbVie is 1st Drugmaker to Challenge Colorado’s New 340B Contract Pharmacy Access & Reporting Law
AstraZeneca Sues to Block Nebraska’s Contract Pharmacy Access Law
Expert Tip from SpendMend
Vermont, Oregon Enact 340B Contract Pharmacy Access Laws; Vermont Measure Includes Controversial Hospital Price Caps
Federal Appellate Court Fast-Tracks Drugmakers’ Appeal of 340B Rebate Ruling
CMS Offers New Details on Medicare Drug Price Negotiations, 340B Advocates Raise Concerns About Impact on Program
Leading 340B and Pharmacy Solutions Firm Maxor Rebrands as ‘VytlOne’
J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges
Expert Tip from The Craneware Group
How Oklahoma Lawmakers Defied Their Governor and Fought Dark Money to Enact a 340B Contract Pharmacy Access Law
Cassidy Staffer, ASAP 340B Head Call for 340B Program Reforms, Comment on Proposed Shift to CMS
Third Straight HRSA Audit Finds Drugmaker 340B Overcharges in 2025
Sandoz to Stop Notifying CEs of 340B Contract Pharmacy Changes, Joins Liquidia in Adding Restrictions to New Drugs; Novartis Updates Restrictions
Drug-Industry Funded Study Finds Utilization Drives 340B Program Growth, Not Rising Drug Prices
In Emergency Motion, Novartis and BMS Urge Appellate Court to Fast-Track Their Appeals of 340B Rebate Ruling
Premier Asks Court to Reject HRSA’s Defense of 340B Hospital Drug Purchasing Restrictions Policy, Requests Oral Arguments
Keeping the Lifeline Strong: Why 340B Matters More Than Ever for Safety-Net Hospitals and Other Providers
Hospital Group-Funded Working Paper Calls for Increased 340B Visibility Among Economists
Amgen Exempts Tennessee Providers From 340B Contract Pharmacy Restrictions Despite New Law’s Carve Out
Indiana’s New Budget Law Sparks Alarm Over Last-Minute Provisions Targeting 340B Medicaid Reimbursement
State Contract Pharmacy Lawsuit Roundup: Drugmakers File Briefs in 5th Circuit Appeals Case, Updates in Utah and Nebraska
Holly Bones, Senior Director, 340B Manufacturer & Supply Chain Relations, Cencora
Expert Tip from CompassRx
SpecGx to Offer Covered Entities Refunds for a Record 30-Plus Years of 340B Overcharges
Oregon Sends 340B Contract Pharmacy Access Bill to Governor; Illinois Falls Short but Advances PBM Reform
EMR Change Ahead: 340B Readiness Starts Now!
340B Stakeholders Offer Mixed Views on Trump’s Plan to Move Drug Pricing Program to CMS
AbbVie Sues Hawaii Over New 340B Contract Pharmacy Access Law
Christopher Hotchkiss, Cofounder, CaptureRx
HHS Submits 340B Rebate Guidance for Review, But Publication Timeline Remains Unclear
Colorado, Hawaii Enact Combined Contract Pharmacy Access and Provider Reporting Laws; Illinois 340B Bill Passes Senate
►
May (78)
Trump’s Full 2026 Budget Request Would Shift 340B Program from HRSA to CMS, Maintain Current OPA Funding
Vermont Passes 340B Contract Pharmacy Access Bill with Controversial Hospital Price Caps, Sends to Governor
Oklahoma Lawmakers Override Governor’s Veto, Enact 340B Contract Pharmacy Access Law
First 340B Administrative Dispute Resolution Panel Decision Sides with Drug Industry
Stretching Scarce Federal Resources: How Conway Medical Center Is Redefining 340B’s Impact
Katie Miller, Key Player in Anti-340B ‘Dark Money’ Campaign, Leaves White House Adviser Role
Cassidy Says 340B ‘Was Never Meant to be Part of an Earnings Call’
Two Drugmakers Appeal Federal District Judge’s 340B Rebate Ruling in Favor of HHS
BI Asks Tennessee Contract Pharmacies to Report Claims Data Ahead of New State Law, BMS Updates Contract Pharmacy Restrictions
State Contract Pharmacy Lawsuit Roundup: Health Center Group Motion Denied in 5th Circuit; Drug Industry Makes Motion in Federal Court in South Dakota
Novo Nordisk, Merck, GSK to Refund 340B Covered Entities for Overcharges
Column: Battlefront Shifts from Contract Pharmacies to Rebates
Expert Tip from CaptureRx
Oregon Senate Narrowly Passes 340B Contract Pharmacy Access Bill
HRSA Defends 340B Hospital Drug Purchasing Restrictions Policy, Asks Federal Court to Reject Premier’s Challenge
House GOP Lawmaker Spartz Introduces Bill That 340B Provider Advocates Say Would Drive Them Out of the Program and Potentially Force Closures
Don’t Overlook the Importance of an HIN on Your Wholesale Accounts
Vermont House Modifies 340B Contract Pharmacy Access and Hospital Reporting Bill, Hospital Advocates Voice Concerns About Changes
Oregon, Illinois State Senators Push for Amendments to 340B Contract Pharmacy Access Bills
Drug Industry Files New Lawsuits to Block 340B Contract Pharmacy Access Laws in Tennessee, Utah
Sponsors of Oklahoma’s 340B Contract Pharmacy Access Bill Call for Veto Override, Slam ‘Big Pharma’ and Dark Money
Amid Federal Court Setbacks, Drugmakers Turn to State Courts to Try to Block 340B Contract Pharmacy Access Laws
Webinar —Behind the Headlines: A 340B Insider Briefing with Ted Slafsky
340B Provider-Drugmaker Lobbying Group Adds Hospital, Drugmaker: Key Thune Staffer Departs for Private Sector
Genentech Tightens Contract Pharmacy Restrictions to Require Hospital Claims Data, Targets 340B Drug Redistribution; 340B Lawyer Pushes Back
State Contract Pharmacy Lawsuit Roundup: Key Briefs in 8th Circuit, Utah, South Dakota; Motion Filed in 5th Circuit
Red Chip Enterprises
RFK Jr. Tells Senate Panel 340B Program ‘Controversial’ But Important to Rural Hospitals; HHS Releases MFN Targets for Drugmakers
Providers Applaud Federal Judge’s 340B Rebate Ruling as Drugmakers Mull Next Steps
Federal Judges Allows 340B Hospital Advocacy Group to Intervene in J&J Rebate Lawsuit
California Assembly Passes 340B Contract Pharmacy Protections for Grantees, Sends Bills to Senate
Drug Industry-Backed AIDS Group Targets 340B in New Ad Campaign
Viatris, Amgen, GSK Announce 340B Refunds; Amgen Issues NDC Change
Oklahoma Governor Vetoes 340B Contract Pharmacy Access Bill Despite Near-Unanimous Legislative Support
Vermont Senate Passes Combined 340B Contract Pharmacy Access and Hospital Reporting Bill
Federal Judge Upholds HHS’ Right to Pre-Approve 340B Rebates, Tosses Four of Five Drugmaker Lawsuits
Mixed Responses So Far to RFK Jr.’s Comments on 340B Program from 340B Provider Groups
AHA Urges RFK Jr. to Reject 340B Rebate Models as HHS Prepares Guidance
House E&C Committee Advances Reconciliation Budget’s Health Provisions Along Party Lines after 24-Plus Hours of Contentious Debate
As Deadline Looms, Dark Money Groups Pressure Oklahoma Governor to Veto Popular 340B Contract Pharmacy Access Bill
Ohio Becomes 29th State to Introduce 340B Contract Pharmacy Access Bill in 2025
Hospital, Pharmacist Advocates File Brief Backing Nebraska’s New 340B Contract Pharmacy Access Law Against AbbVie Challenge
AbbVie Sues Tennessee Over 340B Contract Pharmacy Law with New Legal Arguments, Reveals Plans to Exempt Providers in Dakotas
AbbVie, Sobi, Organon Exempt More States from 340B Contract Pharmacy Restrictions
Drug Industry-Funded White Paper Ties 340B to Rising Commercial Insurance Premiums; Provider Advocates Criticize Study
Chelsea Reddoch, Director of Product - 340B Recovery, R1
Expert Tip from Apexus
HHS Secretary RFK Jr. Weighs in on 340B Program Publicly for 1st Time
Rhode Island Senate Passes 340B Contract Pharmacy Access Bill, Vermont Vote Expected Today
House E&C Committee to Take Up Budget Reconciliation Bill’s Proposed PBM Accountability, Spread Pricing Provisions
Key House Republican and Vocal 340B Critic Launches 2026 U.S. Senate Bid
New England Lawmakers Advance 340B Contract Pharmacy Access Bills in Three States
Trump Signs Executive Order to Impose ‘Most-Favored Nation’ Drug Pricing Model, Unlike April EO, 340B Implications Unclear
Oklahoma Senate Passes 340B Contract Pharmacy Access Bill, Sends to Governor
In Novel Approach, Vertex to Automatically Exempt States from 340B Contract Pharmacy Restrictions as New Laws Take Effect and Apply Exemptions Liberally; Other Companies Exempt Additional States
Drugmakers Press Federal Judge to Quickly Rule on 340B Rebates, Argue HHS’ Plan for Guidance ‘Commits to Nothing’
In Win for Hospitals, Stricter 340B Bill Dies in Colorado One Day After Legislature Passes Provider-Backed Alternative
Drug Industry Advocates Say 340B Providers Would be Unintended Beneficiaries in Effort to Kill Trump Proposed Medicaid Pricing Proposal
Contract Pharmacy Lawsuit Roundup: Key Briefs Filed in Nebraska, South Dakota and 5th Circuit
Powers Law Firm
Indiana Enacts 340B Hospital Reporting Law as Colorado Lawmakers Send Combined Contract Pharmacy Access-Provider Reporting Bill to Governor
340B Antitrust Lawsuit Against Insulin Drugmakers Could Have New Life After Federal Appeals Court Hearing
Tennessee Enacts Law to Block Future Drugmaker 340B Restrictions Placed After July 2025
Colorado Lawmakers Advance Dueling 340B Contract Pharmacy Access Bills with Different Hospital Restrictions
Amgen Exempts More States from 340B Contract Pharmacy Restrictions
Hospital Group Warns that Medicare Drug Price Negotiation Payment Process Undermines 340B
Hawley, Welch Unveil Bipartisan Senate Bill to Lower Prescription Drug Prices
Expert Tip from Bluesight
HHS to Issue Guidance on 340B Rebates, IRA Interaction Within 30 Days
Trump’s FY 2026 Budget Blueprint Includes $33 Billion in HHS Cuts, No Details on 340B Plans
Hawaii Legislature Passes Amended 340B Contract Pharmacy Access Bill with Limited Reporting Requirements
National HIV Group Voices Concerns Over Sen. Cassidy’s 340B Probe Findings, Reform Recommendations
Should We Prepare for a 340B Rebate Model?
Supreme Court Backs HHS in Dispute Over DSH Calculation, 340B Providers Condemn Decision Which Could Impact Eligibility for Some Hospitals
Sumitomo Exempts Four More States From 340B Contract Pharmacy Restrictions, GSK Exempts Nebraska, Utah
State 340B Contract Pharmacy Lawsuit Roundup: New Filings in Utah
Pillr Health
Expert Tip from Cervey
►
April (61)
Federal Judge Grills Both Sides in Key Hearing on 340B Rebate Dispute
Federal Judge Holds High-Stakes Hearings Today on Five Drug Industry 340B Rebate Lawsuits
HRSA Audits Find Two Drugmakers Overcharged for 340B Drugs, Driving Calls for More Drug Industry Oversight
Former 340B Health, Evernorth Executives Join Walgreens
California, Texas, Oklahoma Advance 340B Contract Pharmacy Access Bills with Key Amendments
Takeda Tightens 340B Contract Pharmacy Restrictions, Biogen Exempts Nebraska From Its Restrictions Policy
Stakeholders React to HELP Committee Chair Cassidy’s 340B Probe Findings, Reform Recommendations
Senate HELP Committee Chair Cassidy Calls for Federal 340B Reforms, Releases Findings of Yearslong Congressional Probe
340B Lobbying Remained Strong in Early 2025, Filings Show
Indiana Legislature Passes Sweeping 340B Hospital Reporting Bill, Sends to Gov. Braun
State Contract Pharmacy Lawsuit Roundup: Appellate Court Briefings on 340B Laws in West Virginia, Louisiana
As Trump Pharmaceutical Tariffs Loom, Drug Industry Pledges Investment in U.S. Manufacturing, Warns of Disruptions
RxParadigm
Health System CEOs Meet with RFK Jr. and Encourage Him to Preserve and Strengthen 340B at HHS Roundtable
HHS Continues to Oppose Unapproved Drugmaker 340B Rebate Models in New Legal Filings
Minnesota Finalizes Expanded 340B Provider Reporting Requirements, Extends Submission Deadline to May 30
PhRMA Sues Utah Over New 340B Contract Pharmacy Access Law
Column: A Powerful Statement from the Heartland
Leaked HHS Budget Document Details Plans to Move 340B Program to CMS
Tennessee Legislature Approves Scaled-Back Bill Barring Future Drugmaker 340B Restrictions Placed After July 2025
Hospitals, Health Centers Criticize Trump’s Executive Order Over Controversial 340B Rule, Possible Medicare Payment Cuts
Tariffs on Pharmaceuticals Could Worsen Drug Shortages, Cause Disarray in 340B Prices, Advocates Say
Webinar—Neutral 340B Clearinghouse: Now Live
GAO Report Finds HHS Must Do More to Address Drug Shortages, Doesn’t Mention 340B as a Factor
Merck Exempts Three More States from 340B Restrictions, Novartis Sues Utah Over Contract Pharmacy Access Law
State Contract Pharmacy Lawsuit Roundup: 5th Circuit Appeals in Louisiana, 4th Circuit Appeal in West Virginia
Marcus Hill, Manager, Implementations, VHUB at Verity Solutions
Expert Tip from Ravin Consultants
Trump Revives Controversial 340B Rule for Insulin, EpiPens in Sweeping Health Care Executive Order
Oregon, Oklahoma Advance 340B Contract Pharmacy Access Bills
AbbVie Sues Three More States Over Newly Enacted 340B Contract Pharmacy Access Laws
HHS Briefs House E&C Committee Staff on Restructuring, Senate HELP Postpones Kennedy Hearing
SK Life Science Announces 340B Refunds for Epilepsy Treatment
New Mexico Enacts Law Prohibiting Drugmaker 340B Contract Pharmacy Restrictions on Health Centers
HRSA Allows One Sagebrush Site to Remain in 340B, but Other Sites’ Eligibility Still in Dispute
Part 2 of a 4-Part Series: A Look Into 340B’s Changing Landscape and Whether AI Can Be the Solution
Drugmakers Ask Court to Rule in Favor of 340B Rebate Model, Reject Hospitals’ Arguments; Kalderos Opposes 340B Health’s Amicus Brief
J&J Adds Unbranded Version of Stelara to 340B Contract Pharmacy Restrictions
Greg Wilson, Director of Compliance, SpendMend
Nebraska Becomes 12th State to Enact 340B Contract Pharmacy Access Law
HHS Layoffs, Restructuring Don’t Appear to Have Affected 340B Yet, But Sources Say Program Could Move to CMS
First Drugmaker Sues Utah’s New 340B Contract Pharmacy Access Law
Lawmakers in Indiana, Minnesota, Arkansas Introduce or Advance Provider Reporting Bills, 340B Restrictions
Closed Pennsylvania Hospital Revives 340B Antitrust Lawsuit Against CVS’ TPA Wellpartner
Federal Judge Dismisses Two Drugmaker Challenges to Minnesota’s Contract Pharmacy Access Law, Citing Lack of Enforcement Power
North Dakota Becomes 11th State to Enact 340B Contract Pharmacy Access Law
Senate Confirms ‘Dr. Oz’ as CMS Administrator on Party-Line Vote
AstraZeneca Lifts 340B Contract Pharmacy Restrictions in Arkansas Following State Order
Nebraska Legislature Easily Passes Contract Pharmacy Access Bill, Sends it to Governor
Effective Contract Pharmacy Strategies in an Ever-Changing Landscape
Mississippi’s 340B Contract Pharmacy Access Law Faces Scrutiny in Federal Appeals Court Hearing
Senate HELP Committee Asks RFK Jr. to Testify on HHS Reorganization Amid Mass Layoffs Including Up to One Third of HRSA Workforce
Drugmakers, Kalderos Again Urge Federal Court to Support 340B Rebate Model; 340B Health, Hospitals Look to File Brief
State Contract Pharmacy Lawsuit Roundup: 4th Circuit Appeals in West Virginia, Maryland
Danielle Sylvas, 340B Network Development Manager, Cervey
Arkansas Orders AstraZeneca to Restore 340B Drug Access at Contract Pharmacies
Idaho Becomes Fourth State to Enact 340B Provider Reporting Law
Genesis Health Care Launches Campaign Targeting NACHC’s ASAP 340B Partnership With PhRMA
In Apparent About-Face, HRSA Confirms Sagebrush’s 340B Eligibility During Federal Court Hearing
Trump Administration Creates New Agency Overseeing HRSA Amid Major HHS Staffing Cuts
U.S. Rep. Dusty Johnson: ‘No 340B Savings for Transgender Care Act’ Responds to Drug Industry’s Lies, Clarifies Savings’ Use
►
March (55)
Utah Becomes Tenth State to Enact 340B Contract Pharmacy Access Law After Governor Declines to Act on Bill
Second Sight Solutions’ Parent Company Targeted in Cyber Attack, Firm Says 340B Platforms Do Not Appear to Have Been Affected
Idaho Sends 340B Provider Reporting Bill to Governor; Oklahoma House Passes Contract Pharmacy Access Legislation
Setting the Record Straight
Virginia Governor Signs Bill Protecting 340B Hospitals from PBM Discrimination
Colorado Senate Passes Competing 340B Bills with Varying Contract Pharmacy Protections, Reporting Measures, Hospitals Restrictions
New North Carolina Bill Would Prohibit Most Hospitals from Generating 340B Savings, Add Reporting Requirements for All Covered Entities
Trump-Aligned Think Tank Proposes Lowering U.S. Drug Prices Through IRA and Other Policies, Doesn’t Weigh In on 340B Program
Abel Haile, Senior Director, Health System Strategy & Commercial Analytics, Maxor National Pharmacy Services
North Dakota Senate Easily Passes 340B Contract Pharmacy Access Bill, Sending It to Governor
Senate Committee Confirms Dr. Oz as CMS Administrator in Party-Line Vote, Sends Nomination to Full Chamber
Dr. Oz’s Ties to Company that Partners With 340B Hospitals Draws Scrutiny, Senate Panel Prepares Vote on CMS Administrator Nomination
Idaho’s 340B Provider Reporting Bill Nears Passage, While Legislators in New York, Minnesota Introduce New 340B Legislation
Merck is First to Exempt South Dakota from 340B Contract Pharmacy Restrictions but Reinstates in Kansas, Novartis Exempts Missouri
Column: Heroes in the 340B Contract Pharmacy War
U.S. Senate Bipartisan 340B Working Group Announces New Members, New Mexico Sends Contract Pharmacy Access Bill to Gov.
Kansas Senate Approves New 340B Contract Pharmacy Access Bill Amid Challenges with Existing Law
340B Contract Pharmacy Access Bills Advance in Nebraska, New Mexico, Kansas, Connecticut and Colorado, But Legislation Dies in Kentucky
340B Advocate Slams Federal ‘No 340B Savings for Transgender Care Act’ Proposal
How to Maximize Partner Support for Referral Capture During a HRSA Audit
Trump’s HHS Continues to Oppose Unilateral Drugmaker 340B Rebates in Kalderos Lawsuit
Drugmakers Agree to Take Part in Second Round of IRA’s Medicare Drug Price Talks
Justin Rolling, CaptureRx
Vermont House Passes Contract Pharmacy Access Bill, While U.S. House Republican Introduces ‘No 340B Savings for Transgender Care Act’
Trump Administration Opposes Unilateral Drugmaker 340B Rebates in First Legal Filing on Issue
340B Program Garners National Headlines Over Dark Money Ads, Employer Pharmacy Benefit Plans
Maine, Mass. Introduce 340B Contract Pharmacy Access Bills; Mass. Also Introduces Separate Provider Reporting Legislation
CMS Nominee ‘Dr. Oz’ Grilled Over Potential Medicaid Cuts and Position on Medicare Negotiations at Confirmation Hearing
Sumitomo, J&J Announce 340B Refunds to Covered Entities
New Mexico House Passes 340B Contract Pharmacy Protections for Health Centers, Sending Bill to Senate
State Contract Pharmacy Bill Updates: Anti-340B Ads Anger Okla. Lawmakers; Key Changes to N.M. Legislation; and Bill Killed in N.H.
Federal Judge Dismisses Antitrust Class Action Lawsuit Against CVS Over 340B TPA Policy
Navigating Uncertainty: Reflections from the 340B Coalition Winter Conference
Senate Confirmation Hearing for Dr. Oz, Trump’s Pick to Lead CMS, Set for Tomorrow
Pfizer, Teva Each Add New Drug to 340B Contract Pharmacy Restrictions for Hospitals
Fireside Chat: Strategies for Measuring Success & Ensuring Compliance in Your 340B Program
South Dakota Becomes First State to Enact 340B Contract Pharmacy Access Law in 2025
340B Misinformation Makes Up Small Part of 340B Conversations Online, But Garners Outsized Attention, Analysis Finds
Recap of Recent Webinar: A Closer Look at Battles Over State 340B Contract Pharmacy Access Bills and Laws
Idaho House Unanimously Passes 340B Provider Reporting Bill as Lawmakers Also Introduce Contract Pharmacy Access Bill
Federal Judge Allows Hospital Group to Join Government in Legal Battle Over Drugmaker 340B Rebate Models
Hospital Advocates File Amicus Briefs in Federal Court Cases on Drugmaker 340B Rebate Models, Maryland’s Contract Pharmacy Law
Michigan Senate Easily Passes Bill with 340B Contract Pharmacy Protections, Reporting Requirements for Providers and Manufacturers
Utah, South Dakota Legislatures Pass 340B Contract Pharmacy Access Bills in Landslide Votes, Sending to State Governors
Dark Money Group Labels Five GOP State Lawmakers As ‘Trump Underminers,’ But Efforts Appear to be Backfiring
State Lawmakers Push for 340B Provider Reporting Requirements, Restrictions or Investigations in Indiana, West Virginia, Illinois
AstraZeneca Adds Three Specialty Cancer Drugs to 340B Contract Pharmacy Restrictions
Florida Lawmaker Clarifies His Medicaid Reimbursement Bill Won’t Impact 340B Savings for Providers
In Four Major Votes, Utah, South Dakota, Hawaii and Nebraska Each Advance 340B Contract Pharmacy Access Bills
Utah House Unanimously Passes 340B Contract Pharmacy Access Bill, But Senate Pushes for Changes
Key Votes on 340B Contract Pharmacy Access Bills in Utah, New Mexico, Michigan; Bill Introductions in Kansas and Florida
Florida Providers Concerned New State Medicaid Reimbursement Bill Could Significantly Restrict 340B Savings
AbbVie Adds 340B Restrictions to Cancer, Parkinson's Treatment Drugs
Eli Lilly, Eisai, GSK and Merck Announce 340B Refunds, Other Drugmakers Report NDC Changes
Expert Tip from SunRx
►
February (58)
Federal Judge Partially Dismisses Two More Drug Industry Challenges to Missouri’s 340B Contract Pharmacy Access Law
Texas, Iowa Introduce 340B Contract Pharmacy Access Bills While Utah, Hawaii and Tennessee Advance Similar Bills
Congress Unlikely to Focus on 340B In the Near Term, But Key Bills Could Resurface Soon, Conference Speakers Predict
On Demand Webinar—What's Next for Covered Entities? Navigating 340B Challenges and the Future of Patient Care
House Passes Budget Resolution Despite Concerns Over Medicaid Cuts
Sixth Hospital Sues HRSA Over J&J’s Controversial 340B Audit Requests
Expert Tip from Apexus
Dark-Money 340B Attacks, Rebate Model Among Key Concerns at 340B Coalition Winter Conference
Federal Judge Denies Novartis’ Bid to Block Missouri’s 340B Contract Pharmacy Access Law
California, Michigan Introduce 340B Contract Pharmacy Access Bills; New Hampshire 340B Bill Faces Setback
House Prepares Budget Vote Amid Concerns Over Likely Medicaid Cuts
Pillr Health: A New Era of Innovation in 340B and Beyond
Sagebrush Withdraws Lawsuit Against HRSA, Aims to Work with Agency on 340B Reinstatement Outside Court
GSK is Fourth Drugmaker to Reinstate Contract Pharmacy Restrictions in Kansas
Two State Legislative Chambers Overwhelmingly Pass 340B Contract Pharmacy Access Bills
Vermont Introduces 17th 340B Contract Pharmacy Access Bill of 2025; North and South Dakota Advance Similar Bills
Kentucky Lawmaker Introduces 340B Hospital Reporting Bill After Senate Passes Contract Pharmacy Protections
Health Centers Host 340B Recertification Event In Lieu of HRSA’s Canceled Webinar
E&C Health Subcommittee to Hold Hearing on PBM Practices, Trump Backs GOP House Budget Plan With Health Spending Cuts
Former Kalderos VP Formally Launches Technology Company for 340B Covered Entities
Drug Industry-Funded Study Finds 340B Contract Pharmacy Bills Costly to Employer Health Plans and States; Critics Slam Its Methodology and Funding Source
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi
Conservative Groups Ramp up Misleading Attacks on 340B Over Gender-Affirming Care
Virginia Legislature Passes Bill to Expand Protections from PBMs to Hospitals; Lawmakers in Utah, Mississippi Weigh Separate 340B Bills
Part 1 of a 4-Part Series: What is AI? An Overview, Its Role in 340B, and How You Should Start Thinking About It
UPDATED: North Carolina GOP Lawmaker Lauds NYC Health System After Asking for Financial, 340B Program Info Following Super Bowl Ad
California Hospital Granted Retroactive 340B Eligibility, Drops Lawsuit Against HRSA
Column: Efforts to Derail 340B Contract Pharmacy Protections Hit New Low
Kentucky Senate Overwhelming Passes 340B Contract Pharmacy Bill; Federal Judge Partially Dismisses Novartis’ Case Against Missouri Law
Nebraska Advances Contract Pharmacy Bill Despite Anti-340B Dark Money Campaign; Rhode Island Introduces Similar Bill
Vermont is Sixth State to Introduce 340B Provider Reporting Bill in 2025
Senate Confirms RFK Jr. as HHS Secretary on 52-48 Vote Largely Along Party Lines
Congressional GOP Leaders Consider Budget Proposals That Call for Deep Health Spending Cuts
Study Finds 340B Providers Prescribe More Often Without Increasing Survival Rate of Breast Cancer; Hospital Advocate Challenges Conclusion
Sam Yeghiazaryan, Senior Supervisor, Verity Solutions
Engels Again Takes the Helm at Key 340B Agency
Kentucky Advances Contract Pharmacy Access Bill As Dark Money Group Runs Billboards Outside State Capitols Claiming ‘340B is Subsidizing Gender Transitions for Kids’
Indiana Senate Passes Sweeping 340B Provider Reporting Bill As House Advances Separate Bill to Restrict 340B Hospital Use
Illinois, Tennessee, New Hampshire Join Growing List of States to Introduce Contract Pharmacy Access Bills in 2025
Alkermes to Become Third Drugmaker to Reinstitute Contract Pharmacy Restrictions in West Virginia and Kansas, Providers Condemn Move
Hospital Group, Hospitals Look to Join Lawsuits Challenging 340B Rebate Proposals; J&J Seeks Expedited Court Action
Vertex Adds Pain Medication to 340B Contract Pharmacy Restrictions
Senate HELP Chair Cassidy Signals 340B Legislation Plans, ‘G6’ Senator Promises SUSTAIN Act Update Soon at NACHC Conference
HHS Communications Freeze Disrupts OPA, HRSA 340B Audits
340B Outlook from Capitol Hill and the States
Drugmakers Push Court to Quickly Strike Down HRSA's Opposition to 340B Rebates
Idaho is Fifth State to Introduce 340B Provider Reporting Bill in 2025, Contract Pharmacy Access Bill Expected Soon
Providers Condemn Sanofi's Move to Reinstate Contract Pharmacy Restrictions in Kansas
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Missouri and Mississippi
Kristen Gurley, General Counsel, Avita Care Solutions
Dark Money Group Gave Anti-340B PAC Nearly $5M in 2024, Influential PR Firm Raked in Over $300,000
Senate Committee Confirms RFK Jr.’s HHS Secretary Nomination by 14-13 Vote with Cassidy’s Support
The Future of 340B in a Value-Based Care Era: Can It Survive and Thrive?
Judge Denies STD Clinic’s Bid to Temporarily Regain 340B Eligibility as Fourth Drugmaker Sues
Two Big Mergers and Acquisitions in the 340B Service Industry Announced
South Dakota Introduces 340B Contract Pharmacy Access Bill; Hawaii Advances Legislation; and Three States Push 340B-PBM Bills
Connecticut Bill Would Make Medicaid Reimbursement Contingent on 340B Reporting Requirements
Hospital Group Moves to Join Federal Case to Fight J&J’s Contested 340B Rebate Proposal
►
January (53)
HELP Committee Questions RFK Jr. on Drug Pricing, Medicare and Medicaid but Not 340B
‘Deceit and Lies’: State Providers Slam Dark Money Ad Targeting 340B Contract Pharmacy Access Bills
Georgia is 11th State to Introduce 340B Contract Pharmacy Access Bill in 2025
RFK Jr. Backs PBM, Drug Pricing Reform at Senate Confirmation Hearing, 340B Not Discussed but Could Come Up Today
Trump Administration Signals Support for IRA Drug Price Negotiations
White House Rescinds Funding Freeze, But Concern Among Health Centers Remain
Anti-340B Ads Return: Dark Money Group Targets GOP-Led States Considering Contract Pharmacy Access Bills
GOP Eyes 340B Commercial Pay Rate Cut, Advocates Slam Reconciliation Proposal
5 Questions to Assess the Effectiveness of Your 340B Pharmacy Program and Position it to Optimize Outcomes
PhRMA-backed Conservative Think Tank Suggests DOGE Should Prioritize 340B Reform to Cut Government Costs
HRSA Pushes to Dismiss Health Systems’ Lawsuits Over J&J 340B Audits Amid Uncertainty Under New Trump Admin
Dr. Oz, Trump’s Pick to Lead CMS, Linked to Senior Role in Company that Partners With 340B Hospitals
Senate Sets Confirmation Hearings for RFK Jr.’s HHS Secretary Nomination, HHS Freezes Communications
Compliance with Inflation Reduction ACT (IRA) and Associated Maximum Fair Price (MFP) Rules for 340B Covered Entities
STD Clinic Sues HRSA Over 340B Sites Terminations, Claims Agency Actions Will Force Clinic to Close
California Hospital Sues HRSA Over 340B Removal, Seeks Retroactive Eligibility
New Colorado Bill Would Prohibit 340B Contract Pharmacy Restrictions, Add Hospital Reporting Rules
Indiana Governor Orders Investigation into 340B Hospital Off-Site Clinics as State Legislators Introduce Bill to Significantly Narrow Program Scope
Connecticut Lawmaker Introduces 340B Cost Reporting Bill, Providers Warn of ‘Unnecessary Burden’
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri
NYT Investigation Highlights Federal Law’s Unintended Harm to 340B Providers
Four More States Introduce 340B Contract Pharmacy Access Bills in 2025
Sanofi Reinstates Contract Pharmacy Restrictions in Kansas, West Virginia Following State Legal Developments
Cassidy, Sanders Call for Passing Drug Pricing Bills as Key 340B Committee Holds First Meeting; Kennedy Confirmation Stalls
Federal 340B Lobbying Activity Held Steady in Q4 of 2024, Filings Show
Just Before Departing, Biden Admin Announces Next 15 Drugs for Medicare Negotiations Amid IRA Uncertainty and 340B Questions
CPS
Novartis is Fifth Drugmaker to Sue HRSA to Implement Controversial 340B Rebate Model
NYT Investigative Article Sparks Both Scrutiny and Support for 340B Prime Vendor Apexus
Nebraska, New York Reintroduce 340B Contract Pharmacy Access Bills in 2025
House E&C Convenes Under New Leadership, Senate HELP Committee to Meet Next Week
BMS Allows Additional Contract Pharmacy Designation for Cancer Drug; Vertex Adds Cystic Fibrosis Drug to Restrictions
340B Program Had No Impact on Prostate Cancer Care, Study Suggests
House E&C Health Leader Floats Major 340B Reform; Billions in Cuts to 340B Hospitals Under Consideration, Hospital Group Warns
Katie Miller, Key Player in Anti-340B ‘Dark Money’ Campaign Helping RFK Jr.’s HHS Secretary Bid
Top 10: Visante's Insights for the Biggest Issues in Health System Pharmacy in 2025
HRSA Terminates 20 ‘Ineligible’ 340B Sites from STD Clinic; Clinic Rejects Allegations and Vows to Fight Back
New Mexico is Third State to Introduce 340B Contract Pharmacy Access Bill in 2025
New Missouri Bill Would Significantly Restrict Uses of 340B Savings, Add Provider Reporting Requirements
Column: In the Senate, Keep an Eye on Two Powerful Lawmakers with Very Different Views on 340B
Expert Tip from Maxor
Kentucky, Utah Introduce First Contract Pharmacy Access Bills of 2025
State Contract Pharmacy Lawsuit Weekly Roundup: Appeals in Mississippi and Maryland; Update in Missouri
Webinar—Resolving 340B Noncompliance: From Reversals to Refunds
Cassidy Officially Takes Helm of Senate Committee that Oversees 340B Policy
High-Profile Dems, Including AOC, Win Spots on Key House Panel That Oversees 340B
Heron, Dr. Reddy’s, Organon, CooperSurgical Issue NDC Changes
Optimizing Your 340B Program: Ensuring Accurate Capture and Identifying Data Gaps
Trump Selects Key Player in Anti-340B ‘Dark Money’ Campaign to Join New Department of Government Efficiency
Staff, Members for Key Congressional Committees That Oversee 340B Policy Announced; REH Bill Reintroduced
Drugmaker Lawsuit Targets 340B Eligibility of In-Kind STD Clinics; STD Grantee Denies Allegations
AHA Urges CMS to Block Drugmaker 340B Rebate Models, Improve Medicare Transaction Facilitator
Indiana State Senator Renews Push for 340B Provider Reporting Bill in New Legislative Session
►
2024 (674)
►
December (52)
Fed. Court Rejects AstraZeneca’s Request to Halt Mississippi’s Contract Pharmacy Law, Dealing Another Blow to Drug Industry
After Drama Over Previous Proposals, Congress Passes Year-End Spending Bill with Pared-Down Health Center Funding, No 340B or PBM Language
Senate GOP Selects Republican Members for Key 340B Senate Committee in 119th Congress, Sanders Named Ranking Member
Continuous 340B Program Readiness: Your Two-Part To-Do List
Biogen to Extend 340B Contract Pharmacy Restrictions to Grantees and Add New Requirements for Hospitals, Novartis to Require Claims Submissions for Hospitals
Chaotic Michigan Legislative Session Ends Without House Vote on Senate-Backed 340B Contract Pharmacy Access Bill
Ruling Against West Virginia Contract Pharmacy Access Law May Increase Odds of Eventual SCOTUS Review as State Providers Vow to ‘Not Give Up’
Washington Health Officials Submit Report to State Legislature on 340B Cost Reduction Opportunities, Program Benefits to Community
State Action Year in Review: States Passed More 340B Contract Pharmacy Access Laws as Drugmakers Pursued Legal Challenges and Dark-Money Campaign Threatened GOP Lawmakers
A Year in Review: The Top 10 Most-Read 340B Report Stories of 2024
Rep. Buddy Carter, 340B Critic, to Chair Key Subcommittee That Oversees Program
After Drama from Musk and Trump Over Bipartisan Spending Bill, 340B Legislation, Health Center Funding Faces Uncertain Future
House GOP Names New Members to Key 340B Committee; Staffer with Drug Industry Ties To Serve in Top Post
The Evolving Impact of 340B on Specialty Pharmacy
Drugmakers Drop Lawsuits Against Kansas 340B Contract Pharmacy Law After AG Says Statute Does Not ‘Prohibit or Forbid Anything’
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Missouri
COLUMN: Six Members of the U.S. House that 340B Stakeholders Should Keep an Eye on in 2025
Federal Judge Blocks West Virginia from Enforcing Contract Pharmacy Access Law While Challenges Play Out
Pallone Named Top Democrat on House Committee Overseeing 340B Program
IRA Rollout, Regulatory Gaps May Drive Major 340B Reforms in 2025, Says Adam Fein of Drug Channels
Scoping 340B Referral Capture Opportunity: It’s Bigger Than You Think
AbbVie’s Latest 340B Restrictions Appear to Target Hospital Alternative Distribution Models But May Not Be Enforceable, Experts Say
Evofem Announces NDC Code Change Effective Feb. 1
Russ Barron, Director, The Alinea Group
Sanofi Pauses 340B Rebate Proposal, Sues HRSA to Impose Controversial Model
HRSA Threatens to Remove Sanofi from 340B Program Over ‘Unapproved’ 340B Rebate Proposal
Michigan Senate Overwhelmingly Passes Contract Pharmacy Access Bill, Sending to House for Final Push
It’s Not Just Arkansas Anymore: West Virginia Becomes Second State to Start Enforcing Its Contract Pharmacy Access Law
Michigan 340B Contract Pharmacy Access Bill Moves to Full Senate as Legislative Session Nears End
Questions to Ask as you Evaluate Potential Referral Partners
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Missouri - Dec 24
Despite Rep. Guthrie’s Previous Support for Legislation Opposed by Most 340B Providers, Groups Praise His Ascension to E&C Chairperson
NACHC, ACH Join Forces to Urge Congress for Health Center Funding, Leaving 340B Differences Aside
California Health System Presses Federal Appeals Court to Revive 340B Whistleblower Lawsuit Against Four Major Drugmakers
Rep. Guthrie to Chair Key House Committee That Oversees 340B and Medicaid Programs
With End of Congressional Session Fast Approaching, Time is Running Out for Long-Anticipated Senate Bipartisan 340B Bill Introduction
'A Sense of Hope:' Arkansas 340B Providers and Officials Welcome SCOTUS’ Move Declining to Take Up Challenge of State’s 340B Law
Michigan Lawmakers, Providers Push for Contract Pharmacy Protections Before End of Session As Drug Industry Allies Step Up Opposition
HRSA Seeks Dismissal of Two Health Systems’ Lawsuits Over J&J 340B Audits
Supreme Court Declines to Hear PhRMA’s Challenge to Arkansas’ Landmark 340B Contract Pharmacy Access Law
Experts Predict Impact of Trump, GOP Majorities on 340B Program in Subscriber-Only Webinar
How the GOP’s Incredibly Slim House Majority in Next Congress Could Affect 340B Policy
Maximizing 340B Opportunities Through Effective Pharmacy Reconciliation
AbbVie Will Require Grantees to Submit Claims Data Starting Jan. 1; Grantee Representatives Criticize Move
Safety-Net Hospital Group Urges HRSA to Block Sanofi 340B Rebate, Calling It More Harmful than J&J Model
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Missouri
Rachael Bowser, Lead Technician, Reedsburg Area Medical Center Community Pharmacy and 2024 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
Health Systems Temporarily Avoid HRSA 340B Termination Threats as They Fight J&J Audits in Court
Sanofi Escalates Legal Fight for HRSA 340B Contract Pharmacy Records Amid Controversial Rebate Push
Claim Capture by Provider Type: A Compliance and Maximization Guide
Right-leaning Outlets Publish Contrasting Op-eds on 340B Program
HRSA Sends New York Times More Documents Requested in 340B FOIA Lawsuit
►
November (46)
Fourth Large Manufacturer Fights to Establish Contested 340B Rebate Model
It is Not Just Hospitals: Amid Increasing Drugmaker Contract Pharmacy Restrictions, Health Centers Forced to Lay Off Staff & Cut Services
340B Providers Slam Sanofi’s New 340B Rebate Model for Hospitals and Health Centers
House Places 340B Transparency Act on Floor Calendar, But a Vote is Not Guaranteed
Minnesota Issues 1st State Report on 340B, Critics Say it ‘Misses Critical Context’
State Contract Pharmacy Lawsuit Weekly Roundup: Arkansas SCOTUS Appeal and Updates in West Virginia, Mississippi
The Demise of Chevron Deference – What Does It Mean for the 340B Program?
Hospital Systems Fight HRSA’s Threat to Remove Them from 340B Program Over J&J Audits
Wall Street Journal Reports Sanofi Will Become Third Drugmaker to Push for Controversial 340B Rebate
Proposition 34: Voters Narrowly Back Controversial California 340B ‘Revenge’ Ballot Measure
Trump Picks ‘Dr. Oz’ to Lead CMS, Key Agency that Influences 340B Program
More Dems Back 340B PATIENTS Act Which Would Restore 340B Discounts in Contract Pharmacy Setting
Struggling with Low Pharmacy Capture Rates?
Katheryne Richardson, a Former Senior BMS Leader and Apexus VP, Joins Berkeley Research Group as a Managing Director
Panelists at Healthcare Purchaser Conference Link 340B to Higher Employer Healthcare Costs, Hospital Consolidation
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Missouri
Closing the Loop & Care Gaps
HHS Fights Sanofi’s FOIA Lawsuit Seeking Extensive 340B Contract Pharmacy Records
340B Hospital Group Raises Alarm About Rebates in New Ad Blitz, Health Center Group Revamps 340B Reform Proposal
Onsite Pharmacies: A Win-Win-Win for Entities, Patients & Providers
PhRMA Dismisses Lawsuit Challenging 340B ADR Rule
Lilly Sues HHS, HRSA to Implement Expansive 340B Rebate for All Products and Covered Entity Types
J&J Lawsuit to Test Trump Administration’s Stance on 340B Rebates
Stakeholders Prepare for New Senate with Two Key GOP Players with Vast Differences on 340B
In Major Change from Previous Tenure, President-Elect Trump Selects Vaccine Skeptic RFK Jr. as HHS Secretary
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, West Virginia, Missouri
340B Critic Cassidy to Chair Key Senate Committee
GOP Retains Control of U.S. House to Put Republicans in Charge of Congress, White House
Senate GOP Selects Thune, a 340B Champion, as Next Majority Leader Despite Pushback from Trump Allies
New CMS Rule Mulls Data Repository for 340B Claims in 2026, But Implementation Challenges Loom
Tammy Kinney: A Personal Testament to 340B’s Importance in Rural America
AbbVie, GSK Announce Refunds for 340B Overcharges
Column: Post Election Analysis: Implications for the 340B Program
Webinar—The IRA’s Implications for 340B Stakeholders
J&J Sues HRSA for Blocking Controversial 340B Rebate Model
GOP Returns to Power: How the 2024 Election Outcomes Could Affect the 340B Program
Proposition 34: Results Too Close to Call in Controversial California 340B Ballot Measure Contest
Arkansas Officials, Providers Urge Supreme Court to Deny PhRMA’s Appeal to Overturn 340B Contract Pharmacy Access Law
Supreme Court Hears Arguments Over DSH Calculations That Could Result in More Hospitals Qualifying for 340B
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri, Kansas
A New Era for Value-Based Care: Driving Better Outcomes Through Innovation and Patient-Centered Care
November 5 is Finally Here: How the 2024 Elections Could Affect the 340B Program
Major GPO Sues HRSA over Restrictions on How 340B Hospitals Purchase Initial Drug Inventory
Lilly Backs Sanofi Lawsuit Seeking HRSA 340B Records, Argues Contract Pharmacy Agreements Violate 340B Statute
BI Tightens Contract Pharmacy Restrictions for All Covered Entities
Eli Lilly Announces Refunds for 340B Overcharges
►
October (46)
HHS Appeals Court Ruling That Blocked DSH Calculation Changes That Impact 340B Eligibility
Pfizer CEO Calls 340B ‘One of the Biggest Issues’ During Earnings Call Touting $17.1B in Quarterly Revenue
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Missouri - Oct 24
Ascend, Xellia Announce Refunds for 340B Overcharges
Column: Much-Needed Wins for 340B Providers but Challenges Could Be Lurking
Julie Badger, Technical Training Advisor, Verity Solutions
Kalderos to Resume Legal Battle Over HRSA’s Opposition to Drugmaker 340B Restrictions, Including Rebates
Former Presidential Candidate Howard Dean Calls for More 340B Transparency, Declines to Discuss Op-ed, Alleged Drug Industry Ties
AstraZeneca Announces Change to Cancer Drug Replenishment After Discontinuing Certain Dosage
UCB Extends Contract Pharmacy Restrictions to All Federal Grantees
Organon To Extend Contract Pharmacy Restrictions to CHCs on Dec. 1
Fifth Hospital Sues HRSA for Authorizing ‘Unlawful’ J&J 340B Audits
Drugmakers Urge Federal Appeals Court to Dismiss California Health System’s 340B Whistleblower Lawsuit
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Minnesota, Missouri, Mississippi
Group That Does Not Disclose Its Funding Releases White Paper Calling for 340B Reforms, Advocates Slam Report
Growth in 340B Purchases Driven by Pharma Price Increases, Broader Healthcare Trends, Providers Say
Magic Johnson-Backed Startup Raises $31 Million to Help Build, Expand In-House Pharmacies at 340B HIV Clinics
5 Key Focus Areas in a 340B Audit
340B Lobbying Activity Did Not Slow Down in Q3, Federal Filings Suggest
Total 340B Drug Purchases Reached $66 Billion in 2023
Former Senior Trump Official Talks Drug Pricing Reform, Says 340B Program Is ‘Out of Control’
Former J&J Attorney and Current Kalderos Board Director Says Battle over Rebates Has Not Ended
Dark Money Poured Nearly $4M into Super PAC Opposing State 340B Contract Pharmacy Access Bills
LA Times Says ‘No’ to California Ballot Measure That Would Affect 340B
State Contract Pharmacy Lawsuit Weekly Roundup: New Filings in Missouri, Minnesota
PhRMA Pans Government’s Response to J&J’s 340B Rebate Proposal in Letter to HRSA Administrator
340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed
Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers
Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions
CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models
FQHCs Reinvest 340B Savings in Safety-Net Care, JAMA Study Finds
State Contract Pharmacy Lawsuit Weekly Roundup: Orders and Filings in Arkansas, Louisiana, Kansas, Mississippi Maryland, Missouri
Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed
Edline Victor, Director of Pharmacy, Whole Family Health Center and 2024 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
Expert Tip from Maxor
CMS’ MDRP Final Rule May Impact 340B Covered Drugs, Attorneys Say
GSK Announces Specialty Pharmacy Senderra No Longer Eligible to Dispense Asthma Drug
Amgen Announces NDC Change for Osteoporosis Drug
Arkansas Begins Enforcement Against AstraZeneca for Allegedly Violating Contract Pharmacy Access Law
CMS Finalizes Next Medicare Drug Negotiation Guidance Without Resolving Key Concerns of 340B Stakeholders
Webinar—Neutral 340B Clearinghouse: Ready, Set, Now Go!
Providers Praise Federal Court’s Defense of Louisiana Contract Pharmacy Law as Drug Industry Weighs Next Steps
State Contract Pharmacy Lawsuit Weekly Roundup: Updates on AbbVie, AstraZeneca Cases in Missouri
340B Provider Groups, Key Federal Lawmaker Praise HRSA for Pressuring J&J to Drop 340B Rebate Proposal
Kalderos Launches New Drug Discount Platform with 340B Rebate Capabilities as Lawsuit with HHS Remains Paused
Florida, North Carolina Now Eligible For Immediate 340B Enrollment Under Public Health Emergency
►
September (56)
Federal Judge Upholds Louisiana’s 340B Contract Pharmacy Law in Another Major Blow to Drug Industry
J&J Abandons 340B Rebate Due to HRSA's Enforcement Threats But Defends Model in Letter to Agency
188 Bipartisan House Members Urge HHS Action Against J&J’s ‘Unlawful’ 340B Rebate Proposal
HRSA to J&J: End 340B Rebate by Monday or Lose Access to Key Government Health Insurance Markets
High-Ranking HRSA Official Talks Genesis Decision, Drugmaker Audits During Rare Unscripted Q&A at Industry Conference
Lawmakers Hit Campaign Trail Without Unveiling Highly Anticipated SUSTAIN 340B Act
Consolidated Service Centers and 340B: Can they Coexist?
Sanofi Imposes New 340B Contract Pharmacy Rule in Arkansas Following Legal Deal with State
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Maryland, Minnesota
Norma Carrizales, Senior Account Manager, Cervey
Sen. Cassidy’s Letters to Drug Manufacturers Welcomed by Drug Industry Trade Group, Draw Skepticism from 340B Provider Advocates
CMS Publishes Final Rule on Medicaid Rebates with Significant 340B Implications
7 Tips to Help Covered Entities Navigate ACA Open Enrollment
340B Report Kicks Off Editorial Roundtable Podcast and YouTube Show
Delaware Enacts 340B-PBM Payment Law Without Contract Pharmacy Provisions from Original Version
PhRMA, HHS Seek Continued Pause on 340B ADR Lawsuit
AHA Op-Ed Takes Aim at ‘Big Pharma’s’ 340B Program Growth Rhetoric
Column: CMS Should Heed the Advice of 340B Community on Medicare Negotiations
Senator Cassidy Extends 340B Inquiry to Two Major Pharmaceutical Manufacturers
House Passes Pediatric Enrollment Bill That Would Require 340B Providers to Report Medicaid Managed Care Revenue
HRSA’s Enforcement Threats Against J&J’s 340B Rebate Proposal Could Face Drugmaker Challenge
Federal Judge Upholds Four Drugmakers’ 2021 Contract Pharmacy Restrictions—Without Addressing ‘40-Mile Radius’ Rule
A HRSA Audit Guidebook
State Contract Pharmacy Lawsuit Weekly Roundup: AbbVie Asks 5th Circuit to Reverse Ruling, New Developments in Missouri and Kansas
Equiscript
HHS to J&J: End 340B Rebate Proposal Immediately or 'Face Potential Consequences’—Including Termination from Federal Health Insurance Programs
Sen. Welch Hopes His Contract Pharmacy Bill Will Move Soon, ASAP 340B and PhRMA Push for Broader Bill
Best Practices for 340B Program Savings Management
Fourth Hospital Sues HRSA for Alleged ‘Unlawful’ Authorization of J&J 340B Program Audits
Diabetes Drugmakers Urge Federal Appeals Court to Dismiss Health Centers’ 340B Antitrust Lawsuit
Eli Lilly and Amgen Announce Refunds, Amgen Issues NDC Change
HRSA Adds Louisiana to Eligible States for Immediate 340B Enrollment Due to Hurricane Francine
340B Covered Entities Threaten Action Against Drugmakers Over New Reporting Requirements
HHS Concessions in Contract Pharmacy Lawsuits Unlikely to Signal Shift in 340B Rebate Stance, Attorneys Say
State Contract Pharmacy Lawsuit Weekly Roundup: 5th Circuit Appeals and Updates in Arkansas, Minnesota, West Virginia
How to Leverage AI for Enhanced 340B Program Management: Learn More and Ask Your Questions on 9/24 at 1:00PM ET
AstraZeneca Tightens Contract Pharmacy Restrictions to Require Claims Data Submission
ACA Played Key Role in 340B Growth, Drug Industry Consulting Firm Finds
Expert Tip from The Craneware Group
Welch Introduces 340B PATIENTS Act in the Senate
Arkansas Plans to Challenge J&J’s Contested 340B Rebate Proposal for Violation of State Law
In Another Drug Industry Setback, Maryland Federal Judge Rejects Bids to Block State’s 340B Contract Pharmacy Access Law
AHA Calls on Congress to Defend 340B Access to Specialty, Community Pharmacies Amid Drugmaker Resistance
Pharma-Linked Watchdog Advocacy Group Leader Pens Op-Ed Urging Congress to Advance 340B Legislation
Welch Likely to Introduce Senate Version of Matsui’s 340B PATIENTS Act As Soon As Next Week
Experts Forecast Impact of November Elections on 340B Program, Drug Pricing and the Larger Economy
Webinar -- Navigating 340B Contract Pharmacy Restrictions: The Latest Developments, Field Insights, and Mitigation Efforts
HHS Asks D.C. Federal Court to Rule for Drugmakers in Contract Pharmacy Lawsuits, Ties Outcomes to Kalderos 340B Rebate Case
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Arkansas, Maryland, Missouri, West Virginia
Merck Offers Refunds to 340B Providers for Overcharges of Inhaler in Fourth Notice This Year
Expert Tip from PharmaForce
J&J’s 340B Rebate Vendor to Host In-Person Training Next Monday Despite Government’s Objection to Proposal
Bayer to Extend Contract Pharmacy Restrictions to Federal Grantees, Providers and Advocates Voice Concerns About Recent Trend
J&J Relents on Arkansas Contract Pharmacy Law; AbbVie Exempts MO, MS Covered Entities
UPDATED: Certain NDCs for Four of Ten Newly Announced Medicare Negotiated Drug Prices Are Below Current 340B Prices
EMD Serono Extends 340B Contract Pharmacy Restrictions to All Covered Entities & Adds New Restrictions
►
August (58)
Hospital Groups Urge HRSA to Take ‘Immediate Enforcement Action’ Against J&J’s Contested 340B Rebate Proposal
Analysis Finds Growing Private Equity, Corporate Investments in 340B; Firm Conducting Study Fails to Mention Its Own PE Funding
Preparing for a Neutral 340B Claims Clearinghouse
State Contract Pharmacy Lawsuit Weekly Roundup: Judge Calls Astra Subpoenas ‘Overly Broad,’ Mo. Officials Push to Dismiss Lawsuit
Two More Drugmakers Partially Exempt Missouri Providers from 340B Contract Pharmacy Restrictions
Christina Breckenridge, Senior Director of Client Success, RxStrategies
J&J’s Contested 340B Rebate Proposal Would Further Limit Contract Pharmacies, Give Drugmaker More Control of Program, Attorneys Say
Missouri’s 340B Contract Pharmacy Access Law Takes Effect Tomorrow as More Drugmakers Restore Discounts, Others Sue State
Kedrion Posts 340B Refund Notice; Mylan Issue NDC Changes
Column: Unilateral Imposition of Rebate Model for the 340B Program is a Non-Starter
It's Not a Matter of IF but WHEN
HRSA Says Johnson & Johnson’s New 340B Rebate Model Did Not Receive Agency Approval, Is ‘Inconsistent’ with 340B Statute
J&J Announces Plans to Shift Certain 340B Discounts to Rebate Model, Prompting Backlash from Providers, Regulators
Federal Appeals Court Dismisses AHF’s 340B Lawsuit Against Apexus
Sanofi Asks 340B Hospitals for Information on Purchases of Its Top-Selling Drug
Unlock Your 340B Program Potential Through Data Analytics
Pharmacist, Hospital Groups Release Joint Model State 340B Contract Pharmacy Access Legislation
State Contract Pharmacy Lawsuit Weekly Roundup: New Intervenor in Arkansas; Consolidated Cases in Maryland
Hospital Groups ask Supreme Court to Reverse Ruling that Impacts 340B Eligibility
Drug Industry-funded Think Tank Raises Questions About 340B Hospitals’ Charity Care
Abby Kleczynski, Manager Strategic Accounts, The Craneware Group
Expert Tip From AuthorityRx
Federal Court Grants Texas Hospitals’ Request to Temporarily Block DSH Calculation Changes
AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B
Organon Partially Exempts Missouri, Minnesota Providers from 340B Contract Pharmacy Restrictions
GSK Announces Refunds for 340B Overcharges
340B ESP Updates Claims Submission Policy, Stakeholders Voice Concerns About Compliance
SUSTAIN 340B Act On Track for Possible Early September Introduction After Last-Minute August Delay
Medicaid Drug Rebate Program Summit – MDRP 2024
State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Defends Subpoenas; Updates in Missouri, Mississippi, Maryland
Former Pfizer Exec. Slams 340B, Says IRA Will Worsen Program in New Op-Ed
Expert Tip from AAFCPAs
After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency
UPDATED: AbbVie Ends Voluntary 340B Discount Pricing for Dozens of Orphan Drugs
Patient Turned Advocate: David Alexander Discusses 340B
HRSA Seeks Public Comment On ADR Process and Required Administrative Load
Two New Drug Industry Lawsuits Challenge 340B Contract Pharmacy Access Laws in Kansas, Missouri
J&J Exempts Maryland, Mississippi from Contract Pharmacy Restrictions
Massachusetts’ 340B Contract Pharmacy Access Bill Fails to Move in Formal Session, Stakeholders Remain Hopeful
HRSA Allows for Immediate 340B Enrollment in Three Southeastern States Due to Hurricane Debby
VP Pick Tim Walz Signed Multiple 340B Laws in Minnesota, Including Contract Pharmacy Access, But Faced Opposition from Hospitals Over Certain Policies
Hospital-Backed Candidate Wins Missouri GOP Governor Primary Over Two Candidates Who Vowed to Repeal 340B Contract Pharmacy Access Law
State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Subpoenas in Arkansas, Mississippi; Minnesota AG’s Defense
HRSA Walks Through Hospital Recertification Process Days Before Opening Date
Private Oncologist Group-Funded Study Highlights 340B Contract Pharmacies’ Links to PBMs
Two Researchers Call For More 340B Transparency, but JAMA Fails to Disclose Glaring Conflict of Interest
HRSA to Host Webinar Tomorrow Ahead of 340B Hospital Recertification Window Opening Aug. 12
Senate Committee Votes to Increase HRSA Funding, Flat Fund OPA and Chides Drug Manufacturers on 340B Restrictions
More Drugmakers Exempt New States from 340B Contract Pharmacy Restrictions
Third Drugmaker Sues Kansas Over Its 340B Contract Pharmacy Access Law
Highly Anticipated Bipartisan Senate 340B Overhaul Delayed Ahead of August Recess
U.S. Government, 340B Provider Groups Urge Appeals Court to Reverse Dismissal of Health System’s 340B Whistleblower Lawsuit
As GOP Primaries Near, Lawmakers in Missouri Battle Over 340B Messaging
State Contract Pharmacy Lawsuit Weekly Roundup: Maryland, Louisiana AGs Step Up Defense
PhRMA Petitions Supreme Court to Overturn Arkansas’ 340B Contract Pharmacy Access Law
Federal Bill Introduced to Extend 340B Eligibility to Qualifying Hospitals in U.S. Territories
Rep. Matsui’s 340B PATIENTS Act Picks Up New Co-Sponsors
Donna Tempesta, Northern Bureau Chief / VP of Finance - Pharmacy, AIDS Healthcare Foundation
►
July (56)
Bipartisan Federal Children’s Healthcare Bill with 340B Reporting Requirements Nears House Vote
PhRMA-Backed Conservative Think Tank Tells State Lawmakers Not to Pass 340B Contract Pharmacy Access Bills During Annual Meeting
AHA, RWC-340B Ramp Up Critiques of ASAP 340B-Backed Bill
HRSA Agrees to Send New York Times FOIA-Requested Documents
Column: Three Key Observations from Efforts to Restore 340B Discounts in the States
Two Hospitals Sue HRSA to Block ‘Unlawfully Authorized’ Drugmaker 340B Program Audits
Merck, Wisconsin Health System Join 340B Working Table; 300+ Firms Lobbied on 340B in Q2
Missouri GOP Gubernatorial Candidate Ashcroft Calls to ‘Repeal 340B’ as State Hospitals Back Competitor in Tight Primary
GOP Lawmaker Grills PBM Execs on 340B Profits During House Oversight Hearing
State Contract Pharmacy Lawsuit Weekly Roundup: Mississippi, Maryland and Arkansas Cases Heat Up
Just Days After Legal Setback, Novartis Exempts Mississippi Providers From Contract Pharmacy Restrictions
A Closer Look at Kamala Harris’ Positions on 340B and Other Drug Pricing Issues
Health System Urges Federal Appeals Court to Revive 340B Overcharge Lawsuit Against Major Drugmakers
First Drugmaker Sues Missouri Over its 340B Contract Pharmacy Access Law
Merck, Jazz Pharmaceuticals Exempt States from 340B Contract Pharmacy Restrictions — Including First for Missouri
340B Coalition Summer Conference 2024: Navigating the Heat of Change and Uncertainty
Massachusetts 340B Measures Addressing PBM Discrimination and Medicaid Drug Coverage Fall Short in Senate, Sponsor Plans to Refile Bill Next Session
Trump VP Pick Vance Co-Sponsored Bill Calling for Study of 340B Use Among ‘Noncitizens’
State Contract Pharmacy Lawsuit Weekly Roundup: Updates in Mississippi, Maryland
We Must Partner—With Pride—to Better Serve LGBTQ+ Patients
Massachusetts Senate to Vote on 340B PBM Nondiscrimination Measure; Status of Contract Pharmacy Bill Uncertain
SK Life Science Posts Refund Notice; Dr. Reddy's and Pfizer Issue NDC Changes
HRSA Allows for Immediate 340B Enrollment in Texas Due to Hurricane; Hawaii Remains Eligible
Jennifer Austin, 340B Senior Program Director, Visante
GOP-Led House Appropriations Committee Votes to Cut HRSA Funding, Flat Funds OPA in Party Line Vote
Sen. Cassidy Claims 340B Hospitals Drive Medical Debt During Key Senate Committee Hearing
CMS Proposes Rule to Exclude 340B Claims from Inflation Rebates; Reflects ‘Stronger Understanding’ of 340B than IRA Negotiation Guidance, Says Attorney
Study Finds Oncology Markups at 340B Pediatric Hospitals; AHA Slams Study and Funder
Sumitomo Loosens 340B Contract Pharmacy Restrictions in Five More States
Missouri Become Eighth State to Enact 340B Contract Pharmacy Access Law After Governor Declines to Act on Bill
Upcoming Federal Elections Will Significantly Impact 340B Legislative Agenda, Say 340B Hospital Lobbyist, Drug Industry Analyst
Advocates March on Capitol Hill to ‘Defend 340B’ Amid D.C. Heat Wave
Navigating State-Level Regulations to Safeguard Your 340B Program
Matsui’s 340B PATIENTS Act Gains 5 Democratic Co-Sponsors Ahead of 340B Health Lobby Days
Pharma-Linked Conservative Nonprofit Launches Ad Campaign to ‘Stop the Feeding Frenzy’ in 340B
Drug Industry Takes Issue with IRA’s Drug Negotiation Guidance
New Hampshire Enacts Law to Bar PBMs, Payers from ‘Discriminating Against’ 340B Providers
Apotex to Issue Refunds to 340B Covered Entities
340B Providers Take Issue with CMS Draft Guidance on IRA Implementation Calling It “Problematic, Unworkable and Inconsistent”
Astellas Suspends its Contract Pharmacy Restrictions in More States; BMS and Sanofi Also Announce State Exemptions
TPA Fees: Before You Sign on the Dotted Line
West Virginia AG, Hospital Groups Fight Novartis’ Lawsuit to Block State 340B Contract Pharmacy Access Law
AbbVie, AstraZeneca Sue Minnesota Over Contract Pharmacy Access Law
Texas Hospitals Ask Judge to Block HHS’ DSH Calculation Rule That Impacts 340B Eligibility
Kimberly Lott, Vice President of Patient Care Coordination, AuthorityRx
340B Coalition Conference Keynote: Program Faces ‘Progress Amid Challenges’
AbbVie, AstraZeneca Challenge Kansas’ New Contract Pharmacy Access Law
Federal Judge Denies Drugmakers’ Bids to Block Mississippi’s New 340B Contract Pharmacy Access Law
Missouri GOP Lawmaker Slams State AG’s ‘Irresponsible’ Claims Linking 340B Bill to Abortion As Governor’s Decision Looms
Supreme Court ‘Chevron’ Ruling Increases Pressure on Congress to Act on 340B But Unlikely to Immediately Impact Program Oversight
Viatris Becomes 37th Manufacturer to Place Restrictions on 340B Contract Pharmacy Use; Policy Applies to Hospitals and Health Centers
More Drugmakers Exempt States from Contract Pharmacy Restrictions as Four New State Laws Take Effect
Delaware Legislature Passes Anti-Discrimination Protections for 340B Providers from PBMs but Drug Manufacturer Restrictions Remain
Hospital Groups Urge Federal Court to Uphold Maryland’s 340B Contract Pharmacy Access Law
Hospitals in Texas and Other States Sue HHS Over DSH Calculation Changes That Impact 340B Eligibility
How to Leverage AI for Enhanced 340B Program Management: Learn More on 9/25 at 1PM ET
►
June (63)
New York Times Sues HRSA To Release 340B Data, Communications Between Office of Pharmacy Affairs and Apexus Leaders; Information Could Be Released Soon
Just Days Before New Laws Go Into Effect, GSK, Pfizer Exempt Additional States from Contract Pharmacy Restrictions
Navigating HRSA 340B Program Audits
Health Centers Fear ‘Collateral Damage’ From New Manufacturer Restrictions on Wholly-Owned Pharmacies
Health Centers Urge Federal Appeals Court to Reverse Dismissal of Suit Alleging Drugmaker Collusion on Contract Pharmacy Restrictions
California Hospital Association Pans ASAP 340B-Endorsed Bill, Encourages Congress to Support 340B PATIENTS Act
Nick Gnadt, Director of Pharmacy Professional Services, SpendMend
Expert Tip from Cervey
Key West Virginia Lawmaker Considering Legal Action Against Anti-340B PAC Taking Credit for his Election Loss
IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels
Michigan Hospitals, Former Lawmaker Target State Contract Pharmacy Protection Bill Ahead of Summer Recess
PhRMA Asks Federal Judge to Block Enforcement of Maryland’s New 340B Contract Pharmacy Access Law
Lilly Adds Significant New Restrictions on 340B Contract Pharmacy Access; Alleges Lack of Oversight by HRSA, Pharmacies and TPAs
Lilly Posts 340B Refund Notice for Insulin Product Humulin
It’s Official: Long-Awaited Final 340B ADR Rule Takes Effect, But Findings Still Distant
Senate Companion Bill Introduced to Expand 340B Eligibility to Certain Rural, Outpatient Hospitals
CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry
GAO Reissues Recommendations to Improve 340B Compliance, Medicare Financial Stability
Higher Court Already Rejected AstraZeneca's Claim on Arkansas 340B Contract Pharmacy Law, State Attorney Tells Federal Judge
Hospital Groups Bash Novartis’ ‘Whiplash-Inducing’ Arguments in Mississippi 340B Contract Pharmacy Lawsuit
COLUMN: After 340B Hearing and New Bills Emerging; The Likely Path Forward
Mesfin Tegenu, Founder & CEO, RxParadigm
Expert Tip from Sectyr, LLC
Major Bipartisan Senate 340B Overhaul Could be Introduced by August
Group Representing Large Community Health Centers Slams 340B Bill Endorsed by NACHC and PhRMA
Advanced 340B Education: Staying Informed and Empowered
Delaware House Passes 340B Contract Pharmacy Access Bill that Adds Reporting Requirements, Removes Protections for Hospitals
Despite Unanimously Passing Senate, Rhode Island Fails to Pass Contract Pharmacy Protection Bill
In Op-Ed for Prominent Local Publication, Virginia Health Center Leader Pans Governor for Vetoing State 340B Protection Bill
Three Things Hospitals and Grantees Need to Know About HRSA’s 340B New Administrative Dispute Resolution Rule
Sanofi Sues HHS, HRSA for Contract Details Between Covered Entities, Pharmacies
In Stinging Op-Ed, West Virginia Senate Leader Bashes Drug Industry and Rejects Efforts to Politicize 340B Program
Super PAC with Dark Money Ties Launches New Anti-340B Ad
Range of Motives Likely Behind Surge in Drugmaker Contract Pharmacy Changes, Say Provider Advisers
Draft Senate Drug Shortages Bill Sparks Stakeholder Debate over 340B Provisions
Supreme Court to Review Case that Could Result in More Hospitals Qualifying for 340B Program
Jason Atlas, Senior Vice President, Pharmacy Operations, Maxor National Pharmacy Services
Expert Tip from RxStrategies
Federal Judge Presses Drug Industry on Preemption Arguments During Key Hearing on Louisiana 340B Law
Organon Ends or Loosens 340B Contract Pharmacy Restrictions in Four More States
Merck Fully Exempts West Virginia Providers From 340B Contract Pharmacy Restrictions
Bausch & Lomb Becomes 35th Manufacturer to Impose Contract Pharmacy Restrictions, Policy Applies to All 340B Entities
Alkermes Is 36th Drugmaker to Implement Contract Pharmacy Restrictions, Sanofi Tightens Policy
Michigan Lawmakers, Witnesses Spar Over 340B Contract Pharmacy Access Bill in Key Hearing
Mount Sinai Reports 340B Pharmacy Revenue Losses in Early 2024
340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups
Five Manufacturers Announce Refunds to 340B Providers
Key House Hearing Intensifies Debate on 340B’s Future Amid Multiple Major Reform Efforts
Minnesota Is Seventh State to Enact 340B Contract Pharmacy Law, State Also Expands Covered Entity Reporting
New York Unlikely to Move 340B Contract Pharmacy, PBM Protections Bill in 2024, Sponsors Say
Novartis Follows PhRMA in Seeking to Block Mississippi 340B Contract Pharmacy Law
BMS Requires Re-Designation of 340B Contract Pharmacies and New Requirements Intended to Prevent Alternative Distribution Models
Sobi Becomes 34th Drugmaker to Implement Contract Pharmacy Restrictions, Exelixis Tightens Contract Pharmacy Policy
Expert Tip from The Alinea Group
In Key Hearing, GOP Lawmakers Raise Concerns About 340B Growth and Hospital Use While Democrats Urge Caution
Today’s 340B Congressional Hearing Will Include Multiple 340B Critics, Leading Hospital and Health Center Advocates
Vertex is First to Offer Contract Pharmacy Policy Exemptions to Several States; GSK Restores Discounts To WV Providers
Are You Prepared for an Office of Pharmacy Affairs (OPA) Audit?
Two Drug Industry Lawsuits Challenge West Virginia’s 340B Contract Pharmacy Access Law
UCB is 26th Drugmaker to Exempt Arkansas Providers from Contract Pharmacy Restrictions
Sandoz Adds Drug to 340B Contract Pharmacy Restrictions
OPA to Hold June 11 Webinar on Final ADR Rule
Column: Momentum Continues in States on Contract Pharmacy Access
►
May (62)
PhRMA Sues Mississippi Over New 340B Contract Pharmacy Law
RWC-340B Slams ASAP 340B Bill as ‘Dangerous to Public Health’
ASAP 340B-Backed Bill Would Override State Laws, Could Hurt Contract Pharmacy Agreements, Critics Warn
Novartis Asks Federal Court to Block New Maryland 340B Contract Pharmacy Law
340B Critic, Health Center Leader Among Witnesses at Upcoming 340B Hearing
Expert Tip from Avita Care Solutions
Key House Oversight Subcommittee to Hold Hearing on 340B Next Tuesday
Rhode Island Senate Unanimously Passes Amended 340B Contract Pharmacy Protection Bill
SUSTAIN 340B -The Imperative for a Clearinghouse to Strengthen the 340B Program
New Hampshire Legislature Clears Bill Barring Certain 340B-PBM Policies
Ohio Community Health Center CEOs, Lawmakers Urge Passage of State Contract Pharmacy Protection Bill
Congressional Researchers Provide Contract Pharmacy Report on 340B as Legislators Mull Bills
Bayer Adds Prostate Cancer Drug to Contract Pharmacy Restrictions
No Adverse Findings in First HRSA Drugmaker Audit of 2024
ASAP 340B-Backed Bill Introduced in House
Appeals Court Contract Pharmacy Restrictions Decision Leaves Unanswered Questions, Ups Pressure for Legislative Action
CMS Drops ‘Stacking’ Proposal Which Could Have Boosted 340B Savings
Guidance on 340B ESP Use and Management
340B Hospitals Prescribe Part D Drugs to a Much Higher Share of Vulnerable Populations, Says Hospital-Backed Report
Teva Adds 40th Drug to Contract Pharmacy Restriction Policy
Curtis Frazier, Director, The Alinea Group
Appeals Court Approves Drugmakers’ Federal 340B Contract Pharmacy Restrictions But Leaves Open Possibility of Enforcement Against Stricter Policies
Minnesota Legislature Clears Contract Pharmacy Access Bill But Enforcement Measures Dropped At Last Moment
Ohio Senator Introduces 340B Contract Pharmacy Access Bill in State Legislature
PBM is not a 4-letter word: How an independent PBM and an integrated pharmacy strategy provides value for your organization
New Super PAC Targets GOP 340B Supporters, Takes Disputed Credit for Key West Virginia Lawmaker’s Primary Loss
Novo Nordisk To Provide Refunds on Ozempic and Three Other Drugs to 340B Entities
340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading
340B Hospitals Should Consider Internal Pharmacies, Selective Contracting, Says Consulting Group
Virginia Governor Vetoes 340B Contract Pharmacy Access Law that Nearly Unanimously Passed State Legislature
On Final Day of Session, Missouri House Passes 340B Contract Pharmacy Access Bill, Sends to Governor’s Desk
Kansas Governor Rejects Provision to Delay New 340B Contract Pharmacy Protections
Maryland Is Sixth State to Enact 340B Contract Pharmacy Access Law
CVS Cites 340B Contract Pharmacy Restrictions in 19% Income Drop in Its Pharmacy Services
Federal Court Sets April 2025 Trial for AstraZeneca’s Arkansas 340B Law Challenge Amid State Enforcement Actions
340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds
Four States May Act on 340B Contract Pharmacy Access Bills this Week
Draft Senate Bill Would Pay Hospitals to Stockpile Certain Generic Drugs if They Forgo 340B Discounts, Meet New Contracting Requirements
2024 Provider Audits Begin with No Adverse Findings
Health System Appeal of False Claims Suit Against Drugmakers For Alleged 340B Overcharges Allowed to Move Forward
House Committee Clears Telehealth Medicare Extension Bill with PBM 340B Provision
Missouri House Committees Advance 340B Contract Pharmacy Access Bill as Legislative Session Nears End
Spring Cleaning of Your 340B Program
IRA Draft Guidance Leaves 340B Details Unclear
U.S. Drug Spending Increased 14 Percent in 2023; Clinic, Hospital Trends Diverge
NC Treasurer Report Suggests 340B Hospitals Overcharged State Health Plan, Hospitals Pan the Findings
340B Hospital Groups Ask MedPAC to Oppose Part B Rate Cut
340B Webinar – It’s a Risky Business: Risk Mitigation and 340B Program Compliance
Pfizer Exempts Arkansas Hospitals from All Contract Pharmacy Restrictions
Delaware Lawmakers Introduce 340B Contract Pharmacy Access, PBM Payment Bill
Study Finds Newer 340B Public Hospitals More Likely to Increase Unprofitable Service Lines Than Newer Non-Profit Hospitals
Eight More Provider Audits Closed with Corrective Action Plans in Latest HRSA Audit Findings
Novo to Extend Contract Pharmacy Restrictions to Grantees But Allow Them to Keep Access Under Conditions; Company Also Modifies Hospital Policy
Appeals Court Rejects PhRMA’s Request for a Full Panel Rehearing of Arkansas 340B Contract Pharmacy Case
Arkansas Enforcing 340B Contract Pharmacy Access Law Against AstraZeneca
Takeda Loosens Contract Pharmacy Restrictions on Arkansas Hospitals
Federal Bill Introduced to Expand 340B Eligibility to Outpatient-Focused Rural Emergency Hospitals
340B Program Critics, Supporters Target States
Group Critical of Medicare Negotiation and 340B Program Suggests 340B Providers May Avoid IRA Negotiated Lower-Cost Drugs
Troy Polan, Chief Information Officer, Avita Care Solutions
Expert Tip from Hudson Headwaters 340B
In Victory for Drug Industry, Kansas Legislature Pauses New 340B Contract Pharmacy Law, Sending Issue Back to the Governor
►
April (68)
Missouri Senate Overwhelmingly Passes 340B Contract Pharmacy Bill; New Kansas Law Expected to Face Setback Today
Louisiana AG, Health Centers Defend 340B Contract Pharmacy Law in Response to Drugmaker Suit
Instead of Dismissing Medicare Advantage 340B Case, Judge Allows Hospitals to Amend
Twenty-One Percent of 340B Hospitals Will Not Receive Lump Sum Payments: Research
Cosette Pharmaceuticals Offers 340B Provider Refunds on 38 Drugs
Kansas is Fifth State to Enact 340B Contract Pharmacy Access Law
Key Senator Says 340B Overhaul Bill Could Be Introduced Next Month, But Some are Skeptical of Short Turnaround
Bausch Health Becomes 22nd Drugmaker to End or Loosen 340B Contract Pharmacy Restrictions in Arkansas
CBO Recommendation: Restrict 340B Access to Get Hospitals to Join ACOs
Small Business Group Whose Messaging Mirrors Drug Industry Takes Aim at 340B in New Video, Social Media Posts
Takeda Issues Refunds to 340B Providers for 28 Drugs
Expert Tip from Red Chip Enterprises
340B Lobbying Continues Rapid Pace Including by Big Name Firms
Former Sen. Pryor Dies, Remembered for Key Role Helping to Enact 340B Law
Attorneys Expect Many Filings under Newly Reconstituted 340B Dispute Resolution Process
Drug Industry Vendor, Free-Market Legal Non-Profit Echo PhRMA’s Call for Appeals Court to Rehear Arkansas 340B Contract Pharmacy Case
Maine Issues Draft Rule for 340B Hospital Reporting Requirements with New Data, Enforcement Provisions
Novartis to Refund Covered Entities After Adjusting 340B Ceiling Prices for 100-Plus Products
COLUMN: Despite 340B Opponents’ Unprecedented Tactics, Many States Progress on Contract Pharmacy Protection Legislation
Providers Generally Supportive, PhRMA Pans Final 340B Dispute Resolution Rule
Key Senator Says 340B Overhaul May Clear Congress in End-of-Year Package
Virginia Senate Democrats Narrowly Reject Governor’s Amendment to 340B Contract Pharmacy Access Bill; Bill is Back in Youngkin’s Court
340B Contract Pharmacy Access Bill Clears Missouri House but Faces Tougher Path in Senate
AbbVie, BI Agree to Lift 340B Contract Pharmacy Restrictions in Arkansas, Making It 21 Manufacturers to End or Loosen Restrictions
340B Contract Pharmacy Protection Bill Introduced in NY Senate; Lawmakers Target Other 340B Matters
Merck Adds Biologic to Contract Pharmacy Restrictions
CMS Does Not Address Lump Sum Payments for 340B Hospitals in Latest Medicare Advantage Policies But Might in 2025
California Initiative Targeting Nation’s Largest HIV Provider Submits Enough Signatures to Qualify for Ballot
HRSA Issues Final Regulations Revamping Process to Resolve Disputes Between 340B Providers and Manufacturers
Expert Tip from The Craneware Group
Virginia Legislature to Act This Week on Governor’s Amendment to 340B Contract Pharmacy Access Bill
Mississippi Hospitals, Health Centers Applaud Passage of 340B Contract Pharmacy Access Bill
Tennessee Governor Signs Bill Targeting 340B In-Kind Funding
Appeals Court Judges Press Both AHF, Apexus When Considering Dismissal Appeal
Humana Seeks Dismissal of Medicare Advantage 340B Underpayment Suit by Health System
MedPAC Analysis Estimates Medicare Part B Payments to 340B Hospitals are Significantly Higher than Ceiling Prices
Mississippi Becomes Fourth State to Enact 340B Contract Pharmacy Access Law
Conservative Ad Blitz Urges GOP Opposition to 340B, Praises Virginia Governor’s Drug Industry-Friendly Amendment
White House Completes Review of Final Rule for 340B Dispute Process, Release Expected Soon
340B Webinar—340B Legislation: Navigating Changes, Championing a Better Future
PhRMA Asks Full Appeals Court to Rehear Arkansas 340B Contract Pharmacy Case
AbbVie Replies to Louisiana’s Request for Court to Expedite Decision on Contract Pharmacy Law
Survey Finds FQHC Prescribers May Need More Education on 340B Program
Brandon Patchett, Senior Director of Pharmacy-Clinical Services, AIDS Healthcare Foundation
Expert Tip from Maxor
Virginia Governor Amends 340B Contract Pharmacy Access Bill to Delay Enactment, Add Reporting Measures in Move Denounced by Health Centers
HRSA Names Britton As New Leader of Office Overseeing 340B Program
South Carolina Lawmaker Introduces 340B Contract Pharmacy Access, PBM Reimbursement Bill
AstraZeneca’s Lawsuit Against Arkansas’ 340B Contract Pharmacy Law Reassigned to Judge Who Previously Upheld It
Oregon Enacts 340B Anti-Discrimination Protections in PBM Regulations
Manufacturer Refunds to 340B Providers Have Steadily Increased Since 2019, Says Analysis
Teva Adds Blood Therapy Drug to Hospital Contract Pharmacy Restrictions
Hospitals Raise Concerns on Biden Drug Shortage Proposal
Maryland, Kansas Send 340B Contract Pharmacy Access Bills to Their Governors
Mississippi Legislature Sends 340B Contract Pharmacy Protection Bill to The Governor
Tennessee Bill Targeting 340B In-Kind Funding Heads to Governor’s Desk
Bridging the primary care gap: The role of in-house pharmacies in today’s healthcare marketplace
340B Stakeholders Clash on Patient Definition, 340B Spending Requirements in Comments on Senate ‘Group of Six’ Draft Overhaul
Hospitals Say HRSA Violated Federal Rulemaking in 340B Child Site Waiver Reversal
Genentech Officially Issues Contract Pharmacy Restrictions
AbbVie Adds Cancer Drug to Contract Pharmacy Restriction Policy
Contract Pharmacies Have Proliferated, Conservative Group Says, Citing Data from Pharma-Funded Think Tank
Sectyr
Four More Drugmakers to End 340B Contract Pharmacy Restrictions in Arkansas Following Appeals Court Decision
Sumitomo Is Thirty-Second Company to Implement Contract Pharmacy Restrictions
Astellas Adds Second Drug to 340B Contract Pharmacy Restrictions
Amgen, J&J to Issue Refunds on High-Selling Drugs to 340B Providers
Estimated 340B Revenue Exceeded Charity Care Spending for 85% of DSH Hospitals, Says Pharma-backed Group
►
March (58)
West Virginia Providers Praise Newly Passed State 340B Contract Pharmacy Protection Law
Mississippi Senate Committee Approves State House’s 340B Contract Pharmacy, PBM Bill
Veronica Brisco: A Leading Voice for Those with HIV and AIDS
As Deadline Approaches, First Stakeholders Respond to Senate Group of Six Draft 340B Overhaul
Gaps in Hospital Financial Data Limit 340B Transparency, Analysis Says
Three 340B Terminations, Seven Paybacks to Manufacturers in Latest Provider Audit Findings
Mark Ogunsusi, Associate, Powers Law Firm
West Virginia Becomes Third State to Enact 340B Contract Pharmacy Protection Law
Kansas State Lawmakers Pass 340B Contract Pharmacy Protections in Separate Budget Bills But Face Resistance from House Speaker and Certain Advocacy Groups
As Arkansas Prepares to Enforce 340B Contract Pharmacy Law, Major Drugmaker Files Suit and PhRMA Plans to Seek 8th Circuit Rehearing
Leveraging Cash Cards to Amplify Your Patient Impact
Influential House GOP Group Calls for Major Medicaid Cuts and 340B Revenue to ‘Go Where Intended’
Judge Dismisses Health System’s Penny Pricing Coordination Lawsuit Against Drugmakers
CPS
Senate, House Appropriators Agree on Budget for Office of Pharmacy Affairs but Have Different Priorities
Two More Drugmakers End 340B Contract Pharmacy Restrictions in Arkansas After Appeals Court Decision
Key Considerations for the SUSTAIN 340B Act
Connecticut, Minnesota Join 20 Other States with 340B Contract Pharmacy Bills Introduced This Session
Hawaii Lawmakers Urge State Health Department to Protect 340B
California Ballot Initiative Targets Big 340B Provider Serving HIV Population
Jaclyn Hahn, Director of Pharmacy, Ravin Consultants
Two More Drug Companies Restore 340B Contract Pharmacy Access in Arkansas After Court Decision; Enforcement Action Imminent Against Others
Maryland House Unanimously Passes 340B Contract Pharmacy Bill
Two Reports Critique Financial Dynamics of 340B Program
340B Hospitals’ Low-Income Prostate Cancer Patients Had Better Adherence
Mississippi House Passes 340B Contract Pharmacy Bill, Two Days After Senate Passes Similar Bill
Imminent Enforcement of Arkansas 340B Contract Pharmacy Law to Follow Court Decision Upholding It
Mississippi Senate Unanimously Passes 340B Contract Pharmacy Bill After Similar Legislation Dies in Florida
For Covered Entities, Integrated Care is No Longer an Option
340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report
U.C. Berkeley Researcher Proposes 340B Be Limited to the Indigent or that Providers Pass on their Discounts to Insurance Industry
HRSA Urges Federal Court to Reject Health Systems’ Challenge to 340B Child Site Registration Policy Reversal
Column: Key Takeaways from the SUSTAIN 340B Act and Things to Consider When Weighing In (Part 2)
Expert Tip from Cervey
Joel Wright, President of Pharmacy Services, Maxor National Pharmacy Services
Long-Awaited Federal Bill to Protect Contract Pharmacy Arrangements Introduced
In Key Decision That Could Have National Implications, Federal Appellate Court Upholds Arkansas 340B Contract Pharmacy Protection Law
Genentech Is Thirty-first Company to Implement Contract Pharmacy Restrictions
Biden Budget Request Keeps OPA Funding Flat
As Conservative Media Campaign Continues, Hospital Group Demands Removal of Ads Linking 340B to Illegal Immigration
New Hampshire 340B PBM Bill Passes Senate
Minnesota Lawmakers Introduce More Expansive 340B Provider Reporting Bills
West Virginia, Kentucky Legislative Chambers Pass 340B Contract Pharmacy Bills; Hospital Group Demands TV Stations Remove Ad
As Virginia Contract Pharmacy Bill Decision Nears, Conservative Media Reports GOP Voter Opposition, Ties 340B to Immigration Growth
Rhode Island Is Twentieth State to Introduce 340B Contract Pharmacy Legislation
Making the Most of Your 340B Program with a Comprehensive Pharmacy Strategy
South Dakota Governor Signs More Expansive 340B PBM Bill Into Law
Hospital Groups Slam AbbVie in Legal Battle Over Louisiana’s 340B Contract Pharmacy Law
Massachusetts to Bar Managed Medicaid Payments for GLP-1 Drugs for 340B Patients
Genentech Offers 10 Years of Refunds on High-Selling Drug, Multi-Year on Another; Merck to Give Single-Quarter Refunds
Chris Creamer, Chief Pharmacy Officer, Avita Care Solutions
Expert Tip from Apexus
CMS Directs Contractors to Provide Accelerated Payments as Part of Change Healthcare Cyber Attack Response
Dark Money Group Ominously Warns That 340B Used to ‘Launder Your Money,’ Contributes to Immigration Crisis
340B Contract Pharmacy Bills Advance in Mississippi, Missouri Bill to Get Second Hearing Tomorrow
Minnesota Finalizes 340B Provider Reporting Rules, Data Submission to Start April 1
Liquidia Becomes 30th Manufacturer to Limit Access to 340B Pricing in Contract Pharmacy Setting
Virginia Legislature Passes 340B Contract Pharmacy Bill, Sends to Governor’s Desk
►
February (60)
340B Contract Pharmacy Bills Die in Oregon, Utah; Oklahoma Bills Clear Committees in Both Chambers
100 Days and Counting: ADR Final Rule Still Under White House Review
Visante Webinar: 340B Current Issues and Policy Update
Idaho Becomes Nineteenth State to Introduce a 340B Contract Pharmacy Bill
Takeda Adds Drug to 340B Contract Pharmacy Restrictions
HRSA Lacks Authority to Reverse 340B Child Site Registration Policy, Hospital Group Tells Court
Expert Tip from Sectyr, LLC
Amgen Extends Contract Pharmacy Restrictions to Grantees, Receives Early Pushback
Cybersecurity Disruption of Major Claims Processor Continues to Affect 340B Providers
Part 2 of 2: Understanding the Top Five Challenges Facing Health Center Pharmacies Today
New Hampshire Senate to Vote on 340B PBM Bill; Key Massachusetts State Committee Approves 340B Payment Bill
No Louisiana Move to ‘Investigate or Enforce’ Its 340B Contract Pharmacy Law, AG Tells Federal Judge
Oregon House to Vote Today on 340B Contract Pharmacy Bill
DSH Hospitals Are Using 340B in ‘Margin-Motivated Ways,’ Says Research Review
Column: Key Takeaways from Senate Group of Six Draft 340B Bill (Part 1)
Alex Homkey, Business Development Manager, Hudson Headwaters 340B
340B ESP New Data Request Raises Concerns About Overreach
South Dakota Legislature Clears New PBM 340B Bill; Missouri Debates 340B Bills; Kentucky Contract Pharmacy Bill Advances
Part 1 of 2: Understanding the Top Five Challenges Facing Health Center Pharmacies Today
Soon After Governor Proposes 340B Provider Reporting Legislation, Connecticut Senate Introduces Similar Bill
Two 340B Site Terminations, One Payback to Manufacturers in Latest Provider Audit Findings
Expert Tip from Ravin Consultants
340B Contract Pharmacy Bills Introduced in Utah, Kansas, New York; Committees Approve Bills in Oregon, Oklahoma
Amid Double Digit 2023 Growth in 340B, NACHC Urges Federal Over State Reform
Reflecting on Winter Coalition 2024
AIDS Group Protests Health Center-Drug Industry Alliance Outside NACHC Policy Forum
Health System, Drugmakers Battle Over Dismissal Request in 340B Penny Pricing Fraud Suit
FTC, HHS Seek Comments on Role of GPOs, Wholesalers on Generic Drug Shortages
PhRMA Washington Post Advertorial Highlights Data Critical of 340B Program
Citing U.S. Supreme Court Decision, Health System Sues Medicare Advantage Plan for Past 340B Payments
Republican Heavyweights Enter Race to Lead House Committee that Oversees 340B
PhRMA Map Highlights State-Specific Extent of Hospitals’ Contract Pharmacy Usage
Expert Tip From CPS Solutions
Bucshon Calls for 340B Hospital Transparency at NACHC Policy Forum
Virginia State Senate Unanimously Passes 340B Contract Pharmacy Protections
Connecticut Governor Proposes 340B Provider Reporting Legislation, Faces Pushback from Health Centers
Oregon 340B Contract Pharmacy Bill Moves Toward Vote, Illinois Introduces Its Own Bill
User Fees in Senate Group of Six Bill Raise Provider Concerns But Unlikely To Scuttle Bill
AHA Pans NEJM Study on 340B Price Mark Ups, Lead Author Fires Back
340B Consulting Firm Visante Garners PE Investment, Makes Several Promotions
340B Arises Briefly in Much-Anticipated Senate Hearing on High Prescription Drug Prices
Maryland Bills Introduced to Bar 340B Contract Pharmacy Restrictions
Hospital Groups Urge Supreme Court to Review DSH Payment Case with 340B Implications
Multiple Bills Introduced in Missouri to Protect 340B Providers from Alleged Discriminatory Practices
Hospital Groups Key 2024 Priorities Include Contract Pharmacy Protections Among Other 340B Goals
Broad Stakeholder Support for Senate Group of Six Draft 340B Overhaul
340B Lobbying Reaches Record Levels in 2023
Essential Practices for HRSA Audit Preparedness
Federal Judge Rules for Diabetes Drugmakers in 340B Antitrust Case, Health Center Plans Appeal
Mississippi Bill Introduced to Bar 340B Contract Pharmacy Restrictions, PBM Underpayments
California Hospital Reaches $2.1 Million Settlement Over Alleged 340B Overbilling
GSK Posts 340B Refund Notice on High-Revenue Asthma Treatment
Highly Anticipated Draft 340B Bill Released by Bipartisan Senate Gang of Six
Genesis Ruling Creates Legal, Regulatory Uncertainty for 340B, Says Attorney Panel
Two 340B Terminations, One Payback to Manufacturers in Latest Provider Audit Findings
Potential Senate Flip May Increase 340B Scrutiny, But Congressional 340B Action Unlikely in 2024, Say 340B Advocate, Drug Industry Analyst
Tennessee Bills Introduced to Regulate 340B Funding for Certain STD Clinics
AIDS Group Holds Protest Against NACHC-PhRMA Partnership
340B Hospital Critics Ramp Up Efforts on Capitol Hill and in Media
Ravin Consultants
►
January (49)
Senior HRSA Official Doubles Down on Agency’s 340B Patient Definition in Wake of Genesis Ruling
Former Sen. Cassidy Aide, Trump Administration Executive Criticizes Requiring More Hospital 340B Reporting
Genesis Decision Expected to Increase 340B Scripts, Provider-Owned Pharmacies, Says Contractor to Drug Manufacturers and Former Apexus Staffer
Prepping for HRSA Audits
Health Systems, HRSA Spar in Federal Court Over 340B Registration Policy Reversal
340B Hospitals Had Largest Markups of High-Cost Infused Drugs: Study
GSK, Vertex Offer Refunds to 340B Providers
COLUMN: Action on 340B Contract Pharmacies Turns to the States
Genesis CEO Praises Court Decision, Blasts HRSA, NACHC, State Primary Care Association
Amid Possible Coming Enforcement, PhRMA Again Asks Court to Block Louisiana’s 340B Contract Pharmacy Law
Arkansas Looks to Amend Temporary Contract Pharmacy Agreement with Novo Nordisk
Arizona State Senators Introduce Latest 340B Contract Pharmacy Bill
HIV/AIDS Group Continues Legal Fight with Apexus Over 340B Prime Vendor Contract
340B Provider-Drugmaker Lobbying Group Adds Two More Manufacturers
High-Ranking GOP Lawmakers Introduce Bills to Quantify 340B Use Among ‘Noncitizens’
340B Health System’s Suit Against Drugmakers Seeks to Recover ‘Hundreds of Millions in Overpayments'
New Medicaid Policy Change Could Reduce 340B Savings, Cause Drug Discontinuations, Warn Stakeholders
Iowa 340B Contract Pharmacy Bill Introduced; Companion Bills Debut in West Virginia, Oklahoma
$7.8 Billion in Refunds from Underpayments to 340B Hospitals Begin to Roll In
Latest Cassidy Probe Adds to Growing Scrutiny of 340B Contract Pharmacies, TPAs
AbbVie Pushes to Block Louisiana 340B Contract Law, New State AG Takes Office
Senator Cassidy Expands 340B Inquiry to Two Major Contract Pharmacies
Two More States Introduce 340B Contract Pharmacy Protection Bills
Drug Makers Issue Record Number of 340B Refunds in 2023, Merck First to Refund in 2024
Unlocking the Value of 340B Consultants: Their Roles and Responsibilities
Takeda to Expand 340B Contract Pharmacy Restrictions
HRSA Announces 340B Webinar for Grantees Before Upcoming Recertification Begins
Rhode Island Bills Introduced to Bar PBM and Medicaid 340B Underpayments
Three More States Introduce 340B Contract Pharmacy Protection Bills
First 340B Provider Reporting Bill of the Year Introduced in Indiana
340B Webinar—State of 340B in 2024: Biggest Developments Expected this Year
AHA Warns of ‘Adverse Impact’ from Lack of 340B Provisions in New MA Rule
Expert Tip from Visante
Key GOP House Member Active on 340B Matters to Retire
Nebraska Bill Introduced to Protect 340B Contract Pharmacy Arrangements
Visante's Top 10 Issues Facing Health System Pharmacy for 2024
Health System Pays $7.25 Million in Settlement of 340B-Involved Kickback Allegations, without Liability Findings
2024 340B Contract Pharmacy Outlook: Expect More State Than Federal Action, Say Attorneys and Lobbyists
Novo Says Arkansas Agreement ‘Preserves It’s Position’; More Manufacturer Deals in the Works
Federal Government Passes on Appealing Key Patient Definition Ruling
Two 340B Terminations, Two Paybacks to Manufacturers in Latest Provider Audit Findings
2024 Congressional 340B Outlook: Overhaul Unlikely Without Major Legal Developments, Senate Deal
Top 10 Most Read 340B Report Articles in 2023
Expert Tip from RxStrategies
Novo Nordisk, Arkansas Reach Temporary Deal Amid Contract Pharmacy Fight
Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies
Hospital Groups Urge Federal Court to Dismiss Drug Industry Suit Against Louisiana Law
J&J Offers Refunds on Blockbuster Drug, Other Manufacturers Update NDCs
2023 Contract Pharmacy Developments: Surging Restrictions, State Law Legal Battles
►
2023 (582)
►
December (34)
Louisiana, Health Centers Seek Dismissal of Contract Pharmacy Law Challenge
Critics of 340B Urge Congressional Reforms of the Program
Exploring Key Aspects of the 340B Program
A Tribute to Our Founding Editor in Chief from the Publisher and CEO
Column: Hospitals Are Not the Only 340B Providers Under Scrutiny
Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts
CMS Defers Decision on Adding 340B Modifiers for Part D Drugs
Implementing for Success
DeGette Seen as Possible Successor to Eshoo as Top Dem on House E&C Health Subcommittee
Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions
HRSA Unveils Web Page with Patient Definition Compliance Resources, Guidance
340B Dispute Resolution Coming This Month, White House Says
Minnesota Issues Draft Guidance Implementing 340B Provider Reporting Requirements
Michigan to Increase Medicaid Payment for 340B Hospitals, Adds Reporting Requirements
Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs
House Passes Healthcare Bill with 340B Provider Reporting Requirements
Legislation ‘Is Coming’ to Address Contract Pharmacy Restrictions, Hospital Advocate Says
Missouri State Senator to Reintroduce 340B Contract Pharmacy, PBM Protection Bill
Wisconsin Assembly Bill Introduced to Bar PBM Practices Against 340B Providers
Drugmakers Highlight 340B Developments in Earnings Calls
Federal 340B Leader Moves On After 21 Months
House Committee Approves PBM Transparency Bill with 340B Provision
Unlocking Greater 340B Savings
Amid Record Drugmaker Refunds, No Adverse Audit Findings for Teva
Two Senior GOP Senators Suggest 340B Linked to Generic Drug Shortages
New Part B Drug Claims Modifier Requirement for 340B Entities Starts Jan. 1
Cheryl Hetland, VP of 340B Program Management, Avita Care Solutions
Expert Tip From 340Best
Four 340B Terminations, Eight Paybacks to Manufacturers in Latest Provider Audit Findings
Biogen Adds Drug with Narrow Approval to 340B Contract Pharmacy Restrictions
340B Outlook from Capitol Hill, Federal Courts, and the States
Arkansas, Novo Nordisk Clash Over Court’s Role in Contract Pharmacy Law Enforcement
Wisconsin State Senators Introduce PBM 340B Underpayment Bill
340B Reforms Needed, Says Former Presidential Candidate, Drug Industry Consultant
►
November (51)
‘Relentless’ 340B Policy Leader Among Coming Congressional Retirements
Senate Drug Shortage Hearing to Include 340B-Researcher Witnesses
Unlocking the TRUE POTENTIAL of 340B
N.Y. State, Health Centers Seek Brief Pause in Medicaid Drug Benefit Lawsuit
Column: Why the Genesis 340B Patient Definition Court Decision Could Resolve the Contract Pharmacy Impasse
Expert Tip from Apexus
Massachusetts Senate Passes 340B Contract Pharmacy Protections for Certain 340B Grantees, Hospitals
340B Provides Benefits, Needs Reform, Says Literature Review
340B’s Footprint in Medicare Part D Is Growing, Study Says
Sen. Cassidy Mum on Next Steps for 340B Provider Probes
Senate Democrats Seek Drug Pricing Testimony from Three Pharma CEOs
Two Drugmakers Offer Refunds for 340B Overcharges
Michigan Bill Introduced to Protect 340B Contract Pharmacy Arrangements
340B Reforms Urged by Centrist Democrat Group with Drugmaker Ties
Apexus Asks Appeals Court to Affirm Dismissal of Contract Breach Lawsuit
Jazz Pharmaceuticals Posts Refund Notice on HRSA Website
Harrison Garrett, Director of 340B Solutions, Cervey
Expert Tip from Sectyr, LLC
Influential Senator Extends 340B Inquiry to Community Health Centers
Lilly to Exempt Arkansas Providers from New Tighter 340B Contract Pharmacy Restrictions
Court Sets November 2024 Trial for Novo Nordisk’s Arkansas 340B Lawsuit
3 Things Hospitals and Grantees Need to Know about the Genesis Decision
Hospitals to Meet with White House, HHS About 340B Dispute Resolution Process
Improved Non-Profit Hospital Outlook Helped by 340B Payout: Moody’s
Louisiana Provider Group to Intervene in Second 340B Contract Pharmacy Lawsuit
Hospitals Continue Lobbying Push to Extend Pandemic-Era 340B Eligibility Waiver
Novo Nordisk’s 340B Arkansas Lawsuit Reassigned to Judge Who Previously Ruled Against Drugmakers
Louisiana Provider Group to Intervene in 340B Contract Pharmacy Lawsuit
340B Hospitals Charge Higher Commercial Insurance Prices, Says PhRMA Funded Report
Senate Committee Doubles Down on PBM Bill with 340B Spread Pricing Language
Indiana Health Care Leaders Call for 340B Transparency in Op-Ed
GlaxoSmithKline Posts Refund Notice on HRSA Website
Expert Tip from The Craneware Group
Genesis Ruling Could Expand 340B-Eligible Prescriptions, Say Some Attorneys
Hospitals Urge CMS to Reconsider Future Cuts in 340B Lump Sum Final Rule
Lilly Reinstates Tighter 340B Contract Pharmacy Restrictions
HRSA, Hospital Settle Lawsuit Over Termination from 340B
Senate Finance Committee Republicans Oppose CMS Plan to Redefine Medicaid Best Price
Drug Industry Pushes Federal Court to Block Louisiana’s 340B Contract Pharmacy Law Without Trial
Arkansas Urges Federal Court to Reject Novo Nordisk’s Challenge to 340B Contract Pharmacy Law
Federal Judge Rebukes HRSA on 340B Patient Definition
Medicare to Continue ASP Plus 6% for 340B Drugs in 2024
CMS Finalizes 340B Lump Sum Payment, Retains Offsetting Cuts Starting in 2026
Health Systems Sue to Reverse Elimination of Hospital Registration Waiver
Sixth Drugmaker Loosens 340B Contract Pharmacy Restrictions in Arkansas and Louisiana
Upcoming DIR Fee Changes and Their Potential Impact on 340B Programs
340B Lobbying Still on Track for Record Year
New York State Asks Court to Dismiss Challenge to Medicaid Drug Benefit Shift
340B Program May Lead to Lower Charity Care, Says Drug Industry-Backed AIDS Group
Expert Tip from RxStrategies
Sandoz Is 28th Drugmaker to Adopt 340B Contract Pharmacy Restrictions
►
October (57)
GSK Loosens 340B Contract Pharmacy Restrictions in Arkansas and Louisiana
340B Hospital Registration Waiver Withdrawal Could Draw Legal Challenge
Arkansas Defends Enforcement of 340B Contract Pharmacy Law in Drugmaker Suit
340B…or not to B…?
340B Hospitals’ Community Benefit Surges in 2020, Says Hospital-Backed Report
HRSA To End Waiver for Some Offsite 340B Hospital Locations, Provides Grace Period
340B Provider-Genentech Lobbying Group Boosts Spending, Adds Members
4 Ways Hospital Pharmacies Can Unlock Financial Stability
New House Speaker’s 340B Stance Unclear But Supported 340B Hospitals in 2017 Bill
GSK Adds Drug to Contract Pharmacy Restriction List
Louisiana AG Election to Name Enforcer, Defender of 340B Contract Pharmacy Law
Biocon Announces New NDC for its Lantus Biosimilar
Column: Look to The Senate for 340B Action
Expert Tip from Cervey
Genentech Asks Hospitals to Check 340B Split-Billing Software Settings
CMS Seeks Input on Contractor to Prevent 340B, Medicare Maximum Price Duplication
5 Best Practices for Running and Optimizing a Mixed-Use Program
Teva Adds Drug to Hospital Contract Pharmacy Restriction Policy
Congressional Witnesses Urge Medicare 340B Cuts
340B Dispute Resolution Final Rule Enters Last Stage of Regulatory Review
Five More Providers Owe Drugmakers 340B Repayment: Audits
Rural Providers Urge Congress to Extend Pandemic-Era 340B Eligibility Exemptions
10 Questions to Ask Your 340B TPA about Your Contract and Fees
Most 340B DSH Hospitals Provide Below-Average Charity Care, Says Analysis Backed by Critics
Paper Warns on Duplicate Discounts from 340B Ceiling Price, Medicare Maximum Price
Expert Tip From Visante
Eisai’s New 340B Contract Pharmacy Restrictions to Exclude Arkansas and Louisiana
New BMS Contract Pharmacy Policy May Target Hospital Self-Distribution, Say Attorneys
The 340B Program's Current State of Play
Following Response Deadline, Next Steps in Senator’s 340B Probe Unclear
CMS Says 340B Lump Sum Payments Fueled Increase in Part B Premiums, Deductibles
In Study, Health Center’s Patients Laud its 340B Drug Assistance Program
Novo Nordisk Files Suit to Block $100,000 Arkansas Fine for 340B Contract Pharmacy Violations
HHS and HRSA Urge Judge to Reject Health Center’s Take on 340B Patient Definition
Leading Senator, Provider Groups Publish Dueling Reports on Nonprofit Hospitals
HRSA Audit Finds Fourth Drugmaker Owes Refunds
Expert Tip From Verity Solutions
Astellas Ends 340B Contract Pharmacy Restrictions in Arkansas and Louisiana
Hospital Fighting 340B Expulsion Gets Temporary Reprieve
Hospital Advocates Meet with Regulators on Lump Sum Rule
Drugmaker Overcharge Fines for 340B Drugs Reach Nearly $7,000
Rural Organizations, New Congressional Caucus Push 340B Provider Protections
Two Drugmakers Post Refund Notices on HRSA Website
BMS Expands 340B Contract Pharmacy Conditions, Including for Grantees
Hospital Sues to Stop 340B Expulsion Over Alleged Failure to Recertify
Novartis Offering 340B Refunds on Two Diagnostic Radiopharmaceuticals
Understanding the Impact of the Inflation Reduction Act
Speaker Vacancy Paralyzes House, Stalls 340B Legislation
Major Drugmakers Agree to Negotiate Drug Prices with Medicare
Kim Barron, Vice President of Operations, Hudson Headwaters 340B
Expert Tip From AllianceRx Walgreens Pharmacy
Eisai Adopts 340B Contract Pharmacy Restrictions, Pfizer and GSK Update Their Limits
AbbVie Joins Legal Battle Over Louisiana’s 340B Contract Pharmacy Law
Hospitals Defend 340B Compliance Amid Influential Senator’s Investigation
As Medicare Lump Sum Payment Regulation Heads to Finish Line, Critics Weigh In
In Key 340B Patient Definition Case, Hospital Group Accuses Drugmakers of “Numerous Misstatements”
Government Averts Shutdown with 11th Hour Temporary Funding Bill, Speaker McCarthy Faces Historic Challenge
►
September (60)
Ranking GOP Senator on Key Committee Opens Investigation into 340B Hospital Revenue
Looming Government Shutdown Poses 340B Program Uncertainty, Potential Legal Proceeding Slowdown
As Shutdown Looms, Momentum Slows on Bills with Key 340B Changes
3 Ways to Maximize 340B Program Savings
Lilly and Novo Post 340B Refund Notices, Amgen Posts 340B Replenishment Notice
340B Health, Researchers Spar over Biosimilar Study
Transparency, Patient Assistance Requirements Needed in 340B, Say Drugmaker-Backed Groups
Column: Could the States Resolve the Contract Pharmacy Impasse?
Kirsty Gutierrez, Director of Client Success, Ravin Consultants
Expert Tip From CPS
340B Drug Purchases Reached $53.7 Billion in 2022, HRSA Data Show
Hospital 340B Sites increased by 400% Over 11 Years, Analysis Finds
Providers Try a Range of Responses to Manufacturer 340B Contract Pharmacy Restrictions
Expanding 340B Eligibility Could Double Program Size, Says Report
Senate Committee Rejects 340B Amendment to Bipartisan Health Bill
Federal Appeals Court Judges Press Both Sides in Key Hearing on Arkansas 340B Contract Pharmacy Law
Teva Ends 340B Contract Pharmacy Restrictions in Arkansas in Response to State Law
Rural Reality: A Conversation with a Rural Hospital Finance Director about Adapting to 340B Challenges
Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions
One Quarter of HRSA Provider Audits Closed with No Adverse Findings
GOP Scrutinizes Medicare Price Negotiations in House Subcommittee Hearing
Jason Reddish, Principal, Powers Law Firm
Providers Split on 340B Medicaid Provisions in Major House Healthcare Package
AHF Files Appeal Over Its Claim That Apexus Did Not Obtain Sub-Ceiling Discounts
Health Center Challenging 340B Patient Definition Responds to HRSA’s and Drug Companies’ Court Arguments
Uncertain Outlook for GOP Drug Shortages Bill with 340B Provisions
Novo Nordisk Providing 340B Refunds on Blockbuster Drug Ozempic
AHIP Objects to Hospital Efforts to Target Medicare Advantage 340B ‘Windfall’
House Subcommittee Clashes Over 340B Role in Drug Shortages
Louisiana AG Defends State 340B Contract Pharmacy Law Against Drug Industry Lawsuit
340B Health Centers Appeal Loss in California Medicaid Lawsuit
Provider POV: 340B is Critical. We Must Raise Our Voices.
340B Driving Anti-Competitive Health System Tactics, Says Lawsuit
Two More Drugmakers Owe 340B Provider Repayments, HRSA Audits Find
HRSA Grants 340B Enrollment Flexibility in Georgia Due to Hurricane
Expert Tip From Apexus Advanced 340B Operations Certificate Program
Jazz Pharmaceuticals Is 25th Drugmaker to Implement Contract Pharmacy Restrictions
Sanofi Withdraws Some Health Centers’ 340B Pricing at Contract Pharmacies
How to End the HIV Epidemic in One Word: Retention
House Subcommittee to Examine GOP Drug Shortages Bill with 340B Provisions
California Legislature Passes 27th State Restriction on PBM 340B Discrimination
Arkansas Can Enforce 340B Contract Pharmacy Law, State Attorney Tells Appeals Court
Merck Offering Refunds to 340B Covered Entities
Steve Kuperberg, Partner, Feldesman Leifer LLP
Coming Major GOP Healthcare Package Includes 340B Medicaid Provisions
Sources Cited in Drugmakers’ Brief Question Accuracy in High-Profile 340B Patient Definition Case
Connect and Learn at the 340B Grantees Fall Conference
Appeals Court Decision May Threaten Some State Health Plan Regulations, 340B Protections
Janssen Issuing Refunds for 340B Overcharges
HRSA Allows Immediate 340B Enrollment in Florida Due to Hurricane
Heather Erickson, 340B Consultant, CPS Solutions
Expert Tip From Maxor
As CMS Extends Comment Period on 340B Repayments, Hospitals Urge Changes
Provider Groups Oppose 340B Provisions in Committee Chair’s Drug Shortage Bill
Strengthening 340B Program Integrity to Improve Accountability and Confidence
PhRMA to Federal Appeals Court: Arkansas Enforcing 340B Contract Pharmacy Law; Seventh Drugmaker Sues Over IRA
Tolmar Providing Refunds for Five Years of 340B Overcharges
Five Value Pillars for 340B Program Compliance
UCB Tightens 340B Contract Pharmacy Restrictions for Hospitals
EMD Serono Extends Hospital 340B Contract Pharmacy Conditions to All Products
►
August (52)
Arkansas Initiates First-in-the-Nation Enforcement of 340B Contract Pharmacy Law
Little Chance Congress Clears 340B Overhaul in 2023—Unless Courts Act, Say Lobbyists
“ChatGPT, I Need 340B Help”
HRSA Again Selects Bizzell Group to Audit 340B Covered Entities
Boehringer Ingelheim Sues to Block Medicare Price Negotiations
Expert Tip From Hudson Headwaters 340B
Health Centers Fear Losing 340B Pricing From Sanofi at Multiple Contract Pharmacies
Lawmaker Sponsoring 340B Transparency Bill Honored by PhRMA-Provider Group
Covered Entities and the 340B Program: Avoid Common Pitfalls of the Medicaid Exclusion File
Federal Judge Accepts Drug Company Filings in 340B Patient Definition Case
HHS Announces First 10 Drugs Eligible for Medicare Price Negotiations
AstraZeneca Sues to Block Medicare Price Negotiations Over ‘Unintended Consequences’ to Orphan Drug Development
Health Center Leaders Urge Boards to Push State, Federal Support of 340B
Liz Trenkel, Senior Compliance Specialist, RPh Innovations
Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition
AHA Urges Dropping Bill Language to Exclude Generic Injectables from 340B
Provider-PhRMA Coalition Adds Civil Rights Group
From the Publisher & CEO: The Big Question on the Minds of Every 340B Stakeholder
Federal Appeals Court Schedules Arguments in Challenge to Arkansas Contract Pharmacy Law
Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds
340B Drugs Among Those at Tornado-Hit Facility Requiring Direct Purchase
Three Terminations, 10 Paybacks to Manufacturers in HRSA’s 2023 Pending Provider Audits
Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds
HHS Asks Court to Deny Injunction Against Medicare Drug Price Negotiations
Pfizer Changes Costly Cardiac Drugs’ Access Rules for 340B Providers
Two Drug Makers Post Manufacturer Notices for 340B Overcharges
HRSA Allows Immediate 340B Enrollment in Hawaii Due to Wildfires
340B Lobbying Activity Experiences Historic Surge
Major Drug Company Sues Louisiana Over 340B Contract Pharmacy Law
340B Program Does Not Improve Hospital Inpatient Care for Medically Underserved Patients, HHS-Funded Study Finds
GSK Giving 340B Entities Refunds Again for Asthma Medicine Purchases
Enforceability of State Contract Pharmacy Laws Uncertain Amid Legal Challenges
AHA Warns of “Legal Consequences” from Proposed Cuts to Fund 340B Lump Sum Payments
Let For-Profit Hospitals Into 340B, Trade Association Tells Senators
Five Major Drug Makers Oppose Health Center’s Legal Challenge to 340B Patient Definition
Medicare DSH Changes Will Cut 340B Access, Draw Legal Challenge, Say Attorneys
Making the Case for Your 340B Program
Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program
Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis
Merck Loosens 340B Contract Pharmacy Restrictions in Two States as Louisiana Law Takes Effect
Senate Appropriators Urge HRSA to Penalize Drug Makers That Impose 340B Contract Pharmacy Conditions
Look to Specialty Pharmacy to Address 340B Challenges
Bipartisan AG Group Urges Senate to Protect 340B Contract Pharmacy Agreements, Require Provider Transparency
On Deadline Day for Senate Feedback, Researchers in JAMA Urge 340B Provider Reporting, Tightening Eligibility, Preventing Drug Overcharges
Lee Harris, Principal, Sales and Strategic Relations, SunRx
Louisiana’s New 340B Contract Pharmacy Law Goes Into Effect Today; PhRMA Sues and Teva Suspends its Restrictions in the State
Claims Clearinghouse, Strengthening HRSA Among Few Consensus Areas in Responses to Senate 340B Overhaul Effort
House E&C GOP Leaders' Draft Bill Would Exempt Sterile Generic Injectables from 340B Pricing Requirements
HRSA Tells Federal Court it Still Stands by its 340B Patient Definition in Closely Watched Case
Do 340B Lump Sum Payments Underscore Need for More Transparency or Are They Unrelated?
Amid Historic Financial Challenges, 340B Proposed Payments Will ‘Make a Difference’ for Some Hospitals’ Budgets, Says Rating Official
Broad Support Emerges for Adding Duplicate Discount Modifiers to Medicaid Cards
►
July (48)
Senate Panel Passes PBM Reform Bill With Medicaid Drug Payment Limits and 340B Reporting Requirements
100+ Health Centers and Groups Sign Pro-340C Letter to Congress
Covered Entities' and Manufacturers' 340B Summit
HRSA Sends Previously Audited 340B Hospital a Second Follow-up Compliance Letter
CMS’s 340B Hospital Repayment Plan Leaves Medicare Advantage Cuts Untouched
340B Recertification for Hospitals Starts Aug. 14
Amgen, Vertex, and AstraZeneca Post 340B Refund and Replenishment Public Notices
340B Report Publisher and CEO to Providers: New 340B Reporting Requirements are Inevitable
Tracy Jones, Midwest Regional Director & National Director of Advocacy, AIDS Healthcare Foundation
Large Drug Maker, Big Health System, and Influential Health Center Jointly Lobbying for Senate Bipartisan 340B Initiative
Senate Panel Seems to Be on Track To Vote Tomorrow on Bill With Language that 340B Providers Oppose
RWC-340B Backs Senate Bill That Would Let Ryan White Clinics Cover HIV Prevention Drugs and Services
NACHC Names Prominent Physician with Health Center and HRSA Experience as its Leader
340B May Cause Providers to Buy More Expensive HIV Prevention Drugs, Conservative Policy Group Says
Generic Drugmaker Amring Providing Refunds for 340B Overcharges
NY FQHCs Receive $135 Million to Offset State’s 340B Medicaid Shift, While Other Providers Wait
Johnson & Johnson, Astellas Each Sue to Stop Medicare Drug Price Negotiations
Expert Tip From Sectyr
Senate Panel Could Mark Up PBM Bill Next Week With Spread Pricing Language That 340B Providers Oppose
U.S. House Energy & Commerce Committee Drafting Drug Shortages Bill
Judge Rejects 340B Provider Challenge to California Medicaid Drug Payment Shift
Commentary in NEJM Backs Making Hospitals Report Gross Profits from 340B
340B Is “Off the Rails,” Civil Rights Leader Chavis Says in Nationally Syndicated Op-Ed
Medicare Part B Keeping Default Pay Rate for 340B Drugs, Says OPPS Proposed Rule
U.S. Chamber of Commerce Asks Court to Pause Medicare Drug Price Negotiations
In What Could be a First, Drug Maker Gives Providers Deadline to Request 340B Overcharge Refunds
UPDATED: Contract Pharmacy Restrictions Cut $1.5 Billion in 340B Hospital Revenue, $8.4 Billion More Endangered, Report Says
Some 340B Hospitals Might Get Less Than Expected Under Fix for Illegal Medicare Drug Payment Cuts
Providers March to Capitol Hill for Second Straight Year to ‘Defend 340B’
Tiffany Taylor, Director of Compliance, Allies in Hope, Inc. and 2023 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
Adverse Appellate Rulings in Contract Pharmacy Cases Could Be “Truly Catastrophic,” 340B Health’s Testoni Says
Providers Celebrate 340B Medicare Drug Payment Fix, Object to How It’s Funded
Ease 340B Requirements for Generic Drugs to Ease Shortages, Trade Group Tells Congressional Committee Chairs
As Congress Weighs 340B Changes, Leading HIV/AIDS Group Urges it to Support the Program
Matthew Krah, Senior Solutions Engagement Director, Verity Solutions
CMS Proposes $9 Billion in Lump Sum Payments to Reimburse Hospitals for Past 340B Part B Drug Payment Cuts
White House Clears CMS to Issue Proposed Fix for 340B Hospital Part B Drug Payment Cuts
Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings
Is Your Technology a Triple Threat That Boosts Your Mission?
340B Prime Vendor Apexus and AIDS Healthcare Foundation Are Trying to Settle Lawsuit Over Sub-Ceiling Price Discounts
340B Issues Remain Unresolved in Latest CMS Medicare Drug Price Negotiation Guidance
Christopher Cooper, Health Systems Solutions Director, AllianceRx Walgreens Pharmacy
Top Republican on Senate HELP Committee Calls for 340B Transparency and Accountability Action
Group Seeking New 340C Program for Grantees and Rural Hospitals Is Ramping Up Advocacy
Tips for Specialty Pharmacy Success
NRHA Launches New 340B Policy and Advocacy Campaign
340B Report Bolsters Editorial Staff with Two Key Hires
UPDATED: Astellas and AstraZeneca Make 340B Contract Pharmacy Moves
►
June (53)
U.S. Rep. Matsui Expected to File 340B Contract Pharmacy Bill in Connection with 340B Conference
Maine Enacts Nation’s Second 340B Provider Transparency Law
340B Outlook from Capitol Hill and the States
ASAP 340B, PhRMA and NACHC’s 340B Alliance, Challenges Hospitals to “Join the Conversation”
Sandy Brower, Director, Quality/Risk Management and 340B Program Coordinator for Bonner General Hospital and 2023 Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
Get PBMs to Squeeze 340B Drugs Harder, “Playbook” Advises Employers
Hospital Groups to CMS: Don’t Rob Some Hospitals to Repay 340B Hospitals for Your Illegal Drug Payment Cuts
Hospitals Spend More on Cancer Drugs for Insured Patients After Enrolling in 340B, JAMA Study Finds
California Senate Passes PBM 340B Nondiscrimination Bill
340B Report Publisher and CEO: What Two State Legislative Sessions Tell Us About the State of 340B Policy
Boehringer Ingelheim Extends 340B Contract Pharmacy Conditions to All Covered Entities
Health Center Invokes 340B Contract Pharmacy Ruling in Key 340B Patient Definition Federal Lawsuit
Minnesota Imposes Nation’s First 340B Covered Entity Reporting Requirements
State Roundup: Lots of 340B Action as Many Legislatures Conclude Sessions
PhRMA and Bristol Myers Squibb Sue Separately To Stop Medicare Drug Price Negotiation
Expert Tip From Cloudmed
U.S. Senate “Group of Six” Elaborates on Why it Wants 340B Stakeholder Input
RWC-340B Slams Gilead-funded Study of 340B Grantee Entities
AHA Urges HRSA to Restore Policy Allowing Earlier Use of 340B Drugs in Hospital Outpatient Clinics
MedPAC Still Backs Cutting 340B Hospitals’ Part B Drug Payments
340B Registration for Third Quarter of 2023 Will Run from July 1 to July 17
Six Democratic and Republican U.S. Senators Ask 340B Stakeholders for “Bipartisan Policy Solutions”
Congressional Republicans Want to Know if 340B Plays a Role in Drug Shortages
JAMA Study Says, When it Comes to Insulin, Pharma’s Gross-to-Net Problem Is Mostly its Own Doing
Maintaining the Patient Experience and Continuity of Care
First Merck, Now Chamber of Commerce Sues to Stop Medicare Drug Price Negotiation
Tanya Dudley, Senior Product Manager for Sentrex contract pharmacy management application, The Craneware Group
Expert Tip From Signify
Nonprofit Hospitals’ Profits Are Up But Charity Care Is Not, Study Finds
Federal Court Hearing Next Week on California’s Medicaid Drug Benefit Transfer; Bill Introduced in N.J. with 340B Implications
Nevada Legislature Passes 340B Nondiscrimination Bill
Bausch Health Tightens its Conditions on 340B Pricing to All Covered Entities
Exelixis Extends 340B Price Conditions to Hospitals’ Wholly Owned Contract Pharmacies
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies
Final Connecticut Bill Excludes Both 340B Transparency and Contract Pharmacy Provisions
Protest Held at Indiana Congressman’s State Office Against His 340B Hospital Reporting Bill
New Studies on 340B and Rural Cancer Care and 340B Contract Pharmacy Demographics
Merck Sues to Stop Medicare Drug Price Negotiation
CMS Creates New Group to Lead Medicaid Managed Care Policy
Expert Tip From Verity Solutions
Connecticut Looks Like It Will Be First State to Require 340B Covered Entity Reporting
Louisiana Is Poised to be Second State to Enact 340B Contract Pharmacy Law
New York State Appeals Dismissal of 340B Antitrust Case Against CVS
HHS, HRSA Tell Judge They Don’t Know When They’ll Replace 340B Dispute Resolution Process
HRSA Posts Four Manufacturer Notices to 340B Entities
HRSA Allows Immediate 340B Enrollment in Guam Due to Typhoon
ASAP 340B and AHA Outreach Documents Are Polar Opposites on 340B DSH Hospitals
Merck to Pay Refunds for 340B Overcharges in Q1 and Q2 2020
The Potential Domino Effect of Tennessee's HIV Federal Funding Cuts
Massachusetts 340B Nondiscrimination Bills Would Restore Program’s Intent, Sponsor Says
Expert Tip From SunRx
Organon Is the 22nd Drug Maker to Impose Limits on 340B Contract Pharmacy
Novo Nordisk Tightens its 340B Contract Pharmacy Policy Today, Others Possible
►
May (49)
CMS Is a Step Closer to Saying How It Will Fix Medicare Drug Payment Cuts for 340B Hospitals
CMS Proposes Rules That Addresses 340B Duplicate Discounts in Medicaid Managed Care
How 340B Covered Entities are Disrupting the PBM and Preferred Pharmacy Landscape for Community Health Plans
340B Providers Don’t Systematically Over-Prescribe Brand Drugs for Profit, JAMA Study Says
Arkansas 340B Contract Pharmacy Law Trespasses on Federal “Closed System,” PhRMA Tells Court
340B Report Publisher and CEO: Is a Contract Pharmacy Breakthrough at Hand?
House GOP Rejects Democrats’ Push to Link 340B Transparency and Contract Pharmacy
340B Grantees Need More Scrutiny as Drug Margins Rise, Gilead-funded Study Says
3 Tips for Navigating the Current 340B Environment
340B Advocacy Group CV340B Plans March on Capitol Hill July 12
Maria Kossilos, Associate Chief Pharmacy Officer, Cambridge Health Alliance
House E&C Committee Passes Two Bills That Would Create 340B Entity Reporting Requirements
House E&C Committee to Vote Tomorrow on Bills That Would Bring Big Changes to 340B
Health Centers’ Antitrust Case Over 340B Contract Pharmacy Limits Will be Argued July 20
Providers Added Immediately to 340B Under COVID-19 Flexibility Are Not Losing their Eligibility, HRSA Confirms
Bills Filed in New York to Help 340B Providers Hurt by Medicaid Drug Benefit Transfer
In “Nasty Surprise,” House Subcommittee Votes to Require Billing Medicaid MCOs at Cost Plus Dispensing Fee for Drugs, Including 340B
House E&C Full Committee May Vote on 340B Transparency Bill as Soon as Next Week
Amgen and GSK Announce Refunds for 340B Overcharges - May 23
Expert Tip From Alinea Group
House Subcommittee Votes on Party Lines to Impose Reporting Requirements on 340B DSH Hospitals & Potentially Other Covered Entities
House Subcommittee Says it Will Markup 340B Transparency Bill Tomorrow
New Evidence that HRSA in 2020 Declared Permanent a 340B Policy it Abruptly Ended Last Week
Sanofi Late Yesterday Tightened Restrictions on 340B Pricing
Merck Toughens Conditions on 340B Pricing for Hospitals and Health Centers Effective June 12
HRSA and Prime Vendor Yank FAQs About 340B Use in Hospital Child Sites, and GAO Issues a New 340B Study
340B Did Not Arise in Senate Committee Today, But Might in House Subcommittee Next Week
Two States Move Closer to Enacting Laws Banning 340B Contract Pharmacy Restrictions
Janssen to Pay Refunds for 340B Overcharges in Q2 2020
Minh Hoang, Director of 340B Hospital Operations, Cloudmed
Expert Tip From RxStrategies
“This Is Bananas”: Hospitals Irate About HRSA’s Snap Decision to End 340B Patient Eligibility Clarification
U.S. House Panel Not Expected to Markup 340B Legislation at Hearing Next Week
Lifestar, Chartwell Announce Refunds for Q4 2022 340B Overcharges
Jamila ("Jam") Seibel, Director, Alinea Group
HRSA Says COVID Flexibility About Dispensing 340B Drugs in Unregistered Hospital Offsite Locations Will End Thursday
In Shift, 340B Health and AHA Now Say They Back Congressional Action on 340B Contract Pharmacy
340B Sales Growth Rate Softened for Second Straight Year, Data Show
340B Health Centers Urge N.Y. State Trial Court to Block Medicaid Pharmacy Transfer
Ex-GOP Congressman Burton Slams Current GOP Rep. Rosendale’s 340B Bill
Exelixis Puts 45-Day Limit on Requests to Reclassify Past Sales as 340B Purchases
Anthony Esgro, Director of 340B Programs, Signify Health
Expert Tip From Avita Care Solutions
340B-Related Amendment Might Be Offered to PBM Reform Bill That Senate Panel Is Trying to Mark Up Today
Judge Denies Health Center’s Request for More Government Files in 340B Patient Definition Case
340B Stifles Biosimilar Uptake, Study in Health Affairs Says
340B COVID-19 Flexibilities Will End May 11 as Public Health Emergency Expires
Astellas Notifies 340B Entities for Second Time in 2023 About a Change in Drug’s NDC
Bayer Announces Tougher Limits on 340B Pricing for Hospitals
►
April (46)
AHA Tells House Panel It Opposes New 340B Hospital Reporting Requirements
340B Abuse Claims Raised During House Hearing on Nonprofit Hospitals’ Tax Status
Do it Yourself: 340B Referral Prescription Capture Made Easy
Louisiana Takes Major Step Towards Prohibiting Drug Manufacturer 340B Contract Pharmacy Restrictions
A Cheat Sheet to New Groups that Use “340B” in Their Names
340B Recertification for CDC Grantees Starts May 8
Expert Tip From The Craneware Group
In Surprise Move, Pennsylvania Wants 340B Modifiers on Medicaid Managed Care Drugs
Iowa Set to Enact Nation’s 25th 340B Nondiscrimination Law
Daiichi-Sankyo Offering Refunds for 340B Overcharges on Two Drugs
Fatimah Muhammad, Director, 340B Pharmaceutical Svcs & Drug Replacement, Saint Peter's University Hospital
New 340B Transparency Bill to be Discussed Next Week in House Hearing, U.S. Senate Bills Introduced
HRSA Administrator Open to Congress’ Help Ensuring 340B Accountability and Transparency
Hospitals Urge Fed. Appeals Court to Uphold Novel Ark. Law Protecting 340B Discounts in Contract Pharmacy Setting
Closed Pennsylvania 340B Hospital Sues CVS Health Over 340B TPA Policy
Dual 340B Anti-Discrimination Bills, One Protecting Discounts in Contract Pharmacy Setting, Move Forward in Missouri
California Senate Committee Approves Bill to Protect 340B Providers from Alleged PBM Discrimination
Maureen Huber, Chief Operating Officer, Avita Care Solutions
Expert Tip From Hudson Headwaters 340B
Feds Pass on Asking Full Appeals Court to Reconsider Adverse 340B Contract Pharmacy Ruling and Vacate Enforcement Letters to Three Manufacturers
Lilly Asks Covered Entity to Promptly Repay “Duplicate 340B/Medicaid Discounts”
340B Compliance Issues Requiring Repayment to Manufacturers
New Group 340B Truth Seeks Provider Consensus on Federal Legislation
Louisiana Lawmakers to Address Drug Makers’ and PBMs’ 340B Policies in Thursday Hearing
Calif. Senate Committee to Hold Hearing on 340B Anti-Discrimination Bill Tomorrow
HHS OIG and HRSA Are Mum About 340B Manufacturer Civil Monetary Penalties and Violation Notices
New York State Allots $9 Million in Relief for RWCs Hurt by Medicaid Drug Benefit Transfer but No Funding So Far For Other 340B Entities
340B Policies and Procedures: The Keys to Compliant Savings
New Mexico Governor Signs Bill Protecting 340B Providers from PBM and Payer Discrimination
Calif. Contract Pharmacy Overbilled Medicaid for 340B Drugs, State Appeals Court Holds
Expert Tip From Ravin Consultants
Arkansas and 340B Providers Ask Appeals Court to Back State’s Novel 340B Contract Pharmacy Law
AHA Again Blasts PhRMA and NACHC’s Alliance to Remake 340B
340B Financial Health Check
Senate HELP Panel Likely Leaving 340B Out of Bipartisan Drug Policy Bill That it’s Fast-Tracking
Spanberger and Johnson Reintroduce PROTECT 340B Act in Congress
Novartis to Appeals Court: Our New 340B Contract Pharmacy Policy Doesn’t Affect Our Case Before You
Two GOP Senators Raise Concerns About PBM’s Infringement on 340B Savings in Recent Hearing
Key Takeaways From the 340B Winter Coalition Conference
Maine Becomes Fourth State to Introduce 340B Hospital Transparency Bill
Expert Tip From PharmaForce
Hospitals Shouldn’t Fear 340B Reporting Requirements, House E&C Republicans Say; Democrat Matsui Raises Concern About Scapegoating
New York Implements Medicaid Drug Benefits Transfer, 340B Entities Say Fight Isn’t Over
New Mexico Passes 340B Anti-Discrimination Bill, After Dropping 340B Contract Pharmacy Provisions
Novartis Toughens its Conditions on 340B Pricing for Hospitals
Expert Tip From Visante
►
March (48)
GSK Extends 340B Pricing Conditions to all Covered Entities and all Products
Pfizer Is the Second Drug Maker This Week to Tighten Limits on 340B Sales to Hospitals
ASAP 340B Hires Executive Director and Publishes FAQ in Response to Questions and Criticism
AIDS Healthcare Foundation Protests Against PhRMA/NACHC Alliance During 340B Coalition Conference
The Top 5 Marketing Tips for Building Your Patient Base
As April 1 Deadline Looms, NY Health Centers Urge Courts to Stop Medicaid Pharmacy Benefit Transfer
HRSA Allows Immediate 340B Enrollment in Mississippi Due to Tornadoes
HHS Secretary: 340B “Doesn’t Have the Transparency We Need”
AbbVie Puts Squeeze on 340B Pricing for Hospitals Akin to J&J and Amgen’s Recent Moves
U.S. House Panel Debates 340B in Context of Health Care Transparency and Consolidation
RWC-340B Opposes and Hemophilia Alliance Questions PhRMA and NACHC’s Push to Remake 340B
340B Expected to Be Addressed During U.S. House Hearing Today
AHF: Addressing Syphilis Disparities in Franklin County, OH
N.Y. State Health Centers Sue to Stop April 1 Shift of Medicaid Managed Care Drug Benefits to Fee for Service
HRSA Posts Two Drug Manufacturer Notices to 340B Entities
Expert Tip From CPS
Confidential Document Fleshes Out ASAP 340B's Reform Objectives
340B Hospitals Say Pharma’s Contract Pharmacy Policies Are Costing Them “Billions of Dollars”
Four Best Practices for Running Mock Audits
Sean Dickson, Known for 340B Research, Takes Senior Post at Health Insurance Association
Texas House Bill Addresses Medicaid MCO Bias Against 340B Pharmacies
PhRMA Discusses Joint 340B Reform Deal with Health Centers in Interview; Hospital Groups Denounce Plan
Connecticut Governor’s First of Its Kind Three-Pronged 340B Bill Passes Hurdle in Legislature
How to Make the Most Out of the 340B Coalition Conference
340B Registration for Second Quarter of 2023 Begins April 1, with COVID Public Health Emergency Set to Expire in May
Expert Tip From Cervey
Amgen Expands 340B Contract Pharmacy Limits
U.S. House Subcommittee Could Discuss 340B on Two Consecutive Days This Month
MedPAC’s Call to Replace Medicare DSH Formula Could Spill Over into 340B
CMS Announces First Drugs Subject to Medicare Inflation Rebates, Issues Guidance Addressing 340B and Medicare Negotiated Drug Prices
Robin George, Director Health Systems Solutions, AllianceRx Walgreens Pharmacy
HRSA Wants Reporting Requirements on Use of 340B Savings and Compliance and Reporting Requirements on Use of Contract Pharmacies
340B Prime Vendor Apexus Asks Court to Dismiss AIDS Healthcare Foundation’s Breach of Contract Suit
340B Stakeholders Testify on Conn. Governor’s First-of-Its-Kind Multi-Pronged 340B Legislation
Some Provider Groups Slam NACHC and PhRMA’s 340B Plan, Others Say They’re Studying it
U.S. House Subcommittee Expected to Raise 340B During March 28 Hearing
Major Drug Industry and Health Center Groups Unite to Reform 340B for Patients and “True” Safety-Net Providers
N.Y. State Judge Dismisses 340B-Related Antitrust Suit Against CVS
U.S. House Oversight Committee Launches PBM Investigation
Amneal Offering 340B Refunds on Long List of Drugs for Sales Between Q3 2019 and Q3 2022
NACHC Hill Day Document Calls for 340B Reform and Offers Guiding Principles, Key Hill Staffer Joins Organization
Bottom Line, not Altruism, Could be the Main Driver of Lilly’s Insulin Price Cut, Drug Pricing Expert Says
Zydus Pharmaceuticals USA Announces Refunds for 340B Overcharges During 2022
340B Raised Often During Senate Hearing on Community Health Centers
Health Centers and PhRMA Co-Developing 340B Policies, Hospital Group Says
Exclusive: HRSA Asking Hospitals About 340B Patient Definition, 340B Savings, and Using 340B at Child Sites
Verity Presents: 340B Outlook from Capitol Hill and the States
Feds Considering Asking Full Appeals Court to Rehear Case Over AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Policies
►
February (36)
Senate Democratic Whip Durbin: 340B Hasn’t Cut Pharma Profits Dramatically
Arkansas 340B Contract Pharmacy Law “Trespassed on Exclusively Federal Turf,” PhRMA Tells Appeals Court
Judge Pauses PhRMA’s 340B Administrative Dispute Resolution Lawsuit
340B Report Publisher and CEO: Is Hospital Transparency the Key to a Grand Bargain on 340B?
One-Third of Americans Lack a Source of Primary Care and Health Centers Can Close the Gap, Says Report
Key Lawmaker Introduces Bill to Protect NY Health Centers and Clinics from “Hundreds of Millions” in Lost 340B Savings
Calif. Medicaid Drug Benefit Transfer Will Harm Care at 340B Health Centers, National and State Groups Tell Court
RxStrategies' Launches "340B Insider Podcast" Series
340B Hospital Transparency Bill Dies in Indiana
Study Raises Questions About Using 340B Claim Modifiers to Implement Medicare Drug Price Negotiation and Inflation Rebate Provisions
America’s Essential Hospitals Asks HHS to Swiftly Repay 340B Hospitals for Unlawful Medicare Drug Payment Cuts
Iowa Tries Again to End Alleged PBM Bias Against 340B Providers and Pharmacies
J&J Announces Major Expansion of 340B Contract Pharmacy Limits; Pushback Is Likely
Connecticut’s Democratic Governor Wants Hospitals to Report 340B Earnings and Manufacturers to Resume 340B Pricing
Contract Pharmacies: An Integral 340B Component for 30 Years
Baldwin, a 340B Entity Ally, Will Chair Senate Health Appropriations Subcommittee
Scott Carruthers, Chief Pharmacy Officer, AIDS Healthcare Foundation
340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs
Ex-CMS Leader Verma: Big Health Systems Use 340B to Expand Profit and Monopoly Power
CMS Seeks Input on Excluding 340B Drugs from New Medicare Part D Inflation Rebates
Kansas Bill Targets 340B Contract Pharmacy Limits, Rhode Island Bill Targets PBM Policies
Sanders, Asked About Abuse in 340B, Cites His Past Effort to End a Hospital’s Tax Exemption
More Entities Might Share 340B Contract Pharmacy Claims Data if the Process Improves and Actually Restores 340B Pricing, Survey Shows
What's the Secret to 340B and Specialty Pharmacy Provider and Patient Engagement?
Inspector General Advises CMS to Monitor Non-Hospital 340B Entities’ Use of Modifiers on Part B Drug Claims
340B Stakeholders Weigh in on HRSA’s Proposal to Replace 340B Dispute Resolution Process
340B Hospital Physician Affiliated with Free-Market Think Tank Says Abolishing 340B Should be on the Table in Health Affairs Essay
Bernie Sanders Officially Named Chair and Bill Cassidy Ranking Republican of Senate HELP Panel
GSK Announces Refunds for 340B Overcharges on Respiratory Drugs
Andrew Crawford, Senior Vice President, Business Development, Maxor National Pharmacy Services
Drugmakers Urge Appeals Courts to Follow Third Circuit Ruling and Uphold 340B Contract Pharmacy Restrictions
Bayer: 340B “Is Enriching Middlemen Versus Benefitting Patients”
Upcoming End of COVID-19 Emergency Could Prompt HRSA to End or Scale Back 340B Flexibilities
AHA Seeks Meeting with HHS About Repaying 340B Hospitals for Illegal Medicare Drug Reimbursement Cuts
EMD Serono Is the Second Drug Maker Today to Impose Conditions on 340B Contract Pharmacy, and the 21st Overall
Bayer Is the 20th Drug Maker to Impose Conditions on 340B Contract Pharmacy
►
January (48)
The Day After: Stakeholders Take Stock of Third Circuit Court’s 340B Contract Pharmacy Opinion
Virginia House Subcommittee Defeats 340B Hospital Accountability Bill; Rev. Al Sharpton Says Program Direly Needs More Oversight
In Wake of 340B Contract Pharmacy Restrictions, Biosimilars Deserve Consideration
Mississippi Reintroduces Bill to Ban Drug Makers’ 340B Contract Pharmacy Restrictions
Eshoo and Castor Will Be Top Democrats on House E&C Subcommittees Involved in 340B
340B Report Publisher and CEO Slafsky: Three 340B Observations for 2023
Third Circuit Court Rules for Drugmakers in 340B Contract Pharmacy Cases
New York Times 340B Hospital Exposé Leads to a Vote Later Today in a Virginia House Subcommittee
Missouri Lawmakers Try Again to Stop Drug Companies’ 340B Contract Pharmacy Restrictions
Staffing Success for a 340B Pharmacy
New York State Medicaid Drug Benefit Transfer, on Ice for Two Years, Is Back
Guthrie and Griffith, as Expected, Will Helm House E&C Subcommittees Involved in 340B
ShaiAnn Howard, Director, Health Systems Solutions & Decision Science, AllianceRx Walgreens Pharmacy
House GOP Bill Would Stop Additional Hospitals and Child Sites from 340B Enrollment and Make it Harder for Current Hospitals to Remain Eligible
U.S. House Leaders Agree on Committee Ratios: Energy & Commerce Gets to Work
Astellas Notifies 340B Entities About Antifungal’s Updated NDC
End 340B, Commentary in New England Journal of Medicine Suggests
MedPAC Votes to Recommend Ditching Medicare DSH Patient Percentage for Medicare Purposes
The Mpox Outbreak: What a Swift Response Looks Like
Ryan White Clinics for 340B Access Is Dropping its 340B Dispute Resolution Lawsuit
Pennsylvania Rescinds Directive that Contract Pharmacies May Not Dispense 340B Drugs to Medicaid Beneficiaries
Oregon Bill Targets PBM Policies that Discriminate Against 340B Pharmacies
Federal Court Seals HRSA’s Records in Health Center’s 340B Patient Definition Lawsuit
340B Recertification for HRSA and Indian Health Service Grantees Starts Jan. 30
Improve Quality Outcomes with ACOs and 340B
Pennsylvania Says Contract Pharmacies May Not Dispense 340B Drugs to Any Medicaid Beneficiaries
340B Market News: Avita Acquires PrEP-by-Telehealth Provider Q Care Plus
Rhodie Smith, Vice President, Contract Pharmacy Sales, RxStrategies
First 340B-Related Bill of 118th Congress Filed
Nine New Republicans Named to House Committee with 340B Jurisdiction
Visante’s Top 10 Issues in Pharmacy in 2023 for Health Care Providers
Keep 340B Strong, AHA Says in Wall Street Journal Ad
Health System Makes Improvements at 340B Hospital in New York Times Investigation
CMS Announces Medicare Drug Price Negotiation Dates
Breaking: Judge Declines to Order HHS to Promptly Repay 340B Hospitals for Illegal Medicare Part B Drug Reimbursement Cuts
U.S. District Court Orders 340B Report to Destroy and Not Divulge Legally Obtained Information in 340B Patient Definition Case
Congressional Committee Lineups Still in Flux After McCarthy Installed as House Speaker
340B “Overdue for Reform,” Industry Trade Group BIO Says in Blog
CMS Plans in April to Address Potential Remedies for Illegal Drug Payment Cuts for 340B Hospitals
340B Provider Ally Stabenow Will Not Seek Re-Election to U.S. Senate in 2024
340B Pricing: Navigating Pharmacy Discount Programs to Benefit Your Entity & Patients
Janssen Providing Refunds for 340B Overcharges During Q1 2020
William von Oehsen, Principal, Powers Law Firm
Lilly Says 340B Entities Can’t Designate Central Fill Pharmacies as Contract Pharmacies
PhRMA Takes its Fight Against Arkansas 340B Law to Federal Appeals Court
Alcon Providing Refunds for 340B Overcharges on 22 Products
House GOP Leadership Spat Stymies All Action, Including Any on 340B
Office of Pharmacy Affairs Get Slight Funding Bump
►
2022 (512)
►
December (38)
CMS Requiring All 340B Entities to Use Claims Modifiers When Billing Part B for 340B Drugs
Hospital Groups and Brand Drug Industry React to Wall Street Journal’s 340B Hospital Investigation
Top Referral Specialties And Medications Driving 340B Savings
Viatris Providing Credits Due to Problem that Made 340B Pricing Unavailable in August
Private Oncologist Group-Funded Study Models Effects of Using CMS’s Controversial 2020 340B Hospital Drug Cost Survey
Our Top 10 Breaking News Stories of 2022
Wall Street Journal Says Its Investigation of 340B Hospitals Raises Questions about Program’s Growth and Purpose
Breaking: Congress Wants HRSA Briefing on Action to Safeguard 340B Entities’ “Lawful Access to Discounted Drugs”
Amgen Sues HHS in Defense of the Company’s 340B Contract Pharmacy Restrictions
Merck Providing Refunds for 340B Overcharges During Q4 2019, Q3 2021, and Q2 2022
340B Hospitals’ Share of Part B Drug Administration Continues Rising, PhRMA-Funded Study Finds
U.S. Retail Drug Spending Rose 7.8% in 2021, as COVID Eased and Patients Got Care They Postponed
340B Report Analysis: Federal 340B Law Gives States Room to Regulate their Own Drug Distribution Systems, Judge Rules in Arkansas Contract Pharmacy Case
117th Congress Nears End With No 340B Contract Pharmacy Fix Expected
The Time to Step Up Is Now: Advocating for 340B
340B Registration for First Quarter of 2023 Will Run from Jan. 1 to Jan. 17
Breaking: Biogen Announces 340B Contract Pharmacy Restrictions
Breaking: Federal Law Doesn’t Preempt Arkansas’s Novel 340B Contract Pharmacy Law, Judge Rules
Michigan Senate Rejects Attempt to Weaken Recent 340B Anti-Discrimination Law
340B’s Critics Often Misunderstand its Intent, Ex-House E&C Chair Waxman Says in Health Affairs Commentary
340B Report Publisher and CEO Slafsky: Expect More Attention to 340B in New Congress
Novo Nordisk Announces Third Round of 340B Refunds This Year
Provider of HIV/AIDS Care Refiles Suit Against 340B Prime Vendor
Senior U.S. House Democrat and Republican Say They’re Hopeful Congress Will Act on 340B; Hearings Expected in New Congress
Lilly for the Fifth Time This Year Announces Refunds for 340B Overcharges
Extent of 340B’s Impact on Overall Drug Prices Unclear Due to Lack of Data, Study Finds
Novo Nordisk Updates 340B Contract Pharmacy Policy, Will Allow Claims Submission to 340B ESP
Hospital and Pharmacy Groups Launch Second Pro-340B Ad Campaign This Year
Webinar: 340B Judicial, Legislative and Regulatory Developments
RWC-340B Assessing Dispute Resolution Proposed Rule’s Impact on Its Lawsuit and Current Dispute Resolution Petition
Mike Braun, Key U.S. Senator on 340B Matters, Won’t See Re-Election in 2024
340B Dispute Resolution Proposed Rule Would Eject CMS Staff and HHS Lawyers from Process and Put OPA in Charge
Provider Groups Cite Inaction on 340B Pricing Denials in Their Reactions to Dispute Resolution Proposal
The Importance of Strong Partnerships to Enhance Patient Care, Reduce Costs and Maximize Compliance
AIDS Healthcare Foundation Criticizes Idea of Creating a 340C Program for Non-Hospital Providers
Local Community Group Continues Late Congressman’s Push for 340B Hospital Oversight
HHS Enlists Health Centers in Six-Week COVID Vaccine Drive, GOP Leaders Question Funding and Priorities
Anula Courtis, CEO and Founder, 340Best
►
November (36)
BREAKING: HRSA Proposes Streamlined, Less Trial-like 340B Dispute Resolution Process
CSL Behring Confirms that First Gene Therapy for Hemophilia B Will Be Available at a 340B Price
Health Care as a Human Right? Why Not?
340B Hospitals Use Biosimilars Less Than Others, PhRMA-Commissioned Study Finds
340B Prime Vendor Sued for Allegedly Not Negotiating Sub-Ceiling Pricing on HIV/AIDS Drugs
Arkansas Health System Asks State to Enforce its 340B Contract Pharmacy Law Against Novo Nordisk
Important Operational Insights for Covered Entities Choosing to Access 340B ESP
CMS Defends Delayed Fix for Illegal Medicare Drug Payment Cuts for 340B Hospitals
HRSA Sanctions Manufacturer for Not Issuing Refund for 340B Overcharges
White House Gives HRSA Green Light to Publish Proposed New 340B Dispute Resolution Regulations
A Closer Look at Tuesday’s Arguments in Federal Appeals Court Over the Legality of the 340B Contract Pharmacy Program
Optimize Specialty Pharmacy Outcomes at ASHP Midyear in Las Vegas
With GOP Control of U.S. House, Expect Increased Oversight of 340B Providers
How One Pharmacy Successfully Pivoted to an Entity-Owned Pharmacy to Overcome Mounting 340B Restrictions
Two of Three Appeals Court Judges Question Government’s Stance That Drug Companies May Not Impose Conditions on 340B Sales
Appeals Court To Hear Arguments Today in AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Suits
Hospital Group Says Survey Shows Drug Companies’ 340B Contract Pharmacy Limits Are Harmful
With Democrats Retaining Control of U.S. Senate, Expect New Leadership in Key Committee
340B Law Should Be Amended to Include Emergency-Use COVID-19 Drugs, Health Affairs Opinion Article Says
Fake Lilly Twitter Account Tweets “Insulin Is Free Now,” Temporarily Wiping Billions From Company’s Stock Value
Miles Truesdell, 340Best Board Member
With Party Control of Congress Still Undecided, 340B Providers Lose Some Key Champions but Retain Some Heavy Hitters
MedPAC Is Expected to Make a Policy Recommendation That Could Prompt a Look at 340B Hospital Program Eligibility Criteria
Law Firm Releases Survey of State Action on 340B Amid Mounting Calls for Congressional Action
Arkansas and Providers File Briefs Defending State’s Novel 340B Contract Pharmacy Law in Important Fed. Court Case
Hospital Groups Ask Court Again to Make CMS Promptly Repay 340B Hospitals for Illegally Withheld Medicare Drug Reimbursement
340B TACTICS: Reduce Manufacturer Exclusion Impact + Capture More Claims
GSK and Purdue Pharma Announce New Rounds of Refunds for 340B Overcharges
Hospital Group Blasts CMS for Delaying Redress for Illegal 340B Drug Payments Cuts
Is There a Loophole That Might Let CMS Keep Paying Some Hospital Departments ASP Minus 22.5% for 340B Drugs?
Top 20 Moments in 340B’s History
Alex Hennum, Vice President/General Manager, Macro Helix
CMS Says It Will Announce Sometime Next Year How it Will Repay 340B Hospitals for Five Years of Illegal Drug Reimbursement Cuts
HRSA for Now Will Not Seek More Info from 340B Providers About Ownership of Onsite Pharmacies
Feds and S.C. Health Center Spar Over Center’s Access to Government Info in its 340B Patient Definition Case
HHS Official Under Trump Calls for “Honest Conversation” About 340B at it Reaches Age 30
►
October (36)
Appeals Court Questions Yet Again if it Has Jurisdiction Over Lilly’s 340B Contract Pharmacy Case
Second of Three U.S. Appeals Court Hearings on 340B Contract Pharmacy Is Set for Monday
AIDS Advocates Holding Weeklong Protest Over Gilead’s 340B Contract Pharmacy Restrictions and Changes In Patient Assistance Program
HRSA Cites Almaject for 340B Price Data Lapse, No Sanctions Imposed
Federal Appellate Judges Ask Lawyers, What is a Bona Fide Offer of 340B Pricing?
As Interest in Legislation Grows, Congressional Research Service Issues Back-to-Back Reports on 340B Program
New York State Stands by its 340B-Related Antitrust Claims Against CVS
Your Guide to Navigating 340B ESP
Feds in Mediation with Tenn. Health System that Allegedly Paid for Referrals to Boost 340B Profits
In Key Hearing, Appeals Court Panel Seems to Lean in Favor of Some Drug Manufacturer Conditions on 340B Pricing
HRSA Refers Merck to HHS Inspector General Over its 340B Contract Pharmacy Policy
CMS Says Steps to End Medicare Drug Payment Cut for 340B Hospitals Are in Progress
340B COVID-19 Flexibilities Will Continue Through Mid-January
Kalderos Announces New 340B Drug Claims Verification Tool
NACHC Seeks Meeting with Becerra About 340B Contract Pharmacy Restrictions After “Inexplicable” ADR Decision
HRSA Tells AbbVie and Amgen Their 340B Contract Pharmacy Restrictions Are Illegal
Twice as Many Providers as in May Are Submitting 340B Drug Claims Data to 340B ESP, Pharma Contractor Says
Effort Launched to Create 340C—a Separate Drug Discount Program for Health Centers and Possibly Other Entities
Congressman Who Represents Virginia 340B Hospital Profiled by New York Times Is Exploring Oversight and Legislation
With Elections Nearing, Biden Is Ordering HHS to do More to Drive Drug Costs Down
BIO CEO McMurry-Heath Steps Down Amid Reported Conflict with Board
Hospital Group Urges MedPAC to Drop Part B Pay-Cut Proposal, Cites 340B Impact
Anthony Velasquez, Chief Product Officer, PharmaForce
PhRMA Makes its Case for Invalidating Arkansas’s First-of-its-Kind 340B Contract Pharmacy Law
Amgen Announces Second Round of Refunds this Year for 340B Overcharges
340B Pharmacy Services Company Avita Expands into Clinician and Support Staff Services
Federal Court Clears Way for Medicare to Boost 340B Hospitals’ Part B Drug Payments
340B Report Holding Oct. 28 Webinar on What the Midterm Elections Mean for 340B
CBO Raises Changing 340B Patient Definition to Ease Pressure on Commercial Insurers
Genentech CEO Cites New York Times’ Front Page Story in Appeal for 340B Reforms
Jillian Lichner, Senior Manager of Implementations, 340B Solutions, Maxor National Pharmacy Services
UCB Files 340B Contract Pharmacy Suit Against HHS, the Ninth Company to Do So
U.S. Appeals Court Tentatively Set to Hear Three 340B Contract Pharmacy Cases on Nov. 15
An Innovative Approach to Addressing a Key Social Determinant of Health
New York Times Investigative Story Aftermath: Leading Local Paper Dives into 340B, Emphasizing its Importance for Community Health Centers
HRSA Allows Immediate 340B Enrollment in Florida, South Carolina Due to Hurricane
►
September (46)
Exclusive: HHS OIG Declines to Penalize Drug Manufacturers at This Time Over 340B Contract Pharmacy Restrictions
Groups Representing 340B Hospitals Praise Federal Court Decision Halting Deep Medicare Part B Cuts
Fallout from New York Times’s 340B Investigative Piece Continues as Local Media, Policymakers, and Community Weighs In
Manchin and Braun Call on HHS To Take Immediate Action Against Drug Manufacturers in Contract Pharmacy Battle
CVS Moves to Dismiss New York AG’s Antitrust Suit That Alleges Monopolistic Behavior Related to Wellpartner
Generic/OTC Drug Maker Owes Refunds to 340B Providers, HRSA Audit Shows
National Association of Community Health Centers Calls On Congress “To Move Urgently” To Tackle 340B Contract Pharmacy Impasse “Before It’s Too Late”
New York Times Front Page Story on 340B Program Causes Shockwaves
340B HIV Providers Warn of "Drug Industry Disinformation Campaign"
PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism
Walgreens Takes Full Ownership of 340B Specialty Pharmacy Company Shields Health Solutions
Amber Mitchell, Senior Solution Engagement Executive, Sentry Data Systems, now The Craneware Group
Feds Tell Court They Oppose Health Center’s Effort to Sink 340B Patient Definition
340B Report Exclusive: GAO Is Asking Hospitals if They Share 340B Savings with Low-Income Uninsured Patients at Contract Pharmacies
New Rule Gives Force to Ground-Breaking State 340B Contract Pharmacy Law
Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases
Court Upholds $23 Million Judgement Against CVS Caremark for Unfair Pharmacy Reimbursement
HRSA Grants 340B Enrollment Flexibility in Puerto Rico Due to Hurricane
Feds Tell Judge They Accept that Part B Drug Payment Cuts in 2020-22 Were Unlawful
Arkansas’ Novel 340B Contract Pharmacy Law Doesn’t Conflict with Federal Law, State Officials Tell Court
Are You Ready to See Pharmacy in a Whole New Light?
Judge Issues Stay in Merck’s 340B Contract Pharmacy Lawsuit
340B Provider Groups Decry Federal Judge’s PrEP Coverage Decision
Navigating the 340B Program for Maximum Benefits and Guaranteed Compliance
Federal Appeals Court Will Hear Arguments in Lilly’s 340B Contract Pharmacy Suit on Oct. 31
CMS Gets Conflicting Advice About Unwinding Drug Payment Cuts for 340B Hospitals
Unichem Says 340B Audit Found it Overcharged Just Two Entities and Must Repay Them Just $110.20
U.S. Uninsured Rate Dipped Last Year, Census Bureau Says
Jason Mills, Senior Consultant, 340B Solutions, CPS
Judge Dismisses 340B Contract Pharmacy-Related Antitrust Claims Against Insulin Manufacturers
Comments Due Today on How Feds Should Rectify Drug Payment Cuts for 340B Hospitals
Health Policy Think Tank Commonwealth Fund Issues 340B Primer
In Violation of ‘Spirit’ of Anti-Kickback Law, Drug Manufacturer Donations to Patient Assistance Charities Result in Bigger Profits, Study Finds
Restoring 340B Hospitals’ Part B Drug Payments Would Cut Net Outpatient Payments for 80% of Hospitals, Private Cancer Doctor-Funded Study Finds
Senior HRSA Official Pedley to Deliver ASHP’s Prestigious William A. Zellmer Lecture Next Week
Maximizing 340B Program Value with Specialty Medication Access
Judge Continues Stay in 340B Dispute Resolution Lawsuit
White House Seeks $27 Billion for COVID-19 and Monkeypox Response
Federal Judge Asks About Overdue Status Report in 340B Dispute Resolution Case
MedPAC May Back a Cut in Part B Drug Payments, This Time Not for 340B Hospitals Only
Federal Health Officials with Significant 340B History Play Major Roles in CDC Revamp
Becerra Says Legislation Is Needed to Strengthen HHS Authority to Address 340B Contract Pharmacy Pricing Denials
340B Report Exclusive: CMS May Owe 340B Hospitals More Money Than Anticipated
340B Stakeholders Seek Clarity on HRSA Flexibilities as COVID-19 Public Health Emergency Winds Down
GOP House Leaders Want Answers from Becerra on Implementation and Impact of Medicare Drug Price Negotiation
Kristin Fox-Smith, SVP, Visante
►
August (44)
With Just a Month to Go, HRSA Releases First FY 2022 Manufacturer 340B Audit Result
Advocates Urge Feds to Allow Distressed Rural Hospitals to Remain 340B Eligible
Financial Outlook Deteriorating for Nonprofit Hospitals in 2022 and Beyond, Credit Rating Agency Says
Key Takeaways from New Medicare Law and 340B Implications
Ivy Espendez, Director, 340B Compliance & Audit, Sentry Data Systems, now the Craneware Group
Exclusive: HRSA Hasn’t Posted a Limited Distribution Plan Notice to 340B Entities in Almost a Year. No One Outside of the Agency Knows Why.
Judge Orders HHS to Respond to Ruling Letting Health Center Challenge 340B Patient Definition
House GOP Lawmaker Reintroduces Bill to Collect and Report 340B Hospital Data
Sixth Group of 340B Hospitals Sues HHS Over Medicare Drug Payment Cuts
Colleen DiClaudio, President and Founder, Nuvem
GSK Announces Third Round of Refunds This Year for 340B Overcharges
In Show of Support, House GOP Conference Chair Stefanik Visits 340B Contract Pharmacy
340B Webinar: Optimize Your 340B Program and Cut Costs in 30 Minutes
HHS Has ‘No Real Plan to Stop Underpaying’ 340B Hospitals’ Part B Claims, Groups Tell Court
Apexus Solutions to Support 340B Program Compliance
Development May Expedite Ruling on Widely Watched State Law Intended to Require Rx Manufacturers to Provide 340B Discounts
Appeals Court Will Hear Oral Arguments in October in Novartis and United Therapeutics’ 340B Contract Pharmacy Suit
Melissa Palchak Opraseuth, SVP Operations, Cloudmed, an R1 company
Feds File Briefs in Response to AstraZeneca and Lilly Arguments in Key 340B Cases
Medicare and Hep C Patients Would Save Over $100 Million if Plan Sponsors Adopted Generic Use, OIG Finds
Federal Data Show 340B Sales Hit $43.9 Billion in 2021, Drug Industry Consultant Reports
At Request of Senior GOP Lawmakers, GAO Studying Law That Gave Relief to Hospitals Forced Out of 340B Due to COVID-19
Health Centers Criticize Kaiser Health News Story About Profit Margins
Bill Giving Medicare Drug-Price Negotiating Power Set to Become Law
Let Us Decide How to Remedy Illegal Drug Payment Cut for 340B Hospitals, HHS Asks Judge
Senate Panel Wants HRSA to Tell How It Has Responded to Drug Makers’ 340B Pricing Denials
340B Providers Won’t Share in $183 Million Damages Award Against Lilly for Misstating AMP
HHS Tells Judge Unwinding Medicare Payment Cuts for 340B Drugs Needs Caution, Not Haste
HRSA Grants 340B Enrollment Flexibility in Kentucky Due to Floods
Senate Rejects 340B-Related Amendment to Major Drug Pricing and Climate Change Bill
Senate Passes Historic Bill that Would Let Medicare Negotiate Some Drugs’ Prices
Vermont Passes Bill Enhancing 340B Anti-Discriminatory Protections but Measure Aimed at Drug Manufacturers Fails
Civica Rx Subsidiary Offers First Low-Cost Generic Drug in Outpatient Pharmacy Space, with More to Come
Boehringer Ingelheim Expands its 340B Drug Pricing Restrictions
Providers March on U.S. Capitol Grounds to “Defend 340B”
Ex-Surgeon General Adams Urges 340B Entities to Publicize Program’s Benefits
340B Hospitals Ask Judge to Stop Part B Drug Payment Cuts Immediately
New PhRMA-Funded Study Questions 340B Hospital Eligibility Yardstick
William A. Riley, Senior Director, Health Systems Solutions & Decision Science, AllianceRx Walgreens Pharmacy
Purdue Pharma Is Providing 340B Refunds Spanning 16 Years of Overcharges
340B Coalition Conference Speakers to Providers: Give Us Your Success Stories
340B Hospitals Treat Bigger Shares of Underserved Patients than Non-340B Hospitals and Clinics, Study Finds
Senate Democrats Say They Are on Track to Pass Drug Pricing Bill Before Aug. 8
Scott LaChute, Vice President of Operations, Verity Solutions
►
July (49)
HRSA Unveils New 340B Contract Pharmacy Services Webpage That Is Silent on Manufacturer Obligations
New York State Sues CVS for Allegedly Forcing 340B Entities to Use Third Party Administrator Wellpartner
A Blizzard in July (of Briefs in 340B Contract Pharmacy Lawsuits)
Hospitals Want Expedited Order Stopping Medicare Payment Cuts for 340B Drugs
Essential 340B Reporting
AIDS Healthcare Foundation Calls PhRMA’s Washington Post 340B Ad “Hypocritical Slander”
First-Ever Conference Just for 340B Grantee Entities Set for October in Denver
Part 2: “There Have Been Challenges Up and Down the Supply Chain”: The View from the Field and Responses from Stakeholders
Part 1: “I Don’t Want to Go Through This Nightmare”: Frustrations Grow Over Significant Delays in Restoration of 340B Pricing for Contract Pharmacy Purchases
Biden Administration Kills Trump-era Rules Casting Doubt on HHS Guidance and Enforcement Actions
Hospital Pharmacy Leaders Call Staff Shortages, Vendor Management Their Biggest Operational Challenges
340B Report Publisher and CEO: What to Expect Following Midterm Elections
The Frustrating Realities of 340B ESP Data Submission
War Over Hearts and Minds in 340B Battle Heats Up as Hospitals Launch Their Own Campaign
U.S. Supreme Court Formally Notifies Lower Court and Parties About its Decision Striking Down Medicare Part B Drug Payment Cuts for 340B Hospitals
340B Advocacy – Preserving Underserved Health Care in America
340B DSH Hospitals Upped Services to the Poor During Pandemic’s Brutal First Year, 340B Health Says
Senate Democrats Optimistic About Passing Drug Pricing Bill Before August Recess
As Part of New Ad Campaign, PhRMA Buys Full-Page Ad in Washington Post Blasting 340B Hospitals and Pharmacy Chains
Hospital Groups Cheer, Private Cancer Docs Deplore CMS’s Decision to End Deep Cut in 340B Hospitals’ Drug Payments
HRSA's 340B Program Website Gets a New Look
AHF Sues Express Scripts Over Medicare Part D Reimbursement Claw Backs
How One Leading 340B Services Company Has Taken Action to Stay Ahead of the Contract Pharmacy Restrictions Game
181 House Members Prod HHS to Start Fining Drug Makers for “Unlawful” 340B Overcharges Involving Contract Pharmacies
In Big Win For 340B Hospitals, CMS Will Reverse Massive Drug Reimbursement Cut for 2023 and Seeks Input on Potential Remedies for Prior Years
House GOP Task Force Apparently Takes a Pass on Making 340B Recommendations
Feds Ask Appeals Court to Uphold HRSA’s 340B Program Violation Letters to Novo Nordisk and Sanofi
In Effort to Rein in High Prices, Another Big Player Jumps into the Insulin Market
HHS Warns Pharmacies Not to Turn Away Women Requesting Abortion Medication
Shrujal Patel, Managing Partner, The Alinea Group
The Need for a 340B Uninsured Prescription Discount Card Program
Merck Becomes Eighth Drug Maker to Sue HRSA in Defense of 340B Contract Pharmacy Restrictions
PhRMA and J&J File Amicus Briefs in Support of Novartis and United Therapeutics
Senate Democratic Drug Pricing Bill Buoyed by Large Savings Estimate
340B Hospital Annual Recertification Begins Aug. 27
3 Most Common Ways 340B Referral Savings Are Missed
Analysts Still Digesting Senate Democratic Drug Pricing Bill’s 340B Changes
Appropriations Committee Passes Spending Bill with Increase in OPA Funding and Call to Action on Manufacturer Restrictions
View from Capitol Hill Luncheon: Get the Latest Developments in the Ever-Changing 340B Program
100 Congressional Democrats Urge HHS to Use Existing Power to Lower Drug Prices
Hospital Groups Cite Supreme Court Decision in Latest Briefs Backing Feds in Lilly and AstraZeneca 340B Cases
Castle Family Health Centers Supports Excellence in Its 340B Program
Drug Makers’ 340B Overcharging Must Be Addressed, House E&C Democrat Dingell Says During Hearing
Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019
Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation
340B Sales Were $38.8 Billion in 2020, PhRMA-Funded Study Finds
Meet AIDS Healthcare Foundation Pharmacist, and Artist, Alsean Bryant
In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality
Bausch Health Announces 340B Contract Pharmacy Restrictions on All Covered Entities
►
June (48)
House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials
As UCB Reviews HRSA’s 340B Enforcement Letter, Grassley Presses OIG for Answers
Sponsor Halts California Bill to Shield 340B Providers from Manufacturers and PBMs’ Actions
AHA Tells HHS It Wants Prompt Repayment for All Years Hospitals’ Medicare Drug Payments Have Been Cut
Q3 340B Entity Registration Starts Tomorrow
Jessica Rivas, Chief Pharmacy Officer for Big Bend Cares and Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program
HRSA Tells UCB its 340B Contract Pharmacy Policy Is Illegal
Feds Ask Appeals Court to Partially Reverse Ruling on Lilly’s 340B Contract Pharmacy Policy
Clinics Pay Gilead $33 Million to Settle Fraud Claims Involving 340B-Related PrEP Transactions
Supreme Court DSH Calculation Ruling Leaves 340B Status Quo in Place, Experts Say
Schumer Pledges to Hold Senate Vote Soon on New Bill to Make Insulin More Affordable
340B Report Publisher and CEO: Takeaways from Supreme Court’s Part B Cuts Decision
White House Now Says This Is Target Month for New 340B ADR Rule, but Publication Date Remains a Mystery
Bill Would Give HIV/AIDS Clinics More Leeway to Use 340B Savings and Other Program Income
Gilead Adds 45-Day Lookback Clause to its 340B Contract Pharmacy Policy
Top 5 Considerations for Community Health Centers Seeking a Pharmacy Management Partner
Exclusive: 340B Entities Report Unannounced and Unexplained Claims Reversals Involving CVS and Blue Cross Blue Shield
Feds Urge Appeals Court to Overrule Lower Court in AstraZeneca’s 340B Contract Pharmacy Lawsuit
West Virginia Hardens its 340B Anti-discrimination Law to Explicitly Bar 340B Claims Modifiers
PhRMA and Private Oncology Practices Slam PBMs’ Role in 340B in Comments to FTC
NACHC Asks HHS to Swiftly Punish Drug Makers for 340B Pricing Denials Involving Contract Pharmacies
New Study Finds 340B Contract Pharmacy Growth in Affluent and White Neighborhoods, Hospitals Criticize Research
The Supreme Court Aftermath: What Comes Next in Fight Over Medicare Part B Drug Payments to 340B Hospitals?
Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials
NACHC Tells Merck its 340B Contract Pharmacy Policy for Health Centers Can Be Explained by “Only Greed”
U.S. Supreme Court Strikes Down Medicare Part B Drug Payment Cuts for 340B Hospitals in 2018 and 2019
NACHC Hopes Congress Will Pass Laws Protecting 340B Providers This Year
Drug Manufacturer 340B Overcharge Notices Reach New Record, Novo Nordisk Is the Latest
Arizona Lawmakers Pass and Send 340B Anti-discrimination Bill to Governor
HRSA Seeks Comments on Proposed Changes to 340B Program Forms
Health Centers Ask Congress and Biden to Intervene to Protect 340B Savings from Pharma and PBM “Greed”
Community Voices For 340B Holding Aug. 3 March in Washington
Novartis and United Therapeutics File Briefs in Appeals Court in 340B Contract Pharmacy Lawsuits
Congress Turns House Floor to 340B For an Hour
FTC To Investigate PBMs’ Impact on Drug Access and Affordability
Exelixis, Maker of Expensive Cancer Drugs, Is Latest Manufacturer to Impose 340B Contract Pharmacy Conditions
AstraZeneca and Sanofi Ask 340B ADR Panel to Dismiss Health Centers’ Overcharging Claims
GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs
In a Move to Expand its Specialty Pharmacy Services, CPS Acquires Trellis Rx
Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges
OptumRx Says Providers Can’t Share 340B Claims Data Without its Consent
Judge’s 340B Statutory Interpretation Was “Exactly Backward,” Lilly Tells Appeals Court
Groups Blast PBMs’ Discrimination Against 340B Hospitals in Letters to FTC
340B Report Publisher and CEO: Momentum for 340B Protections Is Growing
PhRMA-funded Study Faults 340B Hospitals’ Financial Aid and Debt Collection Policies
NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue
BMS Updates its Conditions on 340B Pricing Involving Contract Pharmacy
BMS and Merck Announce Refunds for 340B Overcharges
►
May (39)
With Talk of Legislation Heating Up, PhRMA Seeks a New 340B Policy Director
340B ADR Proposed Rule Remains at White House 5 Months Past Expected Publication Date
CMS Asks Court Again to Dismiss 340B Health Centers’ Suit Over Medicaid Drug Benefits Transfer
Maryland Governor Signs 340B Anti-discrimination Bill into Law
Glen Pietrandoni, SVP, Patient and Community Advocacy, Avita Pharmacy
The New Rules of 340B Contract Pharmacy—a Recap of 340B Report’s First-Ever Webinar
In What Would Be the Only Second State to Enact Such Legislation, Calif. Senate Votes to Shield 340B Providers from Manufacturers and PBMs’ Actions
Tennessee Health System Strikes Back Against DOJ Claims It Paid for Referrals to Boost 340B Revenue
Provider Groups File Appellate Briefs in Key 340B Contract Pharmacy Cases
With Screws Tightening on 340B Contract Pharmacy, More Health Centers Plan to Open their Own
State Bill That Would Have Stopped Drug Industry from Imposing 340B Contract Pharmacy Restrictions Dies
Colorado Lawmakers Pass 340B Anti-discrimination Bill
U.S. Uninsured Rate Dipped Slightly in 2021 to 9.2% but Rates for Hispanics and Blacks Remain High
25 States Say Drug Companies’ 340B Contract Pharmacy Actions Are Illegal and Harm Public Health
GOP-aligned Think Tank Alleges that 340B Expansions Contributed to Drug Spending Spurts
HRSA Audits: Scared or Prepared?
HRSA Announces 340B Enrollment Flexibilities in Fire-Ravished New Mexico
Danielle Boehm, Customer Services Manager, Sectyr
25 States File Joint Briefs Backing HHS and HRSA in 340B Contract Pharmacy Cases
Mallinckrodt Is the Third Drug Company This Month to Announce Refunds for 340B Overcharges
340B Providers Lose their Biggest GOP Ally in U.S. House
Drug Makers Ask Michigan Lawmakers to Erase Section from New 340B State Law
Mike Loftus, 340B Director Pharmacy Services, Mercy Health
Letting Pharma Put Strings on 340B is Letting Fox Guard Henhouse, Feds Tell Appeals Courts
Amgen and GSK Announce Refunds for 340B Overcharges - May 22
Drug Industry-Funded Consumer Group Slams 340B on Conservative News Site
340B Publisher & CEO: 340B Ceiling Price Website Is Welcome Step but Needs Improvement
HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months
Survey: Hospitals’ Losses from 340B Contract Pharmacy Restrictions Ballooned During Q1 2022
Fed. Judge Lets 340B Providers Intervene in Closely Watched Contract Pharmacy Lawsuit
Putting a Human Face on 340B
AstraZeneca Stops Voluntary 340B Pricing on Orphan Drugs to Rural and Cancer Hospitals
California 340B Health Centers Blast CMS in Court Over its Role in State Medicaid Drug Benefit Transfer
Non-Hospital Infusion Centers See a Path to 340B Reform that Runs Through the States
Patti Schnieder, Vice President, Caravan Health
Sen. Grassley Presses HHS OIG to Punish Drug Makers Over Denials of 340B Pricing
Merck Adds 45-Day Time Limit on Replenishment Orders to its 340B Contract Pharmacy Policy
Appeals Court Consolidates AstraZeneca, Sanofi, and Novo Nordisk’s 340B Contract Pharmacy Cases
Sen. Manchin Endorses 340B Ally McKinley in Tight GOP Primary Race
►
April (46)
Merck Extends its Conditions on 340B Pricing Involving Contract Pharmacies to Health Centers
340B Report Holding May 18 Webinar on Implementing Drug Makers’ New 340B Contract Pharmacy Rules
Providers Alarmed About 45-Day Lookback Clauses in Drug Makers’ 340B Contract Pharmacy Policies
How 340B Works for People Living with HIV
HIV/AIDS Clinics Tell FTC that PBMs Usurp 340B Discounts for Themselves
With Retired Sen. Hatch’s Passing, a Legendary 340B Tale is Told
Federal Circuit Court Begins Lilly’s 340B Contract Pharmacy Lawsuit Appeal in Earnest
Influential HIV/AIDS Group Asks Gilead to Exempt Ryan White Clinics from Company’s 340B Contract Pharmacy Restrictions
73 Groups Want Congress to Enact Major Drug Pricing Reforms by Memorial Day
Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines
48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic
340B Hospitals’ Pharmacies and Child Sites Often Located in Richer, Less Diverse Areas, Study Finds
JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly
Apexus Releases Its Annual 340B Trends and Hot Topics Learning Module
Harvard Drug Policy Experts Write in JAMA About How Congress Could Fix 340B Contract Pharmacy Mess
At Direction of U.S. Appeals Court, Judge Issues Amended Judgement in Lilly’s 340B Contract Pharmacy Case
AHF Provides Stigma-Free Care with Thrift Store Chain
Sanofi Makes Two Big Changes to its 340B Contract Pharmacy Policy
BMS Fleshes Out How It Will Use Claims Data for 340B Myeloma Drug Purchases
How Sentry Is Helping Covered Entities Contend With Contract Pharmacy Exclusions
340B Providers Say Express Scripts’ New 340B Claims Validation Requests Raise Red Flags
Feds Tell Court Tennessee Health System Paid for Referrals to Recoup “Staggering” 340B Discounts
The Right Prescription: How a Pharmacy Management Partner Can Alleviate Your Workforce Woes
Feds Appeal Court Ruling in AstraZeneca’s 340B Contract Pharmacy Lawsuit
Today Is Last Day for Some Hospitals to File Paperwork for 340B Reinstatement
COVID-19 Public Health Emergency Extended Through July 15
Astellas Providing Refunds for 340B Overcharges from Q3 2020 Through Q2 2021
Don’t Miss Out on 340B Savings from In-Office Injectables
Multiple Developments in 340B Contract Pharmacy Lawsuit Appeals
Lilly Providing Refunds for 340B Overcharges During Q3 2019
Drug Makers’ 340B Pricing Restrictions Hit Small Rural Hospitals Especially Hard, Survey Shows
340B Sales Growth Rate Slowed in 2021, the First Year of 340B Contract Pharmacy Restrictions
Virginia Governor Signs 340B Anti-Discrimination Bill for Grantees
340B Report Publisher and CEO Slafsky: 340B Contract Pharmacy Program Has Fractured Into 17 Pieces
While All Eyes are on 340B Contract Pharmacy Battle, Federal Appeals Court Hears Arguments in Key Case Challenging HRSA’s Patient Definition
340B Patient Definition Is at the Heart of Case Debated Before Federal Appeals Court
340B ESP Makes Changes to Its Terms of Use that Entities Must Accept
340B and Value-Based Payment Keep Safety Net Doors Open
Influential 340B Lawmaker Upton Announces Retirement
Influential Drug Cost-Effectiveness Organization Endorses Partially Lifting 340B Orphan Drug Exclusion
Illinois Legislature Passes 340B Anti-Discrimination Bill
Nick Rebmann, CEO, Hudson Headwaters 340B
Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy
Roundtable Discussion: 340B Drug Pricing Program: Recent Legislative Updates and Key Trends Impacting Hospitals, FQHCs and Other Designated Entities
House Passes Bill to Limit Insulin Co-Pays, but the Way Forward in Senate Is Unclear
Security Matters for 340B
►
March (47)
340B Advocacy Group Expresses Concern About Apparent Unique Feature in J&J’s Contract Pharmacy Policy
CMS Projects that Drug Spending and Drug Prices Will Keep Rising Through 2030
Next Month’s 340B Registration Period Overlaps with Deadline for Hospitals Seeking Reinstatement
Conservative Massachusetts Think Tank Slams State’s 340B Hospitals over Charity Care and Calls for Reform
HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy
HRSA Invokes Contract Pharmacy Fight in Pitch for Comprehensive 340B Regulatory Power
Arkansas Health Centers and Community Hospital Want Role in Challenging PhRMA’s Lawsuit Over State’s Novel 340B Contract Pharmacy Law
BioComp Providing Refunds for 340B Overcharges Spanning a Whopping 8 Years
Ryan White 340B Clinic Association Names New Managing Director
Feds Take Over Prosecution of Whistleblower Suit Against Tenn. Health System Alleged to Have Paid Cancer Docs Illegally for Referrals that Boosted 340B Profits
HIV/AIDS Advocates Protest in Front of Gilead HQ Against Company’s New 340B Contract Pharmacy Policy
Becker’s Hospital Review Webinar: How Health Systems Are Driving Growth Through Specialty Pharmacy Services
BMS Providing 340B Refunds on Cancer Drug Opdivo
California 340B Health Centers Say State “Essentially Admits” Flaws in Medicaid Drug Reimbursement Change
Could J&J’s Decision to Limit 340B Contract Pharmacy Spur Congress to Act?
Influential Group that Offers Conservative Model Bills to State Lawmakers Wades into 340B Debate
Nebraska Governor Signs 340B Anti-Discrimination Bill
Johnson & Johnson Becomes the 16th Drug Manufacturer to Restrict 340B Contract Pharmacy
Exclusive: Leading Health Center Organization Calls Gilead’s New 340B Contract Pharmacy Restrictions “Unconscionable”
HRSA Starts Contacting Hospitals Forced Out of 340B During Pandemic About Possible Reinstatement
Virginia Legislature Passes 340B Bill, One of at Least 14 States With 340B Legislation This Year
Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy
For 2-3 Years, CMS Could Pay 340B Hospitals More for Pricey New Alzheimer’s Drug Than Current Norm
CMS Asks Judge to Dismiss 340B Health Centers’ Claims in Suit Over Medicaid Drug Benefits Transfer
Gilead Announces 340B Contract Pharmacy Restrictions that Apply to Hospital and Grantee Entities
Judge Clears Way for Feds to Appeal His Ruling in AstraZeneca’s 340B Contract Pharmacy Lawsuit
Biden to Sign Bill Today Giving Some Relief to Hospitals Forced Out of 340B Due to COVID-19
Economists Say 340B Hospital and Grantee Entities Use Contract Pharmacy for Different Reasons
Drugmakers Janssen and Kala Providing Refunds for 340B Overcharges
U.S. Senate OK’s Limited Relief for Hospitals Forced Out of 340B Due to COVID-19
U.S. House Approves Partial Relief for Hospitals Forced Out of 340B Due to COVID-19
Novo Nordisk and Sanofi Make Their Cases to Federal Appeals Court in 340B Contract Pharmacy Lawsuit
Learn How to Sustainably Scale Your 340B Program
AbbVie Adds its Top-Selling Cancer Drug Imbruvica to its 340B Contract Pharmacy Restrictions
Congress Is Close to Passing a Spending Bill that Likely Will Address Hospitals’ Loss of 340B Eligibility During Pandemic
Non-Hospital 340B Entities Form Group to Fight on Their Own Behalf at National and State Levels
340B Report Publisher and CEO: Time for Congress to Pass 340B Contract Pharmacy Legislation
AHA Asks Becerra Again to Waive DSH Percentage Eligibility Requirement for 340B Hospitals During Pandemic
340B ADR Panel Wants to Know if Court Decision Affects HIV Advocacy Group’s Claims Against AstraZeneca and Sanofi
As 340B Providers Grapple with High Cost Diabetes Medicine, Civica Plans to Make and Distribute Generic Insulins Priced as Low as $30
Akorn Providing Refunds for 340B Overcharges
Biden Renews Call for Lowering Insulin Costs and Letting Medicare Negotiate Drug Prices
Congressional Democrats Confront PhRMA About Brand Drug Price Hikes
AstraZeneca and Feds Disagree Over Next Steps in 340B Contract Pharmacy Case
340B Stakeholders Congratulate Egwim on Being Named OPA Director
Biden to Address Drug Pricing in Speech Tonight Amid Signs of Shift in Congressional Dems’ Strategy
Bruce Eddins, Administrator, Horizon Ridge Wellness Clinic, Inc.
►
February (43)
HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next 340B Program Director
Despite Expected Jan. Publication Date, White House Review of New 340B ADR Proposed Rule Is Approaching 100-Day Mark
Hospitals Say the Three Confirmed to Have Left 340B Due to Fallout from COVID Are the Tip of the Iceberg
Rural Providers Ask Becerra for Action on 340B Contract Pharmacy and on Hospitals at Risk of Losing 340B Eligibility
New JAMA Study Casts Doubt on CMS Reason for Cutting Hospitals’ Medicare Part B Payments for 340B Drugs
Michigan Governor Signs Three Bills Addressing PBM and Insurer Discrimination Against 340B Entities and Contract Pharmacies
Federal Judge Denies Fla. Healthcare Providers’ Bid to Throw Out Gilead’s Suit Alleging 340B Fraud
Pharma Consultant Sounds Alarm About Potential Sub-Zero 340B Prices on Some Brand Drugs Starting in 2024
Mary Van Hoozer, Vice President of Sales & Account Management, SunRx
AstraZeneca Court Ruling Means All Six of HRSA’s 340B Original Contract Pharmacy Violation Letters are Dead
Drug Makers Ask Judge Again to Dismiss 340B-Related Antitrust Charges
Merck Offering Refunds for 340B Overcharges
California Asks Judge to Dismiss 340B Health Centers’ Suit Challenging Medicaid Drug Payment Change
Signify Health Acquires Caravan Health For $250 Million
Robert Ferraro, Chief Pharmacy Officer, Ravin Consultants
Federal Judge Vacates HRSA’s Finding that AstraZeneca’s 340B Contract Pharmacy Policy Is Illegal
HHS Secretary Becerra Pledges to Keep Fighting Against 340B Contract Pharmacy Restrictions “Because it’s the Law”
In a Win for Health Centers, 340B ADR Panel Says Proceedings Against AstraZeneca & Sanofi Must Go On
In a Move that May Get Significant Pushback, Lilly Signals that it Can Recoup 340B Underpayments from Entities at its Discretion
Hospital Groups Pan GSK’s New 340B Contract Pharmacy Policy, PhRMA Says It Will Continue to Push for Reform
News Alert: GlaxoSmithKline Becomes the 14th Drug Maker to Limit 340B Contract Pharmacies
News Alert: Biden Praises Congresswoman’s “Relentless” Work on 340B During Major Speech on Drug Pricing Reform
Exclusive: AIDS Healthcare Foundation Says Re-Opening 340B Law Over Contract Pharmacy Fight Will Backfire
With Planned Series of House Speeches Delayed, GOP Lawmaker Speaks Out in Support of 340B
Biden and Becerra Slated to Speak at NACHC Event Next Week
GSK Providing Refunds for 340B Overcharges During Q1 2020
HRSA Says at Least Three Hospitals Have Lost 340B Eligibility So Far Due to COVID-19 Patient Mix Changes
Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely
Second Major 340B Stakeholder Says Congress May Need to Stop Drug Makers’ Contract Pharmacy Actions
Apexus Picks Ohio Health System Pharmacy Exec Michelle Wiest For Influential 340B Position
ICER Says Four Drugs Are Cost-Effective in Keeping COVID-19 Patients Out of Hospitals
Ross Halsne, VP, 340B Solutions, Maxor National Pharmacy Services
Despite Initial Optimism, Rural Hospitals Won’t Benefit from 340B Pricing on BMS’s Myeloma Drugs
Spanberger and Johnson Lining up an Hour of Pro-340B Accolades on U.S. House Floor Next Tuesday
Ready to Future Proof Your Business? The Time to Act Is Now.
11 out of 15 Top-Selling Drugs in U.S. Are Subject to 340B Pricing Restrictions, Analysis Shows
Kalderos Hires Veteran Health Care Tech Company Leader Brent Dover to be its New CEO
News Alert: At 340B Conference, Feds Laud 340B Providers, Criticize Drug Makers Embroiled in Contract Pharmacy Fight
Hospital Group Leader Says “We’re Prepared to Go” in Direction of Federal 340B Contract Pharmacy Legislation
Federal Judge Approves Government’s Request to Pause Kalderos’ 340B Contract Pharmacy Lawsuit
Scholarship Created in Memory of Long-Time 340B Leader Carl Taylor
Vertex Providing Refunds for 340B Overcharges on Cystic Fibrosis Drug Trikafta
340B Report Publisher and CEO Forecasts What to Expect After November Congressional Elections
►
January (40)
News Alert: Pfizer Becomes the 13th Drug Maker to Limit 340B Contract Pharmacies
Exclusive: Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price
Novo Nordisk Will Let Hospitals Designate Two 340B Contract Pharmacies—one Retail and one Specialty
In a Relief to Rural Providers, Gilead Is Waiving 340B Orphan Drug Exclusion for its COVID-19 Drug Veklury
Hospitals Taking Heavy Losses Due to Drug Company Limits on 340B Pricing, Survey Says
Vizient Asks Congress to Pass Senate Version of Bill to Protect Hospitals from Losing 340B Eligibility During Pandemic
Julie Valdes, Clinical Pharmacist & 340B Program Coordinator, Zufall Health Centers Inc.
Bipartisan U.S. House Group Wants HHS to Start Punishing Drug Makers Over 340B Pricing Denials
Health Center Opposes AstraZeneca’s Motion to Pause 340B Dispute Resolution Proceedings Over Company’s Contract Pharmacy Policy
FDA OKs COVID-19 Drug Veklury (remdesivir) for Outpatients, Opening the Way for 340B Pricing
PhRMA and Arkansas Seek Faster Court Ruling on State’s Novel 340B Contract Pharmacy Law
AHA Asks Congress to Attach 340B Hospital Protections to Must-Pass Spending Bill
Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices
Democrats Weigh Passing Build Back Better Act—Possibly Including Drug Pricing Reforms—in “Chunks”
View from Capitol Hill Breakfast: Get the Latest Developments in the Ever-Changing 340B Program
Groups and Individual Health Care Providers Grapple with BMS’s New 340B Contract Pharmacy Policy
With Judge in Astra 340B Case About to Get Promotion, What Will Happen to the Highly Anticipated Case?
“Pharma Bro” Who Drew Ire of 340B Providers and Drug Industry Alike Barred from Pharmaceutical Industry for Life
With Public Health Emergency Extended, 340B Flexibilities to Continue
BMS Clamps Down on 340B Contract Pharmacy for Most of its Drugs but Expands 340B Access to its Controversial Myeloma Meds Program
News Alert: NACHC Long-Time Leader Van Coverden Takes Leave, Could Augur Generational Change
340B-Related Conference Organizers Readjust as COVID-19 Persists
340B “Anti-Pickpocketing” Bills Filed in Five States
In Big Win for Pharmacy Groups, CMS Proposes Significant Changes to Medicare Part D Clawbacks
Visante’s Top 10 Issues Facing Hospital & Health System Pharmacy in 2022
PhRMA Says More than Half of Pharmacy and Provider Profits on Brand Drug Sales Come Through 340B
In a Big Relief for 340B Providers, Sen. Thune Will Run Again
N.Y. State and Va. Health Centers Ask Fed. Judge to Let their 340B-Related Antitrust Suit Against Drug Makers Go on
Judge Denies Calif. 340B Health Centers’ Motion to Halt State Medicaid Drug Payment Change
Marcus Cox, Chief Pharmacy Officer, Klamath Health Partnership, Inc
A Personal Look at Some of the Nation's Top 340B Lawyers
Appeals Court Signals it Might Send Lilly’s 340B Lawsuit Back to Lower Court
Judge in AstraZeneca’s 340B Case, on Verge of Big Promotion, Gives Parties Just Two Days for a Status Report
Carole Johnson Takes Charge of HRSA and the 340B Program
California Asks Judge to Reject 340B Community Health Centers’ Request to Stop Medicaid Drug Payment Change
Larry Crowder, Vice President, 340B Solutions, Cervey
Drug Makers Want to Halt 340B Dispute Resolution Proceedings, Citing Lawsuits and Forthcoming Rule
Feds Back and Kalderos Resists Pausing Company’s 340B Lawsuit
Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked
Three Big Predictions for the 340B Program in 2022
►
2021 (550)
►
December (44)
News Alert: Calif. 340B Health Centers Ask Judge to Stop Tomorrow’s “Devastating” State Medicaid Drug Payment Changes
Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.
Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases
John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement
Manchin’s Idea that VA Negotiate Medicare Drug Prices Could Adversely Impact 340B Program, Expert Suggests
Key Considerations to Reduce Impact of Contract Pharmacy Restrictions
Citing Omicron Wave, 340B Coalition Weighs Making Winter Conference a Hybrid Live/Virtual Event
N.Y. and Va. Health Centers Say Discovery Should Continue in their Novel 340B-Related Federal Lawsuit
Novo Nordisk and Sanofi Have Jan. 26 Deadline to File Opening Briefs in 340B Contract Pharmacy Appeal
Boehringer Ingelheim Extends 340B Contract Pharmacy Restrictions to Previously Exempt Specialty Drug Ofev
HRSA Adds Three Days to 1Q 340B Registration Period
Referral Prescription Capture Drives Significant 340B Savings Enhancing 340B’s Mission
More Than 850 Hospitals Ask Feds to Appeal Judge’s 340B Contract Pharmacy Ruling
Provider Groups Pan Lilly’s 340B Contract Pharmacy Policy Change
Is There a New 340B Stakeholder Group for Pharma Companies?
Democratic Defection on Build Back Better Act Sets Back Drive to Lower Drug Prices
Cloudmed Acquires 340B Technology Company par8o
News Alert: Carole Johnson Will Take Over as HRSA Administrator in January
Breaking News: Lilly Will Honor Unlimited 340B Contract Pharmacy Arrangements in Exchange for Entities’ Claims Data
U.S. Retail Drug Spending Hit $348.4 Billion in 2020 but Overall Prices Fell 0.1%
House Committee Releases Report With 340B Implications
A Q&A with Two 340B Industry Experts About the Importance of Innovation and a Competitive Edge
Calif. Health Centers Will Ask Court to Stop State Medicaid Change That Could Reduce 340B Savings Significantly
In What Is Believed to Be the First State Action, W.Va. Says Express Scripts’ 340B Claims ID Policy Violates State Law
Senate Finance Committee’s New Drug Pricing Text Includes a New 340B Provision
Judge Grants Stay in Boehringer Ingelheim’s 340B Contract Pharmacy Lawsuit
Update: Lilly Comments on Forthcoming New 340B Dispute Resolution Rule
340B Covered Entities: Are You Ready for the Changes to Gilead’s Advancing Access Program?
News Alert: Biden Administration Plans to Scrap Existing 340B Dispute Resolution Rule and Publish New One Shortly
Drug Makers May Be Getting Orphan Drug Designations to Exploit 340B Orphan Drug Exclusion, HHS OIG Tells Congress
“Pharma Bro’s” ex-Company and ex-Partner Settling Claims Arising from Daraprim “Scheme,” FTC Says
340B Teaching Hospital Sues Over Medicare Part B Drug Payment Cut
Influential House Lawmaker and Rural Hospitals Upset About J&J’s 340B Orphan Drug Policy Change
GlaxoSmithKline, Exelan, and BioMarin Issue 340B Refunds
House Panel Holding What Might be Last Hearing of its Drug Pricing Investigation
Omnicell Is Acquiring ReCept, a Specialty Pharmacy Management Company with 340B Expertise
News Alert: Johnson & Johnson Ending Voluntary 340B Pricing on Orphan Drugs to Rural and Free-standing Cancer Hospitals
Feds Say They Need Time to Decide Whether to Appeal Ruling in Novartis and United Therapeutics 340B Cases
HRSA Audit Finds Drug Maker and Subsidiary Overcharged 340B Providers
Maker of Plan B One-Step Contraceptive Exiting 340B Program
Five Strategies to Optimize Your Specialty Pharmacy Program
Lilly and Feds Disagree Over Whether 340B Case Is Ripe for Appeal
Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders
Breaking News: Amgen Announces 340B Contract Pharmacy Limits for Hospitals
►
November (48)
News Alert: U.S. Supreme Court Justices Question CMS’s Legal Basis for Slashing 340B Hospitals’ Drug Reimbursement
340B Providers Take Center Stage Before U.S. Supreme Court Today
Clovis Oncology Reverses Decision to Use Kalderos’ 340B Pricing-as-Rebate System
U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic
Peter Welch, Long-Time 340B Advocate in the U.S. House, Announces Run for Senate
UCB Becomes Ninth Drug Manufacturer to Announce 340B Contract Pharmacy Limits
HRSA Weighs in on Recent 340B Contract Pharmacy Court Decisions
Carole Johnson Appears to be Leading Candidate to Run HRSA
AIR340B Releases Study Criticizing DSH Hospital Commitment to the Underserved
340B Report Publisher and CEO: Expect Congress to Act on 340B Contract Pharmacy Before Midterm Elections
Drug Pricing Watchdog Identifies Most Significant Price Hikes
After Successful House Vote, Attention Turns to Senate on Major Drug Pricing Bill
Michael Yount, CEO, Avita
News Alert: Novo Nordisk Joins Sanofi in Appealing Court’s 340B Contract Pharmacy Decision
News Alert: Sanofi Is the Second Manufacturer to Appeal a 340B Contract Pharmacy Court Ruling
News Alert: HRSA Sets Wheels in Motion for a New 340B Administrative Dispute Resolution Proposed Rule
Appeals Court Raises Procedural Questions About Lilly’s 340B Contract Pharmacy Case
GOP Congressman Slams PBMs for Taking Away Safety Net Providers' 340B Savings
HIV Care Providers Sound Alarm About Threats to 340B Savings
For the First Time Since Pandemic, Some 340B Providers Are Being Audited in Person
CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July
As Contract Pharmacy Losses Climb into the Billions, Fine for Overcharging 340B Providers Gets Closer to $6,000 Per Instance Mark
AstraZeneca and Feds Keep Sparring over 340B While Waiting for Judge to Rule
Insulin and Diabetes Drug Makers Ask Judge to Dismiss 340B-Related Antitrust Charges
AHA Criticizes JAMA Study of What Hospitals Charge for Clinician-Administered Drugs
Kaiser Health News Story on 340B Likely to be Read and Seen Widely
Key Questions 340B Providers Should Ask When Choosing a TPA
In What Could be the First of Many Challenges, Lilly Appealing U.S. District Court’s 340B Contract Pharmacy Ruling
In Pursuit of New 340B Leader, HRSA Expands Its Search Beyond Pharmacists
340B Providers Appear to Escape Bullet as Negotiations Continue on Build Back Better Bill’s Drug Pricing Provisions
Attention Turns to Merck and AstraZeneca After Courts’ 340B Contract Pharmacy Rulings
Hospitals, Drug Manufacturers, and Lawyers Give their Takes on 340B Contract Pharmacy Rulings
Two New Studies on Hospital and Health Center Participation in 340B
Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases
Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits
Feds Ask Judges to Follow Judge in Lilly Case and Validate HRSA’s Take on 340B Contract Pharmacy
Biden Taps Judge in AstraZeneca’s 340B Lawsuit for Appeals Court Seat
Kalderos Tells Hospitals its Service to Turn 340B Discounts into Rebates is Operational
Limited Medicare Drug Price Negotiation Placed into Reconciliation Bill; 340B Impact Unclear
3 Requirements for Exceptional Specialty Pharmacy Patient Satisfaction
News Alert: CMS Will Continue Deep Cut in 340B Hospitals’ Medicare Part B Drug Reimbursement
340B Stakeholders Size Up Friday’s Mixed Decision in Lilly’s 340B Contract Pharmacy Lawsuit
CMS Decision on Whether to Keep Part B Drug Payment Cuts for 340B Hospitals Could Come as Soon as Today
Grassley Asks HHS General Counsel Nominee About Drug Companies “Harming Access” to 340B
Sectyr Acquires LicenseTrak, Will Merge Capabilities into Single Platform
Democrats Still Trying to Make a Deal on Federal Drug Pricing Legislation
Biden Administration Wants to Scuttle Azar’s Rule to Automatically Snuff Out HHS Regulations
Kelly Kolker, President, 340B Solutions, CPS
►
October (49)
Breaking: Federal Judge Vacates HRSA’s May 17 Letter to Lilly on 340B Contract Pharmacies, Sends Matter Back to Agency
340B Lobbying Intensifies on Capitol Hill and in Federal Agencies
Both Sides in AstraZeneca’s 340B Contract Pharmacy Case Want a Quick Ruling, but It’s Unclear if They Will Get One
D.C. Federal Judge Picks Up a Fourth 340B Contract Pharmacy Lawsuit
Federal Court Decision on Novel Arkansas 340B Contract Pharmacy Law Might Not Come Until 2023
HRSA Orders Two Drug Makers to Repay 340B Entities After Audits Show Overcharges
Updates on 340B Administrative Dispute Resolution Lawsuits and ADR Panel Hearings
Virginia Health Center Joins 340B-Related Antitrust Suit Against Insulin and Diabetes Drug Makers
California Still Plans to Move Medicaid Pharmacy Benefits to Fee-for-Service in January
News Alert: Boehringer Ingelheim Sues HRSA in Defense of its 340B Contract Pharmacy Policy
Senate Panel Backs Penalizing Drugmakers for their 340B Contract Pharmacy Actions
Biden Moves to End Trump’s Limits on HHS Guidance Including for 340B
Appeals Court Affirms Dismissal of Privacy Lawsuit Involving 340B Contract Pharmacy
BMS Tells 340B Entities It Has Lifted Purchasing Limits on Leukemia Drug
During Crucial Oral Arguments in AstraZeneca 340B Suit, Feds Urge Judge to Take a Fresh Look at Their Case
Arkansas Ending PhRMA Proceeding Against State 340B Contract Pharmacy Law as Focus Turns to Federal Lawsuit
340B ADR Rule Is Fundamentally Defective, PhRMA Tells Federal Court
University White Paper on 340B Says Pharma and Hospitals Will Keep Testing 340B’s Bounds Until Congress Acts
Becerra Extends COVID-19 Public Health Emergency Through Mid-January
340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look
Patient Centered Care: It’s All About the Partnerships
Ben Kelly, RPh, MBA, VP of Pharmacy Operations, Maxor Pharmacy Management
News Alert: Judge Denies Sanofi Stay Against 340B ADR Proceedings, as Stakeholders Brace for Coming Whirlwind of Crucial Decisions in 340B Cases
In Important Development, HHS Close to Rescinding Trump-era Rule that Undercuts its Sub-Regulatory Power
A Closer Look at Critical Court Hearing on 340B Contract Pharmacy Legality
Feds Oppose Sanofi’s Request for Emergency Protection Against 340B ADR Proceedings
Drug Manufacturers May Seek Orphan Designations to Avoid Paying 340B Discounts, HHS OIG Concludes
340B Coalition Says It Will Hold 2022 Winter Conference in-Person
Why Contracting with Specialty Pharmacies Could Seriously Grow Your 340B Referral Script Savings
Judge Expresses Doubt About Government’s Position During Arguments in Novartis and United Therapeutics’ 340B Contract Pharmacy Lawsuits
Lifting of Title X Gag Rule Could Spur Hundreds of Clinics to Rejoin 340B
Feds Have Until Tomorrow to Oppose Sanofi’s Request for Stay Against 340B ADR Proceedings
CMS Rule that Will Set 340B Hospitals’ Part B Drug Reimbursement for 2022 Moves Closer to Release
Managed Care Journal Article Gives 340B Hospitals Low Marks on Uncompensated Care
The 340B ACE Advantage: A Credential that Sets the Standard for 340B Expertise
Kalderos Sues HHS and HRSA, Says Ban on Drug Company Conditions on 340B Sales is Illegal
Sanofi Seeks Emergency Stay Blocking 340B Dispute Resolution Proceedings
In Significant Development, HRSA Assigns Panels to Review 340B Dispute Resolution Claims Against Drug Companies
Boehringer Ingelheim Defends its 340B Contract Pharmacy Policy After HRSA Finds it Is Unlawful
Judge Sets Deadlines for Briefs in 340B Contract Pharmacy Antitrust Suit
New Judge Assigned to PhRMA’s Lawsuit Challenging Arkansas’s First-of-Its-Kind 340B Nondiscrimination Law
Montana GOP Congressman Proposes a Host of New Conditions on 340B Hospitals
340B Providers Might Insure HIV-at-Risk Patients in Response to Gilead’s PrEP Reimbursement Cuts
Half of Congressional Black Caucus Asks CMS to End Medicare Drug Payment Cuts for 340B Hospitals
Federal Appeals Court Hears Arguments in Case Involving Walgreens's 340B Program
Final 340B Registration Period of 2021 Ends on Oct. 15
Claims Manager Plus: Helping 340B Pharmacies Smooth Out the Bumps
Keith Chop, Managing Partner, The Alinea Group
Breaking: HRSA Tells Boehringer Ingelheim its 340B Contract Pharmacy Restrictions Are Illegal
►
September (53)
It’s Official: Biden Administration Rescinds Trump’s 340B Insulin/EpiPen Final Rule
PhRMA Asks Federal Court to Strike Down Arkansas’ Novel 340B Nondiscrimination Law
340B Dispute Resolution Process is Constitutional, Feds Tell Court
Hospital Groups and Drug Industry Vendor File Briefs in Sanofi’s 340B Contract Pharmacy Suit
Rough Sailing for Drug Pricing Reform in Congress
GOP Senator Files Bill to Preserve Trump’s 340B Insulin/EpiPen Mandate
Hospitals Ask Hill Leaders to Shield 340B, as Vote Nears on Drug Pricing Reform
Janssen Providing Refunds for 340B Overcharges Including Diabetes Drug
Seven-Term Senator Grassley, Often Attuned to 340B, Will Run Again in 2022
Cancer Drug Reimbursement Study Could Ramp Up Pressure on 340B Hospitals
Daniel Palestrant, MD, CEO, par8o
Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit
News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income
Parties at Center of Contract Pharmacy Standoff React to HHS OIG Referral
With Delta Variant Persisting, Health Care Groups Struggle with Conference Planning
Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic
Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action
Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts
U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case
House GOP Conference Chair Stefanik Signs on to 340B Anti-Pickpocketing Bill
Capture Cares Foundation Awards $300,000 in Grants to 340B Providers for 2021
HHS Is Vetting OPA Director Applications and Apexus Is Seeking a New Senior VP For High-Profile Position
"The Biggest Crisis Since 340B’s Inception:" 340B Report Leader Provides Input in New Podcast
Biden Picks Academic with Hospital Connections to Run HHS Policy Shop
North Carolina Enacts PBM Oversight Law Protecting Most 340B Covered Entities
House GOP Effort to Amend 340B Falls Short in Key Committee
In His First Public Comments, Ex-HHS Top Lawyer Stands by 340B Contract Pharmacy Advisory Opinion
Divisions Among 340B Provider, Manufacturer, and Oncology Stakeholders on Stark Display During Webinar
340B Hospitals and Independent Oncologists Issue Dueling Reports on Drug Discount Program
Judge Schedules Joint Hearing in Novartis and United Therapeutics’ 340B Contract Pharmacy Cases
Sanofi Reaches Out to 340B Entities that Complained to HRSA About its Contract Pharmacy Restrictions
Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule
Keys to Ensuring Adherence in HIV Treatment and Care
Arkansas Insurance Dept. to Rule Next Month on PhRMA’s Petition to Block Novel 340B Contract Pharmacy Law
U.S. Supreme Court Gets Several Briefs Urging Rejection of CMS’s Drug Payment Cuts for 340B Hospitals
Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug
Jeff Spencer, Senior Director, Sales and Account Management, Omnicell 340B
News Alert: Key House Committee Excludes “Spread Pricing” Language that 340B Entities Feared from Drug Pricing Legislation
In Largely Symbolic Move, Becerra Expresses “Strong Support” for 340B in Drug Pricing Plan
N.C. Lawmakers Leave 340B DSH, Children’s, and Cancer Hospitals and HTCs Unprotected from PBM Pickpocketing
As Hospital Recertification Deadline Nears, 340B Eligibility Challenges Appear Not to Be Widespread for Now
340B Report Publisher and CEO: Congress Needs to Intervene to Resolve Contract Pharmacy Impasse
340B Hospitals Provide Almost $68 Billion Annually in Community Benefits, AHA Says
HRSA Grants 340B Flexibilities to N.J. and N.Y. Due to Hurricane
Providers Concerned About Drug Pricing Reform’s Potential to Undermine 340B
340B Hospitals Make Their Case to Supreme Court for Ending Deep Medicare Drug Payment Cuts
Hearing Friday on PhRMA’s Push to Quash First State Law to Protect 340B Contract Pharmacy Program
A Level Best Compliance Approach to 340B Optimization
After HRSA Notification, NACHC Refiles 340B Dispute Complaints Against Drug Manufacturers
Feds Are “Trying to Muscle” Pharma on 340B Contract Pharmacy, Manufacturer Says in Legal Brief
Genentech Notifies 340B Entities of Limited Distribution of Key COVID-19 Drug
Medicare Trustees Say Part B Drug Payments Will More than Double by 2030
In Hurricane Ida’s Wake, HRSA Announces 340B Registration Flexibility in Louisiana and Mississippi
►
August (37)
Merck Due to Impose 340B Pricing Policy Changes Tomorrow
HRSA Veteran Herzog to Oversee 340B Program as Agency Begins Search for New OPA Director
Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline
News Alert: Becerra Signs off on HRSA Reorganization that Elevates 340B Program’s Status
Health Centers Plan to Resubmit 340B Dispute Resolution Petitions
As Frustration Mounts Over 340B Contract Pharmacy Impasse, Arguments in Highly Anticipated AstraZeneca Lawsuit Postponed to Mid-October
Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case
House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures
As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings
Key House Democrats Keep Up Pressure on Insulin Manufacturers
BioMarin Paying Refunds for Two Years of 340B Overcharges on Pricey Drugs
N.C. Lawmakers Debate Over the Reach of 340B “Pickpocketing” Protections
Jim Donnelly, President, Hudson Headwaters 340B
340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly
PhRMA Challenges First State Law Protecting 340B Contract Pharmacy Program
Merck Defends and Hospitals Slam the Company’s Tougher 340B Contract Pharmacy Policy
Recent Supreme Court Ruling Could Affect 340B Dispute Resolution Lawsuits
Breaking: Merck Will End 340B Contract Pharmacy Pricing for Hospitals That Don’t Share their Claims Data
In Strongly Worded Brief in United Therapeutics Case, Feds Defend 340B Contract Pharmacy Actions
Feds and AstraZeneca Trade Punches in Drug Maker’s 340B Lawsuit
340B to Be Key Agenda Item for Biden’s New HHS General Counsel Pick
Biden Lays Down Markers for Action to Lower Drug Prices
U.S. Senate Sets Stage for Action on Lowering Drug Prices
PhRMA Urges Court Again to Strike Down 340B Dispute Resolution Process
Biden Wants to Rescind Trump’s Most Favored Nation Proposal That Received Widespread Criticism from Drug Industry and 340B Providers
In Fight with National Implications, Calif. 340B Providers Try to Stop Move That Could Result in Millions of Lost Savings
Wisconsin Lawmakers Introduce 340B Anti-Discrimination Measure but Leave Out Most 340B Hospitals
Contrary to Reports, Judge in AstraZeneca Lawsuit Did Not Strike Down 340B Unlimited Contract Pharmacy, Court Clerk Says
Insulin Manufacturers Colluded on 340B Contract Pharmacy After Joint Lobbying Push Failed, Lawsuit Alleges
340B Report Publisher and CEO Says New Bipartisan 340B Bill is Win for Providers and Drug Industry
Biopharma Company Apellis Posts 340B Limited Distribution Notice
Jennifer Lockwood, CEO/Founder, Ravin Consultants
Health Center Files 340B Contract Pharmacy Antitrust Suit Against Insulin Makers, Seeks Nationwide Class Action Certification
Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs
Infrastructure Bill Excludes Spread-Pricing Language That 340B Entities Oppose
Young Firebrand Lawmaker Gets into Shouting Match with 340B Champion
Distressed Critical Access Hospitals that Devolve to Stay Open Would Lose 340B Eligibility
►
July (48)
Feds and Lilly Make Their Case to Federal Judge in Key Hearing Today
Key GOP Congressman Opposed 340B Amendment to Spending Bill During Committee Hearing
In AstraZeneca’s 340B Lawsuit, Focus Shifts to HRSA’s May 17 Violation Letter
340B Won’t be Overlooked if There’s a Grand Bargain on Drug Pricing, Analyst Predicts
Novo Nordisk Providing Refunds for 340B Overcharges on Insulin
Kalderos Urges Feds to Protect Hospitals from Losing 340B Eligibility During Pandemic
Retired Senator Enzi, Who Backed 340B Inquiries, Dies Following Accident
Building the Case for Dedicated 340B Program Management
News Alert: U.S. House Votes to Highlight Need to Halt Pharma’s “Unlawful” 340B Actions
HRSA Posts Novartis Notice About 340B Refunds on a Top-Selling Drug—With Contract Pharmacy Strings Attached (Updated)
With COVID-19 Surging Again, Hospital and Pharmacist Groups Back Employee Vaccine Mandates
For 340B Hospitals, Some Consolation in Otherwise Disappointing CMS Drug Reimbursement Rule
340B Contract Pharmacy Litigation Could Drag on for Years, Hospital Group Leader Says
Pedley Provides 340B Update but Avoids Contract Pharmacy Controversy
House GOP Starts Crafting Health Care Bills in Anticipation of Retaking Majority
340B Program Flexibilities to Continue As COVID-19 Emergency Extended
With 340B Hospital Recertification Set to Begin Soon, HRSA To Host Webinar Aug. 11
Thriving with HIV: How a Compassionate Pharmacy Technician Made All the Difference
Biden Administration's Proposal to Retain 340B Hospital Drug Payment Cuts Draws More Fire
One-Fourth of 340B DSH Hospitals at Risk of Losing Eligibility Due to Pandemic, Analysis Finds
Help Wanted Ads Suggest HRSA Reorganization Is in Gear
Judge Consolidates Arguments in Two 340B Contract Pharmacy Lawsuits
United Therapeutics Fleshes Out its 340B Contract Pharmacy Legal Arguments
Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule
Evolving Payor Strategies to Control Spending on Specialty Medications
In Surprise Move, Biden Administration Proposes Keeping Trump’s Nearly 30% Cut in 340B Hospitals’ Drug Reimbursement
Key Congressional Committee Urges HRSA to Fine Drug Makers Over 340B Contract Pharmacy Denials
House Appropriators Want an Update from HRSA on its Plans to Clarify 340B Patient Definition and Provider Eligibility Criteria, Calls for New GAO Report
Law Firm Sues HRSA Over FOIA Request for 340B Contract Pharmacy Documents
Feds, Novartis, and UT Weigh in on Consolidating 340B Contract Pharmacy Lawsuits
Lilly Updates its Arguments in 340B Contract Pharmacy Lawsuit
FQHCs Say Patients Will Suffer if Telehealth Flexibilities Aren’t Extended
Sixth Drug Manufacturer Sues HHS and HRSA Over 340B Contract Pharmacy
Multiple Developments in 340B Contract Pharmacy Lawsuits
Biden Gives Becerra 45 Days to Deliver a Plan to Fight Excessive Drug Prices
Rosen Introduces Bill to Boost Nonprofit Drug Makers’ Competitiveness
News Alert: Bipartisan Bill Introduced to Protect 340B Providers From Reimbursement Cuts and Address Duplicate Discount Challenge
Hospital Groups Outraged at Boehringer Ingelheim, Company Defends Its Plans and Calls for 340B Overhaul
Two High Profile Opioid Makers Among Companies Announcing Refunds to 340B Providers But Refunds for Mallinckrodt’s Top-Selling Drug Remain Elusive
In Taking Up 340B Case, Supreme Court Could Reverse Longstanding Legal Doctrine
Medicare Part B Payment Challenge Not Only Supreme Court Case That Will Impact 340B Program
BREAKING: Supreme Court Will Take Up Case Involving Medicare Part B Cuts to 340B Hospitals
Boehringer Ingelheim Will Stop Shipping 340B Drugs to Hospitals’ Contract Pharmacies on Aug. 1
Judge Rejects Government’s Contention that AstraZeneca’s 340B Lawsuit Is Moot
Hospitals File New Suit To Reverse Steep Part B Payment Cuts for 340B Drugs
Pfizer Invokes 340B Contract Pharmacy Ruling in its Lawsuit Over Copay Assistance
16 States Have Passed Laws Since 2019 Targeting PBMs’ 340B Payment Cuts
HRSA Makes Tweaks to 340B Program Database
►
June (51)
Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly
DOJ Says Lilly and Novo Nordisk’s 340B Actions Cost Providers Over $125 Million a Month and Hurt Patients
CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program
NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month
Recent Supreme Court Ruling Frees States to Stop PBMs’ 340B Two-Tier Pricing, Health Care Lawyers Say
340B Report Publisher and CEO Examines Four Burning Questions in Contract Pharmacy Standoff
HRSA’s Order for 340B is a Win for Rural Accountable Care
News Alert: Becerra Puts His Imprint On Long-Awaited 340B Dispute Resolution Board
Pharma’s 340B Contract Pharmacy Limits Are Costing Providers $3.2 Billion a Year, DOJ Tells Court
DOJ and AstraZeneca Far Apart on How Company’s Lawsuit Should Proceed
DOJ Asks Judge to Toss PhRMA Suit Against 340B Dispute Resolution System and Audit Guidelines
Government Notifies Drug Companies About 340B Contract Pharmacy Advisory Opinion’s Withdrawal
340B Sales Totaled $38 Billion Last Year, Industry Friendly Blog Reports
Biden Nominates Acting HHS Inspector General for the Job Full Time
BREAKING: HHS Withdraws 340B Contract Pharmacy Advisory Opinion, and Becerra Appoints 340B Dispute Resolution Board Members
340B Entity Groups Accentuate Positives in 340B Contract Pharmacy Court Opinion
Supreme Court Preserves ACA and, with it, the Health Care Reform Law’s 340B Provisions
Congressman Asks Becerra to Commit to Pause 340B Hospitals’ DSH Percentage Requirement
AHA Wants Express Scripts to End 340B Claims ID Policy Immediately
340B Hospitals Concerned About New UnitedHealthcare Claims Reimbursement Policy
“Need to Know” – Visante’s Series of Key Takeaways for HRSA Grantees
BREAKING: Judge Hands HHS Major Setback in AstraZeneca’s 340B Contract Pharmacy Lawsuit
Biden Administration Proposes to Rescind Trump’s 340B Health Center Insulin Rule
MedPAC Recommends Part B Drug Payment Changes That Could Exacerbate Financial Strain for 340B Hospitals
Health Centers and 340B Play Integral Role In Filling Gaps After Rural Hospital Closures, MedPAC Finds
Two Closely Watched 340B Lawsuits Will Soon Get a New Judge
Rep. Porter Files Bill to Require Medicare Part B inflation-Based Rebates
Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 6
Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 5
Sentry Data Systems Is the Latest 340B TPA to Change Hands
CMS Seeks Medicare DSH Calculation Change That Could Disqualify Some Hospitals From 340B
In First of Its Kind Legislation, Louisiana Cracks Down on White-Bagging Requirements
More Than a Third of State Lawmakers Accept Pharma Campaign Contributions, Analysis Shows
Becerra’s Message to Pharma on 340B: “You Violate the Law, You Pay the Consequences”
Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4
Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3
Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2
Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1
Novartis Says Its Reputation Has Been Injured By HRSA’s 340B Demand Letter
White House Clears Path for HRSA to Rescind Trump’s Health Center 340B Insulin Rule
Health Centers Launch a New National Advocacy Group
Lynn Barr, a Value-Based Payment and 340B Champion, is Appointed to MedPAC
Judge Declines to Issue Stays Against HRSA Stemming from its May 17 Demand Letters
340B DSH Hospitals More Likely To Treat Black, Disabled, and Low-Income Patients With Chronic Conditions, Study Indicates
CMS Moves to Delay Multiple-Best-Price Rule For Value-Based Drug Purchases
Sanofi and Novartis Fight HRSA’s 340B Contract Pharmacy Demand Letters
340B Hospitals Ask Supreme Court Again to End Steep Medicare Drug Payment Cut
Two Drug Makers Providing Refunds for 340B Overcharges
Brooks-LaSure Sworn in as CMS Administrator
Grassroots Group Launches Regional Events to Promote 340B’s Importance
BREAKING: Novartis Sues HRSA in Defense of its 340B Contract Pharmacy Policy
►
May (42)
HHS Wants to Audit 340B Providers to See How They Use 340B Net Income
Late Breaking Developments in Lilly and AstraZeneca’s 340B Contract Pharmacy Lawsuits
As June 1 Deadline Looms, Drug Manufacturers and Feds Make Their Case in New Jersey Federal Court
Key Hearings Today in AstraZeneca and Lilly’s 340B Contract Pharmacy Lawsuits
Vermont Places 340B-Related Strictures on PBMs and Adds Protections to Contract Pharmacies
HHS Contract Pharmacy Advisory Opinion Author Returns to Private Sector
Ex-HRSA Administrator Wakefield Back at HHS, Hospital Association Exec Joins Too
PhRMA Sues to Block Medicaid Best Price Change
New Developments in 340B Contract Pharmacy Lawsuits
Much Cheaper PrEP Drugs Could Mean Financial Upheaval for 340B Covered Entities
Brooks-LaSure Poised to be Confirmed as CMS Administrator
BREAKING: Developments in Multiple 340B Contract Pharmacy Lawsuits
BREAKING: Developments in AstraZeneca’s 340B Lawsuit
Drugmakers Show No Sign So Far of Giving in to HRSA on 340B Contract Pharmacy
Health Centers, HIV/AIDS Clinics, and Feds Agree on Keeping Stays in Place in 340B Lawsuits
AbbVie Abused Humira’s Orphan Drug Designation, House Panel Says
Year 2 of 340B Contract Pharmacy Fight Starts With a Bang
Drug Makers Defensive, Providers Thrilled About HRSA’s 340B Contract Pharmacy Letters
Montana Enacts Expansive Bill Intended to Protect 340B Providers
BREAKING: HRSA to Six Drug Makers—Your 340B Contract Pharmacy Policies Are Illegal, Resume Offering 340B Pricing Immediately
HHS Asks U.S. Supreme Court to Reject 340B Hospital Request to Hear Medicare Part B Case
Bipartisan Lawmakers Re-Introduce Bill Shielding Hospitals From Lost 340B Eligibility Due to COVID-19
Will New Administration Reverse Deep Medicare Part B Cuts to 340B Hospitals?
DOJ Cites 1996 HRSA Letter to PhRMA in Request to Dismiss Novo Nordisk’s 340B Contract Pharmacy Suit
OTC Drug Manufacturer Owes 340B Entities Refunds, HRSA Audit Finds
United Therapeutics Delays its 340B Claims Data Upload Requirement
Andrea Palm Confirmed as HHS Deputy Secretary
Breaking: Becerra, on 340B Pricing Denials, Tells House Panel, “Everyone Has to Follow the Law”
Takeda Pharmacy Partner Forcing 340B Pricing Opt-in/Opt-out Choice on Entities
HRSA Signals It Will Rescind Trump’s 340B Insulin Rule
House GOP Leadership Shake Up Could Benefit 340B Providers
Lilly Wants Judge To Schedule June Arguments in 340B Suit Against HHS
North Dakota Is the Latest State to Pass a 340B Non-Discrimination Law
What Covered Entities Should Know About Contracting with Specialty Pharmacies
340B Non-Discrimination Bills Signed in Arkansas and Indiana and Passed in Tennessee
Multiple Developments in AstraZeneca’s 340B Contract Pharmacy Lawsuit
Bristol-Myers Squibb Hires Apexus VP Richardson to Be its 340B Strategist
Study: Better Use of 340B Can Help Shrink Urban “Pharmacy Deserts”
Expect to Hear a Lot About Drug Pricing During Next Week’s House Hearing With Becerra
State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing
Hospital Groups Want FDA to Curtail Specialty Drug White Bagging
Study: Patients with Deductibles and Coinsurance Pay More When a Drug’s List Price Rises
►
April (42)
Arkansas Passes First-of-its-Kind Bill to Counter Pharma’s 340B Contract Pharmacy Moves
Vermont AG Issues Subpoena to Novartis for 340B Documents and Information
Tech Firm Convening Working Group to Address 340B Duplicate Discounts
Biden Wants to Let Medicare Negotiate Drug Prices, but Not Via His American Families Plan
Key Factors To Consider To Ensure Effective Management of a 340B Pharmacy Program
Hospitals Could Get Another Shot to Intervene in AstraZeneca’s 340B Lawsuit
Nonprofit Generic Drugmaker Civica Is Providing Refunds for 340B Overcharges
Will Biden’s American Families Plan Include an Rx Drug Pricing Measure?
BREAKING: Judge Nixes Hospital Groups’ Participation in AstraZeneca’s 340B Contract Pharmacy Case
340B Providers Escape Bullet in House Dem Rx Bill, but Not in GOP Version
Feds Asks Courts to Reject Lilly and Sanofi’s 340B “Self-Help”
Hospital Groups Ask HHS to Start Fining Pharma Over 340B Pricing Denials
Kalderos: 3-5% of 340B Discounts and Medicaid Rebates Are Duplicates
Congress Passes Bills Aimed at Boosting Generics and Biosimilars
CBO Report: R&D Costs Do Not Influence Pharma Pricing
HHS Tells Judge 340B Dispute Resolution Is Back on Track and It Is Weighing Other Pharma Enforcement Steps
AstraZeneca Tells Court: Congress Didn’t Make 340B to Generate Profits for Providers
Public Relations War Over 340B’s Intent Intensifies
24 Health Systems List 8 Ways HHS Can Stabilize 340B Without Involving Congress
BREAKING: Key GOP U.S. Senator Presses HHS Deputy Secretary Nominee to Take Action on 340B
Pharma’s Plans to Rebuild Health Care Include Overhauling 340B
Could Concern About Hospital Price Transparency Boost Push for More Hospital 340B Transparency?
Historic U.S. Rise in STDs Boosts 340B’s Importance, STD Program Directors Say
340B Report Publisher and CEO Slafsky: Providers Need Swift Action on Contract Pharmacy
News Alert: United Therapeutics Unveils 340B Contract Pharmacy Claims Submission Requirement
Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say
340B Could Come Up During Congressional Hearings Thursday
MACPAC Backs Medicaid Change That Could Lower Some 340B Prices
Express Scripts Defends 340B Claims ID Requirement
340B Entities Won’t Share in BMS’s $75 Million Medicaid Drug Pricing Settlement
Optimizing 340B Savings Through Referral Capture
340B Sales Grew 18% from 2019 to 2020, Drug Industry Consulting Firm Says
NY State 340B Providers Get More Time to Challenge Reimbursement Change
Panel Lauds Women’s Role in Creating and Leading 340B
340B Groups Ask Express Scripts to Drop Claims Submission and ID Requirement
340B Hospitals More Likely to Make Medicine More Accessible, Study Finds
Study in Health Affairs Could Reignite Debate Over Some 340B Hospitals Charity Care
AHA Warns MedPAC its Recommendations Would Harm 340B Hospitals
Panelists Share Insights on Using 340B in Prisons and Jails
HHS’s Latest Regulatory Agenda Is Silent on 340B, but Program Rulemaking Is Possible
AHA Asks Becerra to Waive a 340B Hospital Eligibility Requirement During COVID-19 Emergency
For-Profit Hospitals Back Medicare’s 340B Hospital Cuts in Legal Brief, Study, and Blog
►
March (45)
For-Profit Hospitals Make Major Pitch for Keeping Medicare’s 340B Hospital Cuts
Feds Oppose Hospitals’ Intervention in Three More Pharma 340B Lawsuits
340B Entities Keeping Watch on Bills to Create State Drug Affordability Boards
Q2 340B Registration Period Starts April 1
Origin Biosciences Posts Limited Distribution Notice on 340B Program Site
HRSA Takes Step Forward on 340B Dispute Resolution Petitions
Merck Pitches Its Voluntary 340B Integrity Initiative to Providers as a Better Option than Audits
Feds Oppose Hospitals’ Motion to Intervene in Novo Nordisk’s 340B Lawsuit
340B Gets Cameo Role in Senate Hearing on Government Drug Price Negotiation
340B Dispute Resolution Injunction Is Having Ripple Effects
Federal Judge To Get Status Report Today from Ryan White Clinics and Government
Drug Pricing Is Heating Up in Congress Again
Survey: Pharma’s 340B Contract Pharmacy Actions are Putting the Squeeze on Hospitals
Health Centers Get Reprieve as 340B Insulin Pricing Rule Delayed Again
Becerra Expected To Usher in Sea Change to 340B Governance
Six Senators Reintroduce Bipartisan Bill to Protect 340B Hospitals From COVID Fallout
The Patient Journey: Are You Missing Something?
Sanders Holding Senate Hearing on Drug Prices Next Week
Amazon Is Opening its Employees-only Primary and Urgent Care Service to Companies Nationwide
Injunction in Lilly Case Could Cause HHS to Re-Issue 340B Dispute Resolution Rule
Breaking: Federal Judge Grants Lilly’s Motion to Halt 340B Dispute Resolution System
Opposition to Express Scripts’ 340B Claims ID Requirement Grows
FQHCs Fiercely Oppose Trump’s 340B Insulin Pricing Rule in New Round of Comments
Medicare’s 340B Drug Reimbursement Cuts in 2019 Were Exacerbated by Change in Drugs’ Payment Status
Biden Nominates Veteran Capitol Hill Aide to be HHS Assistant Secretary
Utah Might Soon Outflank Express Scripts’ New 340B Requirement
State Activity to Rein in PBM Discrimination Against 340B Entities Heats Up
Biden Wants to Delay 340B Health Center Insulin Rule Again, to July 20
Sanofi Calls 340B ADR System “a Faux Judicial Process”
COVID Relief Bill With Implications for 340B Set to Become Law Tomorrow
PhRMA: Providers Use 340B as “Slush Fund”
Biden Names Health Care Advisers with Strong Ties to Hill Democrats
News Flash: State Attorney General Orders Sanofi to Hand Over 340B Information
Providers Worried About Humana’s 340B Claims ID and Data-Reporting Conditions
COVID-19 Relief Bill Includes Many Provisions Affecting 340B Providers
Hospitals Want Role in Three More Pharma Lawsuits Over 340B Contract Pharmacy
Senator Cassidy Again Cites 340B in Opposing Becerra for HHS Secretary
A Recap of the Acentrus Specialty Conference
Orphan Drug Study’s Authors Say Findings May Warrant Lifting 340B Exemption
Senate Democrats Soften, But Don’t Yank, COVID Relief Bill’s Medicaid Rebate Language
340B Report Publisher/CEO: Look for a Return to an Era of 340B Guidance
DOJ Opposes Sanofi’s Move to Head Off 340B Dispute Resolution in Contract Pharmacy Battle
340B Providers Cheer Bipartisan House Letter to HHS on Manufacturer Actions
N.Y. and Calif. 340B Pharmacies Get Reprieve From Medicaid Cuts
Huge COVID Relief Bill That Would Lift Medicaid Rebate Caps Moves to Senate
►
February (54)
226 Bipartisan U.S. House Members Ask HHS to Stop Pharma From Unilaterally Changing 340B
Express Scripts’ New 340B Rules Will Have Big Impact on Contract Pharmacy and Drug Reimbursement, Providers and Consultants Say
Bipartisan U.S. House Members Corralling Last-Minute Signatures on 340B Letter to HHS
Becerra Reconfirms Strong Support for 340B During Finance Committee Hearing
Express Scripts' New 340B Claims ID Requirement Has Covered Entities Worried
Hospitals, Health Centers, and HIV/AIDS Clinics Want Roles in Lilly’s 340B Contract Pharmacy Lawsuit
Health Care Reporter Foresees Federal Action on Drug Pricing, But Not Immediately
36 State Hospital Groups Ask U.S. Supreme Court to End Part B Drug Payment Cuts for 340B Hospitals
BREAKING: HHS Secretary-Designate Becerra Pledges to “Build On” 340B Contract Pharmacy Advisory Opinion
HHS-Designate Becerra May Face 340B Questions Today During First Nomination Hearing
Biden Staffs Up with 340B Policy Experts in Key Positions
Ex-Energy & Commerce GOP Chair Walden Launches Lobbying Firm
HRSA Allows 340B Enrollment Flexibility in Storm-Battered Texas
AEH Asks Biden to Prioritize Three 340B-Related Issues
Biden Will Turn to Drug Pricing Once COVID-19 Ebbs, Shalala Predicts
Federal Judge Dismisses Hospitals’ 340B Contract Pharmacy Lawsuit Against HHS
DOJ Slams Lilly’s Arguments for Derailing 340B Dispute Resolution
CBO Says Lifting Medicaid Drug Rebate Cap Would Save $16 Billion
Senate Hearings Next Week on Becerra’s Nomination to Head HHS
Biden Reportedly Has Settled on His Choice to Run CMS
Generic Drug Manufacturer Posts 340B Refund Notice
Muted by Litigation, Pedley Avoids Hottest 340B Topics But Provides Some Nuggets
AstraZeneca Tells Court HHS’s 340B Enforcement Poses “Imminent Irreparable Harm”
Legislation Lifting Maximum Cap on Medicaid Rebates Advances
PolitiFact Calls Senate Candidate’s 340B Insulin Claim “Mostly False”
Bausch Health Confirms 340B Rapprochement with AmeriSourceBergen
PhRMA Slams 340B Hospitals in Report, AHA Returns Fire
Indiana House to Vote on Stopping PBMs From Squeezing 340B Entities
In Key Hearing, Federal Judge Expresses Doubt About Court’s Ability To Take Action on Contract Pharmacy Matter
House Set To Act on Bill that Could Result in Higher Medicaid Rebates and 340B Discounts
Hospitals Ask U.S. Supreme Court to End “Crushing” Medicare Payments Cuts for 340B Drugs
AHA Asks CMS to Rein In UHC’s Specialty Pharmacy Policies
Biden Administration Position in Supreme Court ACA Case Has 340B Implications
Drug Manufacturers GSK and Esperion Offering Refunds for 340B Overcharges
Health Centers to Begin Receiving COVID-19 Vaccines Directly
Burr Named Ranking Republican On Committee with 340B Oversight
Court Hearing Today on Hospitals’ 340B Contract Pharmacy Suit Against HHS
Welch and McKinley Will Try Again to Get Rural and Cancer Hospitals 340B Pricing on Orphan Drugs
Failed Amendment to Federal Budget Bill Could Have Required All Providers to Pass 340B Savings on Insulin to Patients
Calif. Health Centers Ask Newsom to Delay Medi-Cal Drug Benefit Shift Until 2022
Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges
Surprise Amendment to Senate Budget Bill Could Portend Busy 340B Legislative Session
EXCLUSIVE: Bipartisan U.S. House Group Circulating 340B Sign-on Letter to Becerra
Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure
Democrats Shake Up Lineup on Key Health Committees Impacting 340B
Two New Manufacturer Notices to 340B Entities on HRSA Website
Court Freezes Trump’s Rule Banning Pharma Rebates to PBMs
Sanofi Lifts 340B Contract Pharmacy Requirements for Some Providers But Many Are Still Affected
AmeriSourceBergen Has Resumed Distributing 340B-Priced Bausch Health Drugs
Half of Health Care Execs Surveyed Expect Biden to Act on Pharma’s 340B Pricing Denials
USA Today Fact-Checks Claim that Biden Raised Insulin Prices by Freezing 340B Rule
44 New York State Lawmakers Urge Cuomo to Reverse Medicaid Drug Benefit Transfer
TV Humorist Bestows “Baldy” Award on Co-Author of 340B Law
Proven Strategies 340B Covered Entities Can Use to Enhance the Specialty Pharmacy Experience for Patients
►
January (37)
340B Guidance Documents Removed from HHS Public Database
340B Report Publisher/CEO: It Will Take Time for Contract Pharmacy Battle to Play Out
AHA Asks CMS to Withdraw Trump’s Most Favored Nation Drug Pricing Rule
Generic Liquid Drug Manufacturer Providing Refunds for 340B Overcharges
Drug Company Eton Posts 340B Limited Distribution Notice
New Walgreens Leader Will Be Fortune 500’s Sole Black Female CEO
340B COVID-19 Flexibilities Expected to Run Through the End of 2021
Portman’s Retirement in 2023 Will Deprive 340B Entities of a Key GOP Ally
Conservative News Sites Cast Shade on Biden’s Freeze on 340B Insulin Rule
BREAKING: PhRMA Asks Court to Strike Down 340B Dispute Resolution Rule and Manufacturer Audit Guidelines
Biden Administration Withdraws Azar’s Notice of Appointments to 340B Dispute Resolution Board
Biden Team Freezes 340B Insulin Rule, to Health Centers’ Relief
In Surprise Move, 340B Dispute Resolution Board Members Appointed
Pedley’s Promotion May Presage Hiring of a New 340B Program Director
Biden Appoints Acting Leaders at HRSA, CMS, and HHS
Health Centers Scramble to Secure a Freeze on 340B Insulin Rule
House E&C Leaders Announce Leadership Team and New Committee Members
Our First Issue Behind Our Paywall
Gilead Adjusts Planned Change in its Patient Assistance After HIV Community Pushes Back
HHS Asks Court to Toss Out Hospitals’ 340B Contract Pharmacy Lawsuit
Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions
Azar and Verma Touch on 340B in Valedictory Remarks
340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot
Top 10 Issues to Consider in 2021 - Sponsored Content
Important Information About Accessing 340B Report
Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers
Lilly Asks Court to Shield it From “Crippling” 340B Sanctions
Nevada ADAP Postpones Controversial 340B Policy Change
Top 10 Issues to Consider in 2021
AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies
Welcome to The New 340B Report
HRSA Releases Details and FAQs About New 340B Dispute Resolution System
340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor
Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers
Nevada Ryan White Clinics Furious About State ADAP’s 340B Policy Change
340B Providers Welcome Democratic Control of Congress and White House
Chicago Tribune’s 340B Article Grabs Senior U.S. Senator’s and Governor’s Attention (Updated)
►
2020 (152)
►
December (18)
BREAKING: HHS’s Top Lawyer Says Pharma’s 340B Contract Pharmacy Actions Are at Odds with the Law
BREAKING: HHS Says 340B Discounts Apply to Contract Pharmacies
Trump Pardons Disgraced 340B Critic
HRSA Releases 340B Insulin Final Rule Over Health Centers’ Strong Objections
White House Clears 340B Insulin Final Rule for Publication
Kalderos Expects its 340B Rebate Model Will Finally Lift Off During Q1 2021
The New York Times, Often a Public Policy Shaper, Runs Article on 340B Pricing Denials
Providers Are Pleased, PhRMA Isn’t, With Becerra and State AGs’ 340B Letter to Azar
BREAKING: 28 State AGs—Including HHS Nominee Becerra—Want Action on Pharma 340B Pricing Denials. Also, New GAO Report on HRSA 340B Oversight. (Updated)
BREAKING: Hospitals Sue HHS Over Drug Companies’ Denials of 340B Pricing
After a 10-Year Odyssey, HRSA Finally Releases 340B Dispute Resolution Rule (Updated)
BREAKING: 340B Dispute Resolution Final Rule Released
BREAKING: Amgen Ending 340B-Like Price Reductions on Orphan Drugs on Jan. 1 (Updated)
White House Clears 340B Dispute Resolution Final Rule for Publication
BREAKING: Florida Medicaid Asks Rx Manufacturer to Suspend “Broad Brush” 340B Pricing Restrictions, Will Other States Follow?
340B Hospitals Face Another Year of Deeply Reduced Medicare Drug Reimbursement
BREAKING: Novo Nordisk Will Cease 340B Pricing for Hospital Contract Pharmacies on Jan. 1
Coming Proposed Rule Could Shed Light on HRSA’s 340B Enforcement Power
►
November (12)
News Digest: 340B Insulin Rule, Hospital Eligibility Protection, Purdue Pharma Credits
RWC-340B Seeks Quick Judicial Relief from 340B Contract Pharmacy Rollbacks
United Therapeutics Imposes Limits on 340B Contract Pharmacy Pricing
BREAKING: Trump Issues Drug Pricing Rules That Impact 340B; Says 340B Health Center Final Rule Is Coming
Stakeholders Weigh in on Forthcoming 340B Dispute Resolution Rule
BREAKING: A Decade Overdue, HRSA Puts 340B Dispute Resolution Final Rule in Motion
Lilly’s 340B Policy Tweak Pushes Contract Pharmacy Farther Out of Reach
BREAKING: Bipartisan Group of 217 U.S. Representatives Ask HHS to Stop 340B Rebate Model and Look Into Third Party Vendors
Biden Names Ex-HRSA Leader Wakefield to His HHS Transition Team
Gilead Accuses Florida 340B STD Clinics of “at Least $43 Million” in Fraudulent PrEP Transactions
U.S. Sen. Braun Introduces Bill to Collect and Report 340B Hospital Data
GOP Committee Leaders Asked for and Got 340B Reform Ideas. What Happens Now?
►
October (15)
BREAKING: Novartis Retreats, But Not Entirely, on 340B Contract Pharmacy (Update 2)
EXCLUSIVE: Lilly’s Letter to HRSA on Why it Thinks 340B Contract Pharmacy is Unlawful
Health Centers to White House: Don’t Implement “Misguided” 340B Executive Order
Iowa’s U.S. Senators Meet With HHS Top Brass About Pharma’s 340B Moves
U.S. House Democrats and Republicans “Deeply Concerned” About 340B Rebate Model
BREAKING: Health Centers Sue HHS Over Drug Company Denials of 340B Pricing
340B Hospitals Ponder Next Moves After U.S. Appeals Court Setback
BREAKING: Major Developments in 340B Hospital Lawsuit and in 340B Contract Pharmacy Dispute
HIV/AIDS Activists March To Protest AstraZeneca’s 340B Contract Pharmacy Cutbacks
Sanofi Reportedly Is Not Providing Some Promised 340B Pricing
BREAKING: HIV/AIDS Clinics Sue HHS Over Drug Manufacturers’ Denials of 340B Pricing
BREAKING: Congressional GOP Committee Leaders Seek 340B Reform Ideas by Oct. 30
More than Half of Health Care Industry Execs Expect 340B Reporting Requirements Within Five Years
BREAKING: Connecticut Attorney General Demands Five Manufacturers Cease 340B Actions
AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)
►
September (18)
The Calm Before the 340B Storm?
Only 30 Providers Are Supplying Merck with Requested 340B Claims Data
BREAKING: Novartis Says It’s Weighing Whether to Start Cutting Off 340B Contract Pharmacy Discounts on Oct. 1. Sanofi Says it Will. (Update 1)
Is Novartis Backing Off its Oct. 1 Deadline for 340B Covered Entities? (Update 2)
BREAKING: HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy
Supreme Court ACA Overturn Could Cut Rural Hospitals from 340B, Gut HRSA Enforcement
BREAKING: Rule Implementing 340B Executive Order on Insulin Might be Imminent
HHS Inundated with Concerns About Pharma’s and Administration’s 340B Actions
BREAKING: 22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions
In Partisan U.S. House, Consensus Emerges Over Manufacturer 340B Actions
BREAKING: More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately
Lilly’s 340B Contract Pharmacy Ban Has Crept Into In-House Pharmacies
Health Centers Are Preparing to Sue Over Drug Makers' 340B Actions
BREAKING: House Democratic Committee Chairs Say Drug Companies’ Actions Could Put 340B on “Treacherous Path”
White House Fast-Tracking 340B Executive Order on Insulin, Epinephrine
BREAKING: HRSA is Investigating Whether Manufacturer Policies to Restrict 340B Pricing at Contract Pharmacies Violates Statute
BREAKING: Eli Lilly Comment on Today's Actions
Eli Lilly Dramatically Escalates Efforts to Restrict Access to 340B Pricing
►
August (11)
Drug Store Chains Want HHS to Block Pharma’s Moves Against 340B Contract Pharmacy
BREAKING: Kalderos Wants to Give Drug Manufacturers a Way to Pay 340B Rebates in Lieu of Discounts
340B Supply Chain Partners Push Back Against Manufacturer Contract Pharmacy Requests
BREAKING: Novartis the Latest to Seek 340B Contract Pharmacy Claims Data
BREAKING: AstraZeneca Raises the Ante in Drug Industry Push Against 340B Contract Pharmacy
A Closer Look at Democratic VP Choice Harris’s Positions on the 340B Program
BREAKING: Omnicell Buys PSG’s 340B Line of Business, the Latest in a Trend of 340B TPA Acquisitions
Health Centers Seek Meeting With Merck About its 340B Contract Pharmacy Data Request
Hospitals Slam Proposal to Deepen Medicare Payment Cuts for 340B Drugs
After Big Win in Court, CMS Proposes Cutting 340B Drug Payments Even More
Could CMS Follow Up 340B Court Victory with Deeper Cuts for Hospitals?
►
July (15)
BREAKING: U.S. Appeals Court Upholds Deep Cuts in 340B Hospitals’ Medicare Part B Drug Reimbursement
340B Bill Introduced in House; Senate 340B Bill Gets Two More Sponsors
Sanofi Joins Growing List of Drug Companies Challenging 340B Contract Pharmacy
BREAKING: Health Centers Challenge Administration Suggestions They Put 340B Profits Over Patients
BREAKING: Presidential Executive Order Targets 340B Health Centers’ Savings on Insulin and EpiPen
A Bipartisan Bill Will Be Introduced in the U.S. House Soon to Protect 340B Hospitals During the Pandemic
Pedley: HRSA’s Power to Enforce 340B Guidance is Limited.Testoni: Some in Pharma Want to Make 340B a Rebate Program.
HRSA Updates 340B Covered Entity Registration and Recertification Requirements
BREAKING: Hospitals and Other Providers Ask HHS to Halt Lilly and Merck’s Clampdowns on 340B; Companies Defend Their Positions
340B ESP Wants to Be Pharma’s Go-to on 340B Duplicate Discounts. Kalderos Says Not So Fast.
Key House Committee Rejects HRSA Request for More Regulatory Authority
HRSA Says its 340B Contract Pharmacy Guidance Is Not Legally Enforceable
Eli Lilly Says It Doesn’t Have to Provide 340B-Priced Drugs to Contract Pharmacies
BREAKING: New U.S. Senate Bipartisan Bill Would Preserve Hospitals’ 340B Eligibility During Pandemic
More Evidence That 340B Program Guidance Is Unenforceable
►
June (11)
Brace Yourselves: A Major 340B Hospital Court Ruling and CMS Proposed Rule Are Coming
Hospitals Might Not Get 340B Discounts on Drugs Being Investigated as COVID-19 Treatments
House Bipartisan Bills Address Worries About COVID-19 Drug Price Gouging
MedPAC Report Endnote Sheds Light on Hospital Losses Due to CMS 340B Drug Payment Cuts
340B Drug Manufacturer Audits: A Q&A with HRSA
HRSA Takes Step to Improve 340B Pricing Consistency
340B Experts Welcome HRSA’s Policy Clarifications on Hospital Child Sites and Telemedicine
EXCLUSIVE: HRSA Confirms 340B Hospital Offsite Location and Telehealth Flexibilities Are Permanent
BREAKING: HRSA Moves Forward on Plan To Allow for Expedited 340B Hospital Clinic Enrollment
HRSA Lifts Major Barrier to Using 340B Drugs at Hospital Offsite Locations
Possibly Hundreds of Millions of Dollars Annually in Lost 340B Savings Draw Closer in California
►
May (7)
Largest Hospital Group Asks Congress to Reject Administration's "Harmful" 340B Policy Requests
The CMS 340B Drug Cost Survey Is a Wrap. So, What Happens Now?
Sasse Reintroduces Bill in U.S. Senate to Keep Hospitals from Losing 340B Eligibility During Pandemic
340B Hospital Provisions Left Out of Latest COVID-19 Bill
Over 100 U.S. House Members Want More Help for 340B Hospitals During Pandemic
Two More National Hospitals Groups Urge CMS to Stop 340B Drug Cost Survey
Largest Hospital Group to CMS: 340B Drug Survey Is Burdensome, Ill-Timed, Illegal
►
April (11)
Bipartisan Duo in Congress Wants to Protect 340B Hospitals During Pandemic
The COVID-19 Pandemic Is No Time for a 340B Drug Cost Survey, Hospitals Say
BREAKING: CMS Begins Controversial 340B Hospital Drug Cost Survey
Nation’s Biggest Hospital Group Asks HHS to Waive 340B Requirements and Suspend Audits During Pandemic
COVID-19 Casts a Shadow Over 340B-Related Meetings, Including the Year’s Main Event
Hospitals Concerned About Limits of HRSA’s 340B Enrollment Flexibility During Pandemic
340B Protections and Clarifications Sought in Next COVID-19 Relief Bill
BREAKING: HRSA Now Says it Will Let Some Providers Enroll in 340B Immediately During COVID-19 Pandemic
Congress Is Starting to Ask About Drug Shortages Due to COVID-19
Telehealth Is Becoming the New Normal. What Does it Mean for 340B?
New York State Poised to Cut 340B Providers’ Medicaid Drug Reimbursement, Could Other States Follow?
►
March (13)
NY Lawmakers to Decide by Midnight on Medicaid Cuts to 340B Providers
HRSA Relaxes Policy on GPO Prohibition During COVID-19 Pandemic
Kentucky Health Centers Sue State To Block 340B Claims Requirement
HRSA Answers More Questions About 340B Compliance During Pandemic
Senate Stimulus Bill Would Put Space Between Health Centers and Funding Cliff
All Indications Are CMS Plans to Launch its 340B Drug Acquisition Survey on Monday
For Now, HRSA Doesn’t Plan to Change Its April 340B Registration Period
HRSA Tells COVID-19 Responders Concerned About 340B Compliance to Contact it Directly
Congressional Medicare Advisers Say 340B Has Minor Effect on Cancer Drug Spending and Patient Cost-Sharing
HRSA: 340B Dispute Resolution Will Stay on Hold Until We Get Broader Regulatory Authority
Hospital Groups to OMB: Quash 340B Hospital Drug Acquisition Cost Survey
DOJ Says Mallinckrodt Owes Medicaid Hundreds of Millions in Rebates, but Is Silent About 340B Overcharges
340B Providers Could Face Drug Access Challenges Due to Coronavirus
►
February (21)
Update: 340B-Related Action in the States
Welcome To 340B Report From Publisher & CEO Ted Slafsky
Distressed Rural Hospitals that Downgrade into Emergency Centers Could Gain 340B Eligibility
Think Tank to States: Use 340B to Reduce Drug Prices
Drugmakers Are Doing a Better Job of Supplying 340B Ceiling Price Data, 340B Program Head Pedley Says
In Budget, Trump Seeks 340B Changes Congress Has Taken a Pass on Before
A Message to Our Inaugural Subscribers
CMS Takes Another Step Toward Collecting Hospitals’ 340B Acquisition Costs
President Expected to Address Drug Prices in State of the Union Message
CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear
Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law”
BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts
Vermont Bills Would Require 340B Hospitals to Report Drug Discount Savings and Spending
Another New Study of Differences in Cancer Drug Spending Could Have 340B Implications
Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts
Massachusetts Medicaid Wants to Stop Covering “High Cost” Drugs Bought Through 340B
MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs
BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility
BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says
BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus
BREAKING: Drugmaker Xspire Owes 340B Refunds